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Mesenchymal stromal cell therapy for liver fibrosis 
Substantial uncertainty exists from pre-clinical liver fibrosis models as to whether mesenchymal 
stromal cells (MSCs) are anti-fibrotic, and yet clinically they have been proposed as a putative 
anti-fibrotic therapy for patients. This research was set out to examine whether MSC therapy can 
reduce liver fibrosis.  
An assessment of the depth and persistence of fibrosis in two murine liver fibrosis models (12 
doses of intraperitoneal carbon tetrachloride, or 16 weeks of oral thioacetamide) allowed a 
statistically powered analysis of MSC intervention. Human umbilical cord MSCs were peripherally 
injected after liver fibrosis was established, or during fibrogenesis. Finally, the effect of MSC 
conditioned medium on the biology of human stellate-cell line, LX2 cells, was examined.  
MSC administration neither resolved established fibrosis, nor abrogated fibrogenesis in either 
model. Peripherally injected MSCs were sequestered in the lungs. However, MSC conditioned 
medium attenuated the expression of collagen type-1 mRNA and promoted apoptosis in LX2 cells. 
The discordance between the in vivo and in vitro findings requires further exploration. 
Nevertheless, this statistically powered robust examination of human umbilical cord MSCs 
suggests no discernible anti-fibrotic influence in vivo, and future testing would require a 
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TRAIL  tumour necrosis factor-related apoptosis-inducing ligand 
TNF  tumour necrosis factor 
UCT  umbilical cord tissue 
UDCA  ursodeoxycholic acid 
UK  United Kingdom 
USA  United States of America 
WB  whole body 
WT  wild type 
αMEM Minimal Essential Media- alpha 







1.1. The clinical imperative for an anti-fibrotic agent 
Liver disease is the third commonest cause of premature death in the United Kingdom (UK), with 
62,000 years of potential working life lost every year1. The HEPAHEALTH project – established to 
describe the epidemiology of liver disease and their risk factors in European countries - estimates 
the prevalence of cirrhosis (advanced liver scarring) to be approximately 600 per 100,000 
population in the UK – equating to approximately 0.6% of the population2. Of those with cirrhosis, 
approximately 1 in 10 will get hepatocellular carcinoma. Alcohol and obesity are the two primary 
causes of liver disease, and the combined costs of these two entirely preventable drivers of disease 
to the UK National Health Service is almost £10 billion per year1.  
 
These numbers only give a snapshot of the current state of affairs. Of greater concern are the 
adverse trends. There has been a fivefold increase of cirrhosis in people between the ages of 35 
and 55 over the past 10 years3. Mortality from liver disease has increased fourfold since 1970, and 
fivefold in those of working-age4. Rates of premature deaths continue to increase, with those 
living in the most deprived areas being considerably more vulnerable and being twice as more 
likely to die prematurely from liver disease5.  
 
The systematic under-prioritisation of liver disease in health policies was epitomized by the 
absence of a National Liver Strategy and emphasized in a striking summary statement in the 2012 
Chief Medical Officer’s Annual Report whereby liver disease was recognised as “the only major 
cause of mortality and morbidity which is on the increase in England”6. It was highlighted as one 
of the three key issues for population health, and reassuringly, since this report, there has been a 
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greater impetus to tackle “tomorrow’s catastrophe”7. The 2014 All-Party Parliamentary Hepatology 
Group Inquiry into Improving Outcomes in Liver Disease made 20 key recommendations centering 
on themes of early recognition and prevention. The Lancet commissioned a blueprint to address 
liver disease in the UK, which it described as “the glaring exception to the vast improvements 
made during the past 30 years in health and life expectancy for chronic disorders”.1 Four Lancet 
Commission reports have now been published, which not only outline the evidence base for 
action, but set out priorities1,3,8,9. Moreover, the National Institute for Health and Clinical 
Excellence, the British Association for the Study of the Liver, the British Society of Gastroenterology 
and the Royal Colleges of Physicians and General Practitioners have published several clinical 
practice guidelines for afflictions of the liver.  
 
90% of liver disease is preventable10. Thus, it is entirely appropriate that the focus of the multi-
faceted efforts have been on public health measures and strategies directed at early detection 
and prevention3. These measures will undoubtedly dampen the risk and scale of “tomorrow’s 
catastrophe”, but we still face the legacy of “today’s complacency”7. This is not just the case in the 
UK where 600,000 people have some sort of liver disease, accounting for over 60,000 hospital 
admissions and 11,000 deaths per year. The estimated 5-10% of the world population with 
established chronic liver disease are at risk of cancer, morbidity and premature death11. Global 
burden of disease estimates suggest that 3.5% of all deaths worldwide are attributable to cirrhosis 
or liver cancer – an increase of 0.5% since 200012. Effective measures to address viral hepatitis have 
unmasked the burdens of alcohol-related liver disease (ARLD)13 and non-alcoholic steatohepatitis 
(NASH)14 - lifestyle diseases in areas of the world where the infrastructure to deliver widespread 
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screening and behavioural change may be considerably limited. Thus, today’s successes in health 
policies should not seed complacency in the fight to tackle an evolving problem.  
 
Nobel laureates Burnet and Medawar’s work on immune tolerance paved the way for organ 
transplantation in the 1960s15,16. Tom Starzl, Roy Calne and colleagues took brave, innovative and 
field-changing steps to introduce and subsequently refine procedures in liver transplantation17,18. 
50 years later, it remains the mainstay of treatment for those with end-stage liver disease, with 
most recipients living for over 10 years after a transplant.  
 
The successes of public health and preventative measures and improvements in transplantation 
techniques, technologies and peri-operative care have been the highlights of the past 50 years of 
endeavour. The relative scarcity of donor organs and limitations of transplantation service 
infrastructure remain steep barriers to a wider availability of transplantation to all in need and has 
resulted in an increase of liver transplant waiting list mortality in North America and Europe to 
almost 20%19. Moreover, over 30 years of research have heralded a greater understanding of the 
pathways of fibrosis, cirrhosis and resolution without yielding a clinically available anti-fibrotic 
agent that can resolve established fibrosis to augment the natural capacity of the liver to 
regenerate20. This is not an isolated failing of those investigating liver disease. Common and 
unique mechanisms are known to regulate fibrosis in various chronic fibroproliferative disease 
that are thought to account for nearly 45% of all deaths in the developed world; yet, despite this 
enormous impact, there are currently no approved treatments that directly target mechanisms of 
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fibrosis in any disease setting21. A safe and effective therapy to tackle dysfunctional fibrosis and 
cirrhosis remains the holy grail of Hepatology.  
 
Liver fibrosis is a dynamic, bi-directional process. The progression of fibrosis can be halted and 
advanced fibrosis and cirrhosis can be reversed in both animal models and in real-world clinical 
practice if the primary disease aetiology can be eliminated or suppressed. Historically this has 
been most evident as a consequence of effective antiviral therapy against hepatitis B22–24 and C25, 
iron depletion in patients with haemochromatosis26, and immunosuppression in those with 
autoimmune hepatitis27,28. Lifestyle interventions can interrupt disease progression and promote 
fibrosis resolution in NASH29 and ARLD30. However, certain phenotypes of cirrhosis, or advanced 
fibrosis may not regress spontaneously31–33. Patients are consequently subject to the risk of liver 
failure, hepatocellular carcinoma and death – it is for these patients that an anti-fibrotic agent 
may be most impactful.  
 
Autologous cell therapies have been explored in the treatment of liver fibrosis, with 
haematopoietic stem cells and macrophages showing potential promise34,35. Modest evidence of 
efficacy alongside practical and cost constraints with autologous cells have resulted in the 
consideration of allogeneic approaches, in particular mesenchymal stromal cells (MSCs). They 
have been demonstrated to home to areas of inflammation36–38, reduce inflammatory damage39 
and oxidative stress40,41, and even contribute to differentiated epithelium42. These findings have 
led to many clinical trials using MSCs to modulate the body’s response to injury in different organs 
including the liver43. Alongside the anti-inflammatory action of MSCs, there are suggestions they 
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may be able to exert direct anti-fibrotic effects, although enthusiasm for their use in patients with 
liver fibrosis has been tempered by concerns about a possible pro-fibrotic role of endogenous 
MSCs in response to injury.  
 
The overarching aim of my PhD was to investigate the therapeutic potential of MSCs to treat liver 
fibrosis. This introductory section will summarise the current evidence base and highlight the 
remaining controversies and unanswered questions in the field, and thereby provide context for 




1.2. Mechanisms of fibrogenesis and resolution in liver disease 
Fibrosis is a wound healing response to chronic injury characterised by the accumulation of 
extracellular matrix (ECM) or “scar” tissue44. The primary mediators of fibrogenesis and the 
composition of scar are generally conserved across different types of injury. ECM replaces 
damaged regions of tissue; a process that ultimately leads to cirrhosis whereby normal hepatic 
architecture is replaced by a nodular structure of functional regenerative hepatocytes 
encapsulated by fibrous septa45. An associated increase in vascular tone, maladaptive micro- and 
macro-circulatory changes and hepatocellular dysfunction results in the clinical sequelae of portal 
hypertension, liver failure and increased risk of hepatocellular carcinoma. A simplified depiction 
of the complex interplay of fibrogenic and resolution pathways is shown in figure 1.1.  
 
The liver’s response to tissue injury is multifaceted, and the component parts, which mediate both 
fibrosis and its resolution, are interlinked in an exquisitely complex way. The initial consequence 
of injury is almost invariably hepatocyte death or activation, which drives inflammatory and 
fibrogenic pathways in infiltrating and non-parenchymal cells46. This includes activating hepatic 
stellate cells (HSCs) - the principal precursor population for myofibroblasts.  
 
Myofibroblasts are the primary effector cells and the major source of ECM (including fibril-forming 
collagens (I, III, V), glycoproteins (e.g. laminin, fibronectin)) during liver fibrogenesis. Following 
liver injury HSCs undergo trans-differentiation to become matrix-secreting myofibroblasts45,47,48. 
They shed their vitamin A stores, up-regulate expression of markers such as myosin and alpha-
smooth muscle actin (αSMA), transdifferentiate and proliferate in response to locally increased 
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cytokines such as platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF
β1)49. Myofibroblasts also secrete tissue inhibitors of metalloproteinases (TIMP), which act to 
block ECM degradation by matrix metalloproteinases (MMP), thus supporting ECM persistence. 
With time and fibrotic density, myofibroblasts gain a progressive resistance to death or 
inactivation which is thought to contribute to resistance to regression50. Further to their scar-
production and maintenance, the pro-fibrotic myofibroblast acquires proliferative, migratory, 
immunomodulatory, phagocytic and contractile properties, that directly contribute to sinusoidal 
tone and portal hypertension. In resolution, myofibroblasts either die by apoptosis, or undergo a 
change to a non-fibrogenic phenotype – inactivation or senescence, whereby they do not secrete 
ECM or TIMP45,48. Fate-tracing experiments using Cre-loxP-based labelling to mark the fate of 
collagen type-I expressing myofibroblasts in a murine model of hepatic injury (carbon 
tetrachloride (CCl4)) demonstrated that the majority of the remaining HSCs in resolution (1 month 
after injury) were inactivated myofibroblasts51. 
 
Macrophages derived from circulating monocytes are equally critical to the biology of tissue 
injury, with different subpopulations playing functionally distinct roles45. However, the traditional 
classification based upon their mode of activation (M1 and M2 macrophages), does not fully 
reflect the range of distinct sub-populations involved in fibrogenesis and resolution52,53. Though 
less well characterised in humans, rodent studies have shown that the expression of Ly-6C and 
Gr1 on macrophages better describes their role in fibrosis45. Macrophages with a high expression 
of Ly-6C or Gr1 are pro-fibrogenic54,55 and are the dominant source of TGFβ, PDGF and insulin-
like growth factor-1 (IGF1), which serves to activate HSCs, as well as providing an NF-κB-
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mediated survival signal to myofibroblasts56. They also recruit other circulating inflammatory cells 
by their secretion of chemokines, cytokines and growth factors57. Conversely, macrophages with 
low expression of Ly-6C55,58,59 describe a terminally differentiated, collagenase-secreting, 
phagocytic “restorative” macrophage responsible for the resolution of fibrosis35. They produce 
MMPs which directly break down ECM31,60, and promote HSC apoptosis via caspase-9 and a 
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) dependent mechanism. Their 
effects are augmented by the recruitment of phagocytic neutrophils35 and natural killer (NK) 
cells61. This duality of macrophage function has been demonstrated in a range of murine models 
of fibrosis including CCl4, dimethylnitrosamine (DMN), and thioacetamide (TAA))52,62,63, whereby 
macrophage depletion during chronic injury abrogates fibrogenesis, and macrophage depletion 
post-cessation of chronic injury abolishes the resolution of fibrosis52. 
 
Matrix is continually turned over during the liver’s response to injury, and there is an increased 
expression of MMPs and collagenases even in the fibrotic liver45,64. However, ECM accumulates in 
fibrogenesis owing to the activity of high levels of TIMP (especially myofibroblast-derived TIMP-
1), which inhibits the activity of MMPs45. TIMPs also provide an autocrine anti-apoptotic stimulus 
for myofibroblasts33. A reduction in functional TIMP in resolution allows the unopposed action of 
MMPs to degrade scar tissue65, and promote myofibroblast apoptosis66. The most potent 
collagenase is MMP-1 in humans and Mmp-13 in rodents, both of which are predominantly 




The reversibility of fibrosis remains a matter of debate, and the concept and its definition is likely 
to change with advancing knowledge and understanding. Dense and longstanding fibrosis or 
cirrhosis is marked by thick bands of ECM with extensive cross-linking67,68 and elastin60 on a pauci-





Figure 1-1 A summary of major mechanisms and pathways that regulate 
liver fibrosis45 
Adapted from Haldar et al.45 
Fibrosis pathways are in red, and resolution pathways are in green. Fibrogenesis: myofibroblasts are activated 
and stimulated by a number of different stimuli. They produce ECM and TIMPs, which inhibit MMPs. Ly6chi 
macrophages are recruited and secrete pro-fibrotic cytokines, in turn recruiting other inflammatory cells, and 
augmenting myofibroblast survival. Resolution: myofibroblasts undergo inactivation, senescence or apoptosis. 
Ly6clo restorative macrophages stimulate apoptosis and inactivation of myofibroblasts, secrete MMPs and 
recruit other mediators of resolution including neutrophils and NK cells. TIMP levels decline, which allows 
unopposed ECM degradation by MMPs. DAMP, damage associated molecular patterns; EGF, epidermal 
growth factor;  IL, interleukin; PAMP, pathogen associated molecular patterns; PDGF, platelet-derived growth 
factor; ROS, reactive oxygen species; TGF, transforming growth factor; TNF, tumour necrosis factor; TRAIL, 
TNF-related apoptosis-inducing ligand.  
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1.3. Potential targets for therapy in fibrosis pathways 
Myofibroblasts and ECM are the primary targets of any putative anti-fibrotic therapeutic agents. 
However, the complex interplay with other cells in the microenvironment governs fibrogenic 
activation or regression. Our current understanding is distilled to the existence of two multicellular 
functional units – one centred around perisinusoidal pericytes (HSCs) that is likely to be dominant 
and the other around portal myofibroblasts69,70, though some investigators have also described 
intermediary myofibroblasts with distinct morphology and functional microenvironment71. There 
are nuanced differences in the nature of myofibroblast precursors from different sites72, though 
in advanced fibrotic disease the boundaries between the functional units overlap as dense septa 
form cirrhotic nodules.  
 
Fibrogenic and resolution pathways are complex. A putative anti-fibrotic agent could interfere at 
a crucial bottleneck of the fibrogenic pathway, simultaneously interfere with discrete pathways or 
enhance the resolution phase45. Moreover, any anti-fibrotic effect must be appropriate to 
requirements and reset homeostasis to a non-injured, non-fibrotic set point.  
 
Therapies that target myofibroblasts or ECM are labelled direct anti-fibrotic agents, whereas those 
that target other aspects of the fibrosis or resolution pathways are indirect agents73. A vast 
catalogue of agents have been trialled pre-clinically, but only a few have made it to phase 2 clinical 
trials or beyond and are the subject of an excellent recent review74 – yet as stated, none have 




1.4. Mesenchymal stromal cells – a therapeutic option? 
MSC are stromal cell progenitors with the ability to differentiate down mesodermal cell lineages66, 
and have wide-ranging immuno-modulatory properties45. The current concept of MSCs can be 
traced to classical experiments by Friedenstein and colleagues in the 1960s and 1970s who 
demonstrated the osteogenic potential of a subset of bone marrow (BM) derived cells by 
heterotopic transplantation75. They are now thought to reside in perivascular niches/matrices 
within tissue76, and can be isolated for use from almost every postnatal connective tissue including 
adipose tissue (AT)77, umbilical cord (UCT)78, dental pulp79, synovium80 and many others. Their 
three defining properties, as decreed by the International Society of Cellular Therapy (ISCT)81,82, 
are: (i) the ability to adhere to plastic, (ii) a characteristic immunophenotype with expression of 
CD73, CD 90 and CD105, and lack of expression of class-II major histocompatibility complex (MHC) 
and CD14, CD34 and CD45, (iii) and ability to readily differentiate to form multiple skeletal tissues 
(bone, cartilage, adipose tissue).  
 
Early therapeutic interest in MSC revolved around their capacity for multi-lineage differentiation 
including reported epithelial and endodermal differentiation83, although the current focus relates 
to their immunomodulatory effects45. MSC have been found to modify the activity of both the 
innate84 and adaptive immune system85–87, and can also exert other cytoprotective40, pro-




Table 1-1: Clinical studies investigating the effect of MSC therapy in chronic liver disease45 
Primary author; 
year 
Type of Study Cell Therapy Dose/Route Disease 
aetiology 






BM-MSC; 10 - 60x106 
Single dose /  
peripheral vein 
Cryptogenic; AIH 4 12 months ↓ MELD* in 50% of 







Single dose /  
portal vein 
HBV; HCV; ARLD; 
Cryptogenic 
8 24 weeks ↓ MELD 
Amer92; 
2011 
Controlled trial Autologous 
BM-MSC; 2x107 – 2x108 
Single Dose / 
intrahepatic, intrasplenic 
HCV 10 intrahepatic;  
10 splenic; 20 controls 
6 months ↓MELD; ↓ oedema 
Peng93; 
2011 
Controlled trial Autologous 
BM-MSC; 3.4x108 
Single dose /  
hepatic artery 
HBV 53 treatment 
105 controls 
192 weeks ↓ MELD  
Shi94; 
2012 
Controlled trial Allogeneic 
UCT-MSC; 0.5x106/kg 
bw 






72 weeks ↓ MELD; Improved 
PT, bilirubin, albumin 
El-Ansary95; 
2012 
Controlled trial Autologous 
BM-MSC; 1x106/kg bw 
Single dose /  
peripheral vein 
HCV 15 treatment 
10 controls 








Multiple doses / 
peripheral vein 
HBV 30 treatment 
15 controls 






BM-MSC; 1.2 – 2.9x108 
Single dose /  
peripheral vein 








Controlled trial  Autologous 
BM-MSC; 0.5x108 
Single dose /  
peripheral vein 
HCV 20 6 months ↓ MELD; Improved 






UC-MSC; 0.5x106/kg bw 




7 12 months ↓ ALP, ↑ QoL; No 











19 (2 doses) & 18 (1 dose) 
treatment; 18 control 











56 treatment;  
54 controls 






Allogeneic; UCT- or cord 
blood or BM; 1x106 




23 UCT-MSC, 2 cord 
blood-MSC, 1 BM-MSC 
2 years ↑ albumin; no 
change in MELD 
Adapted from Haldar et al.45 
*Model for end-stage liver disease (MELD) is a composite measure for the extent of liver disease. MELD-Na is a variant thereof. Higher scores equate to more advanced 
disease. ACLF, acute-on-chronic liver failure; AIH, autoimmune hepatitis; ARLD, alcohol-related liver disease; ALP, alkaline phosphatase; BM, bone marrow; bw, body 
weight; CC, cryptogenic; CPS, Child-Pugh score; HBV, hepatitis B virus; HCV, hepatitis C virus; MSC, mesenchymal stromal cells; PBC, primary biliary cholangitis; QoL, 
quality of life; UCT, umbilical cord tissue; UDCA, ursodeoxycholic acid.  
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The highlight of translational MSC-therapy research has been the successful application to treat 
patients with steroid-refractory severe graft-versus-heart-disease (GvHD). In May 2012, the United 
States of America (USA)-based biotech Osiris received market approval in Canada and New 
Zealand for their proprietary plastic adherent (PA)-MSC formulation (ProchymalTM) to treat specific 
cases of GvHD – representing the world’s first market approved allogeneic (“off-the-shelf”) stem 
cell medicine. Furthermore, MSC therapy has been shown to be safe and effective in the treatment 
of patients with systemic lupus erythematosus and fistulising bowel disease (Crohn’s disease)103. 
This work has culminated in TiGenixTM (Euronex Brussels) acquiring Food and Drug Association 
approval in the USA through Special Protocol Assessment for use of their proprietary platform of 
allogeneic AT-MSC (Cx601) in a phase III randomised, double blinded, parallel group, placebo-
controlled multicentre study to treat complex perianal fistulas in Crohn’s disease patients104. Other 
phase I and II trials are underway in different disease settings. 
 
There have been a number of published MSC trials investigating the therapeutic effect of plastic-
adherent MSC in patients with liver cirrhosis (Table 1.1), with many more on going45. The majority 
of these studies recruited patients with advanced cirrhotic disease, in whom MSC therapy was 
deemed safe. Though the majority of these studies suggested a clinical benefit too, only four 
randomised controlled trials have been reported to date, with three demonstrating a favourable 
clinical effect. Despite these findings, the scientific community still has significant concerns about 
the efficacy and safety of their use in patients with liver fibrosis. One major cause for apprehension 
is borne out of pre-clinical studies reporting MSC may be inherently fibrogenic, making their use 




In the following sections, the pre-clinical evidence supporting MSC therapy for liver fibrosis will 
be critically appraised to provide a balanced exploration of the evidence surrounding their role in 




1.5. Do mesenchymal stromal cells prevent fibrosis, rather than promote its 
resolution?  
There is an increasing body of work supporting the anti-fibrotic effects of adoptively transferred 
MSC in rodent models of liver fibrosis (Table 1.2), however, the timing of therapy may be a critical 
consideration as the effect on fibrosis may be mediated through a reduction in inflammation 
rather than promoting its degradation directly45.  
 
Notably, the majority of rodent studies have infused MSC during on-going injury and provided 
evidence to suggest that MSC reduce inflammation and subsequently fibrosis. Tsai et al injected 
5x105 human UCT-MSC into the sub-hepatic capsule of CCl4-injured rats78 four weeks after the 
onset of injury (twice per week CCl4 by oral gavage), with the injury continuing for a further 4 
weeks until the rats were sacrificed. MSC reduced metabolic activity in the injured liver to pre-
injury levels, as detected by MicroPET (positron emission tomography) after 18F-FDG injection; this 
was crudely used as a surrogate for inflammation – an assumption that has its limitations105. The 
presumed reduction in inflammation translated to a dramatic reduction in fibrosis compared to 
those injured for 8 weeks without MSC treatment. Morphometric analysis of collagen-
proportionate area (CPA) (picrosirius red (PSR) staining: 0.07 ± 0.02% vs. 9.56 ± 2.03%; p<0.05) 
suggested fibrosis was reduced to uninjured levels, and this was supported by a 66% relative 
reduction of TGFβ protein expression in the MSC treated group. Similarly, Seki et al established 
that injection of MSC whilst injury is on-going can affect both inflammation and fibrosis77. They 
injected 1x105 green-fluorescent protein (GFP)-labelled murine AT derived stromal cells every two 
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weeks in a NASH model of fibrosis (34 weeks of atherogenic high-fat diet) and demonstrated a 
50% reduction in fibrosis by morphometric analysis (p<0.05), allied with fewer detectable αSMA+ 
myofibroblasts (p<0.001). They interrogated the hepatic inflammatory infiltrate by 
immunohistochemistry (IHC) and flow cytometry to show that MSC led to a significant decrease 
in the number of cells of myeloid (CD11b+) origin and granulocyte/antigen presenting cells (Gr1+) 
in the liver, whilst increasing CD4+ T-cell numbers. Ezquer et al also observed injection of 
syngeneic BM-MSC into mice 33 weeks into 50 weeks of high-fat diet (HFD) prevented 
development of fibrosis106. MSC-treated mice did not develop fibrosis, whereas the untreated 
mice did, although both groups of mice did developed obesity, insulin resistance and hepatic 
steatosis. Gene expression for both Col-1 and Tgf-β1 were significantly reduced with treatment 
(p<0.01), though there was no significant change in the hepatic expression of αSMA. The 
decreased fibrosis was allied to attenuated levels of inflammatory cytokines (IL-1ß, IFN-γ, and TNF-
α), though only the expression of TNF-α was significantly reduced (p<0.05)
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MSC treatment Injury model  Output:  Significant effects on fibrosis 
Source of MSC; 
Route of delivery 
Dose (cells) Timing of treatment 
Oyagi 
2006 
Rat; BM;  
HGF-primed 
Tail vein 
3x106  At onset of injury Fisher 344 rats;  
chronic IP CCl4 
• HGF-primed MSC led to ↓ in fibrosis; un-primed 





1x106 At onset of injury, or 
1 wk after injury start 
Mice;   
chronic OG CCl4 
• MSC delivered at onset of injury led to a ↓ in 
fibrosis; later delivery did not. 
Seki 
2013 
Mouse ; AT 





Twice every 2wks C57Bl/6 mice; chronic Ath 
+ HFD 
• MSC treatment led to ↓ in fibrosis and changes in 







1x106; 3x106; 6x106 
During injury 
 
Sprague Dawley rats;  
chronic DEN in water 
• Comparison of effects of MSC therapy at varied 
doses given during injury: ↑ doses led to greater ↓ 
in fibrosis.  
• Splitting the dose trended to deliver a greater ↓ in 
fibrosis against the single equivalent dose.  
Split 
1x106; 3 doses or 
1x106; 6 doses 






5x105 4wks after onset of injury Sprague Dawley rats;  
chronic OG CCl4 













1x105 4wks after onset of injury C57Bl/6 mice; chronic IP 
CCl4 
• FGF-unprimed MSC led to ↑ fibrosis; FGF-primed 







4wks after onset of injury  NMRI mice; chronic IP CCl4 • Comparison of effects of MSC therapy delivered as 
single dose, or split dose: single dose did not ↓ 
fibrosis; split dosing did. Split 
1x106 ; 3 doses 





Exosomes 6wks after onset of injury Kunmingbai mice; 
chronic IP CCl4 






1.5x106 During (unclear exactly when) DBA-1 mice; BDL or  
chronic SC CCl4 






2x106; 2 doses 
At wk 6 and 8 of injury Sprague Dawley rats; 
chronic IP TAA 





0.25x106 8wks after onset of injury C57Bl/6 mice; chronic IP 
CCl4 







8wks after Schistosoma 
injection 
Balb/C mice; single SMc 
injection 
• MSC led to ↓ in fibrosis. 
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Adapted from Haldar et al.45 
Ath+HFD, atherogenic + high fat diet; AT, adipose tissue; BDL, bile duct ligation; BM, bone marrow; CCl4, carbon tetrachloride; DBA, dilute brown nonagouti; DMN, 
dimethylnitrosamine; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; IP, intraperitoneal; MSC, mesenchymal stromal cell; NMRI,  Naval Medical Research 
Institute; NOD-SCID, non-obese diabetic-severe combined immunodeficiency; NSG, NOD-SCID-gamma; OG, oral gavage; SC, subcutaneous; SMc, Schistosoma Mansoni 






0.5x106 ; 2 doses 
At 33 and 37wks of HF diet C57Bl/6 mice; chronic HFD • MSC treatment prevented the establishment of 
fibrosis, no effect on obesity, insulin resistance or 








0.5x106 ; 2 doses 
Day 60 and 61 of injury C57Bl/6 mice; chronic IP 
CCl4 
• MSC led to ↓ in fibrosis. ; associated with changes 
of hepatic cytokine and inflammatory cell infiltrate 
profiles.  
• All MSC-related effects negated if mice were pre-







2x106 ; 4 doses 
At wk10, 11, 12, 13 of injury NOD/ 
SCID mice;  chronic IP TAA 







3x106 At cessation of injury Albino rats;  chronic SC 
CCl4 






3x106 At cessation of injury  Wistar rats;  chronic IP CCl4  • ↓ in fibrosis when MSC given at cessation of CCl4 
injury. 
Day 10, or day 20 of injury chronic IP DMN • ↓ in fibrosis was more marked when MSC were 





1x106 At cessation of injury (details 
unclear 
Sprague Dawley rats;   
chronic IP CCl4 






1x107 At cessation of injury (details 
unclear) 
Wistar rats;  chronic IP CCl4 
& simultaneous alcohol 
liquid diet 
• MSC did not ↓ fibrosis. 
M’heimer 
2011 
Rats; BM (cirrhotic) 
Portal vein 
1.6x107 • MSC did not affect injury-related changes in portal 





3x106 1 day after final injury Wistar rats; chronic IP CCl4 • MSC led to ↓ in fibrosis. 
Briquet 
2014 
Human; BM, UCT, Liver 
Tail vein 





1x106 3.5 days after final injury Wistar rats; chronic SC CCl4 • MSC led to ↓ in fibrosis. 
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Fang et al compared the therapeutic effects of MSC given at the onset of injury to that given 
during injury, and demonstrated that syngeneic BM-MSC infusion (1x106 cells via tail vein) 
administered at the onset of injury (5 weeks of CCl4 by oral gavage twice per week) significantly 
reduced surrogate markers of fibrosis (hepatic hydroxyproline, serum hyaluronic acid and pro-
collagen III-N-peptide) and inflammation compared to no treatment (all p<0.01). However, the 
anti-fibrotic and anti-inflammatory effects were not seen if the MSC therapy was given 1 week 
after the onset of injury, which is an unexpected finding in light of other studies showing an anti-
fibrotic effect when MSC are given during injury. This may reflect the use of Balb/C mice in this 
study, which are prone to a more profound fibrotic response107, and thus conceivably more 
resistant to resolution once fibrosis starts to form.   
 
A number of studies have shown that MSC injected at or near to the end of injury also lead to a 
reduction in fibrosis. Chen et al injected 0.5x106 syngeneic BM-MSC on the last 2 days of a 61-day 
hepatic injury (twice per week CCl4 by oral gavage)108 and then analysed the effects 3 and 6 days 
later. Morphometric analysis of CPA showed the MSC treated group had a significant reduction in 
fibrosis compared to the untreated group (4% vs. 7%; p<0.001), with a significant reduction in 
αSMA+ cell staining by IHC (4% vs. 12%; p<0.001). MSC led to a statistically significant reduction 
in serum inflammatory markers IFNγ, TNFα, IL-1β (all p<0.001) and IL-17A (p<0.01), and an 
increase in IL-10 (p<0.01). Overall leucocyte infiltration into the liver was abrogated by MSC 
infusion; CD4+/IFNγ+ and CD4+/IL-17+ T-cells were significantly decreased (p<0.001), whereas 
regulatory T-cells (CD4+/CD25+/Foxp3+) were increased (p<0.01). These results differ from those 
of Ezquer et al who demonstrated that CD4+ cells increased after MSC infusion (with no effect of 
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CD8 cell infiltration). However, they did not sub-stratify the CD4+ population, and the experiment 
used a different, NASH, model of injury106. Quintanilha et al also showed the anti-fibrotic effects 
of MSC administered near the end of injury. They administered 2x106 canine BM-MSC into mice 
subjected to hepatic injury by twice-a-week intra-peritoneal (IP) injection of TAA for 13 weeks. 
MSC were given by tail-vein injection at weeks 10, 11, 12 and 13, and the mice analysed 3 days 
after the last injection. MSC significantly reduced fibrosis in comparison to untreated mice, when 
analysed by CPA (5.1±2.9% vs. 8.3±1.7%), serum hyaluronic acid or procollagen N-terminal 
peptide expression (all p<0.05). Moreover, the authors demonstrated that MSC treatment was 
associated with better redox homeostasis with higher total antioxidant levels (p<0.001) and lower 
lipid peroxidation (p<0.05) establishing a possible cytoprotective effect on hepatocytes (which 
was subsequently demonstrated in vitro).  
 
Jung et al demonstrated that MSC continue to have an anti-fibrotic effect even when administered 
in the absence of on-going injury109. They administered 1x106 hUCT-MSC via tail vein to rats at 
the end of eight weeks of CCl4 injury (IP, 3/week). There was a significant reduction in fibrosis 
compared to untreated control, as measured by histological staging and serum hyaluronic acid 
and laminin (p<0.05). Furthermore, the authors determined an 80% relative reduction in the gene 
expression of hepatic Col-I, αSMA, and Tgfβ, four weeks after MSC therapy (p<0.05). This was 
allied to a significant reduction in serum AST and ALT in the treatment arm (p<0.05), but the 
inflammatory signature and mechanisms of therapeutic effect were not explored further. Similarly, 
Chang et al showed a reduction in fibrosis from MSC treatment 3.5 days after cessation of injury110. 
They injected GFP-transfected human BM-MSC into the portal vein of rats that had been injured 
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by subcutaneous (SC) CCl4 injections twice a week for 4 weeks, and analysed the effects 4 weeks 
later. Masson’s trichrome staining demonstrated large bands of collagen in the untreated cohort, 
whereas collagen accumulation was not seen in the MSC-treated cohort. The authors suggested 
that the MSC might have directly contributed to the degradation of fibrosis by expressing MMPs; 
they showed that human-specific MMP co-localised with MSC in treated livers. Motawi et al also 
established that MSC given at the cessation of injury can lead to a reduction in fibrosis, and allied 
this to a significant increase in MMP-1 (p<0.01), and decrease in TIMP-1 (p<0.001). They 
administered syngeneic BM-MSC via the tail-vein of CCl4-injured rats (IP twice a week for 6 weeks), 
1 day after the cessation of injury, and analysed the effects 8 days later. Zhao et al demonstrated 
the anti-fibrotic effect of rat BM-MSC, in two different chronic models of rat liver fibrosis, and 
compared the administration of MSC at different points during, and at the end of injury111. They 
injected 3x106 MSC via tail vein at the end of CCl4 injury (2x per week SC injections for 6 weeks), 
and sacrificed the mice 28 days later. MSC led to a significant reduction in fibrosis and 
myofibroblast numbers compared to sham treatment as measured by CPA (40% reduction; 
p<0.05), hepatic hydroxyproline, serum laminin and hyaluronic acid (p<0.01), and staining for 
αSMA+ cells (p<0.05). They then showed very similar results in a DMN-induced liver injury (3 
consecutive days every week for 6 weeks), in which they infused MSC at day 10 of injury, or at day 
20 of injury, before sacrificing the mice 7 days after the end on injury. This demonstrated that the 
anti-fibrotic effect was apparent in both treatment arms, but more pronounced in the earlier 
treatment arm. The authors did not explore this further, though it is clear that MSC had an anti-
fibrotic effect in both models of injury, and at all three time points. Collectively these studies 
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suggest multiple mechanisms by which MSC may attenuate fibrogenesis or degrade established 
fibrosis, which may in turn be governed by the timing of therapy in relation to on-going injury.  
 
However, at least three studies have demonstrated that MSC given at, or after the cessation of 
injury may not deliver an effect on fibrosis. Carvalho et al112 administered 1x107 syngeneic BM-
MSC via the portal vein of rats at the end of injury (alcohol-infused diet and IP CCl4) and 
demonstrated no improvement in serum biochemical markers of liver disease, nor in 
morphometric analysis for CPA 2 months later (4.8±0.6% in MSC-treated group vs. 5.4±1.1% in 
sham-treated group; p=0.6). The MSC were both radiolabelled and labelled with Hoechst 3342, 
and were seen to be viable and concentrated in the liver 6 hours after injection, but were not 
detected after 4 or 8 weeks. Mannheimer et al undertook a similar experiment using MSC isolated 
from the bone marrow of cirrhotic rats and found no difference in fibrosis nor portal-vein diameter 
in the MSC treatment arm compared to the control113. The authors did deliver a bi-modal hepatic 
injury (alcohol-infused diet and IP CCl4) and did so over a much longer time than other 
experiments (14 weeks vs. 4-8 weeks in other papers), which may deposit a more resistant scar. 
Furthermore, Mannheimer used BM-MSC from cirrhotic rats, which may affect the functionality of 
MSC. Briquet et al injected human BM-MSC, UCT-MSC and liver MSC, into NOD/SCID/IL-2Rγ-null 
(NSG) mice subjected to 4 weeks of IP CCl4-induced liver fibrosis, 2 days after the cessation of 
injury. They demonstrated no therapeutic effect of MSC therapy on relative fibrosis area, plasma 
albumin, ALT and AST after injection, despite evidence of homing and persistence in liver114. The 
NSG mice develop only very mild peak fibrosis (0.7% CPA by morphometric analysis), which makes 
it difficult to observe differences in response to therapy. 
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1.6. Can mesenchymal stromal cells have a direct anti-fibrotic effect?  
The mechanisms by which MSC reduce hepatic fibrosis are not well developed, though clues exist 
from existing data (Figure 1.2). In the setting of on-going inflammation, MSC may influence the 
pro-fibrotic stimuli by immuno-modulation, or act to protect parenchymal cells from oxidative 
stress. MSC may also influence the degradation of ECM, either directly by secreting locally acting 
MMPs, or indirectly by stimulating the influx of restorative macrophages or dendritic cells to up-
regulate MMPs. Furthermore, they may effect myofibroblast inactivation or death, which is the 
main determinant of fibrogenesis/fibrinolysis. Myofibroblasts not only secrete the majority of 
ECM, but are also the main source of TIMP-1, which acts to stem the collagenase activity of MMPs. 
MMP concentrations are increased in both fibrosis and resolution, although different MMPs may 
dominate in injury and resolution, and the TIMP:MMP balance favours the latter in resolution. In 
the following sections, we will discuss the purported direct ant fibrotic effects of MSC.  
 
1.6.1. Tipping the balance of TIMPs and MMPs 
A number of studies that have demonstrated the anti-fibrotic potential of murine MSC after 
syngeneic treatment in models of chronic hepatic injury have also investigated the effects on 
MMPs and TIMPs. It is not possible to extract a consistent profile of effects on MMPs, due to 
inconsistencies in what has been tested. Nevertheless, syngeneic rodent MSC treatment in models 
of CCl4-induced liver injury leads to increased expression of MMP-1/13115–117 and MMP-12118, a 
reduction in the expression of MMP-2108,119, and no or limited effect on MMP-9108,115,118 in the 
setting of resolving fibrosis. What remains unclear is whether these fluxes in MMPs reflect 
26 
 
maturation/changes in the inflammatory infiltrate77,120 – including HSCs, neutrophils, 
macrophages and dendritic cells (driven by MSC), or whether MSC actually secrete MMPs 
themselves.  
 
MMP-12 is an elastase (metalloelastase) and is critical to the resolution of advanced scars in which 
elastin is a prominent feature. They are secreted by hepatic restorative macrophages60, and it is 
likely that the changes seen with MSC therapy reflect the maturation of macrophages to a 
restorative phenotype. Rodent MMP-13 is an interstitial collagenase (human MMP-1) that is also 
expressed by mature macrophages31, and which is also expressed transiently by maturing HSC 
early in their activation121, but is subsequently down-regulated when HSC reach a fully fibrogenic 
phenotype122.    
 
MMP-2 (Gelatinase-A) is secreted by myofibroblasts and has been functionally linked with the 
naïve/proliferative phenotype123. Thus, it follows that the MSC-induced resolution leads to a 
reduction in MMP-2.  
 
Seki et al reported a decrease in both MMP-8 and -9 following syngeneic AT-MSC injection in a 
NASH model of murine liver injury77. They also described a significant decrease in the number of 
cells of myeloid lineage (CD11b+), and granulocytes/antigen presenting cells (Gr1+), which may 
account for the flux of MMPs. This was not investigated further, but it is known that neutrophil 
collagenase (MMP-8) is expressed by both neutrophils and macrophages124, and that Gelatinase-
B (MMP-9) is expressed by inflammatory macrophages, dendritic cells125 and Kupffer cells126. 
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Therefore, it is likely that the changes in the inflammatory profile described by Seki et al explain 
the reported changes in MMPs.  
 
Of note, none of the cited studies designated MMP secretion directly to MSC. Chang et al 
administered human BM-MSC to rats via the portal vein 3.5 days after cessation of chronic CCl4 
injury and demonstrated an improvement in biochemical markers of liver injury and function 
(albumin, ammonia, fibrinogen)110. They reported that engrafted human GFP-transfected BM-MSC 
co-localised with human-specific MMP expression in the injured liver, and had no fibrosis 4 weeks 
after therapy. However, the effect of sparsely engrafted MSC secreting MMPs is unlikely to be 
functionally significant by itself. 
 
TIMP molecules inhibit the extracellular function of MMPs by stabilising the pro-enzyme, and 
inhibiting the active moiety127. Both TIMP-1 and -2 are expressed by myofibroblasts; TIMP-1 
expression mirrors that of other markers of HSC activation (such as αSMA, and collagen-1), to the 
extent that TIMP-1 correlates with numbers of activated HSC. TIMP-2 is also expressed by both 
active and quiescent phenotypes of HSC, and during resolution myofibroblasts undergo apoptosis 
or revert to a quiescent state. As such, the expression of TIMP-1 falls128–130. Despite, no major fluxes 
in MMP expression, they are liberated to remodel fibrotic matrix. Thus, the downregulation of 
TIMP is critical to allow the degradation of scar tissue.  
 
MSC therapy leads to a decrease in the expression of TIMP-1 in the setting of resolving liver 
fibrosis115–117,119, which was invariably allied with either a decrease in αSMA+ staining, collagen-1 
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or TGFβ expression. It is likely to be a consequence of HSC inactivation or apoptosis, though the 
exact mechanisms by which MSC enact this have not been well developed in these studies.   
 
1.6.2. Secreted anti-fibrotic agents and the effects on the fate of myofibroblasts 
The switch from fibrogenesis to resolution in the body’s response to injury requires control of the 
injury and the inactivation of myofibroblasts (by reversion to a quiescent state or apoptosis). 
Investigators have tried to determine methods by which MSC may influence myofibroblast fate. 
Purported hypotheses include a direct effect by cell-cell contact, a direct effect by MSC-secreted 
cytokines / growth factors, or an indirect effect by cellular mediators such as macrophages or even 
hepatocytes.  
 
In vitro experiments have demonstrated that MSC can suppress HSC activation and proliferation 
by direct cellular contact. Chen et al established that HSC undergo proliferative arrest on direct 
cell-cell contact with BM-MSC131. MSC induce HSC cell arrest of in G0 through a Notch-dependent 
pathway – blockade of Notch signalling pathway with Notch1 siRNA increased expression of 
phospho-Akt and increased the proliferation of co-cultured HSC. Whilst adoptively transferred 
MSC preferentially home to areas of injury, they never do at levels to make sufficient direct cell-
cell interactions for this to be a plausible mechanism of their effect 39.  
 
Evidence suggests that secreted factors are critical to the therapeutic MSC armamentarium. Meier 
et al elegantly demonstrated that MSC mediate an anti-fibrotic effect by releasing soluble 
molecules in vitro and in vivo132. The authors encapsulated human BM-MSC in an alginate-
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polyethylene glycol hybrid hydrogel, which is permissive to soluble factors (oxygen, glucose 
cytokines), but not to antibodies or direct cellular interaction. The authors observed that IP 
injected micro-encapsulated MSC decrease inflammation and liver fibrosis in murine models of 
chronic liver injury – CCl4 and BDL – suggesting the effects can be solely attributed to factors 
secreted by MSC; in particular they were shown to secrete IL-1Ra, increase endogenous serum IL-
10 levels and hepatic MMP-9 expression. In vitro experiments subsequently suggested a direct 
anti-fibrotic effect of MSC conditioned medium (CM) on TGFβ-stimulated LX-2 and primary HSC, 
implicating a possible role for insulin-like growth factor binding protein-2 (IGFBP-2), IL-6, IL-1Ra, 
and monocyte chemotactic protein-1 (MCP-1) without wholly interrogating the mechanism.  
 
Similarly, Li et al determined the anti-fibrotic effects of microvesicles (or exosomes) from hUCT-
MSC in a CCl4-induced model of chronic hepatic injury in rats133. Microvesicles are cell-derived 
vesicles that act as functional parcels containing proteins and nucleic acid variants that are 
characteristic of the parent cell134. Li et al directly transplanted microvesicles into injured livers 
whereby they significantly attenuated the fibrotic response. Allied in vitro experiments 
demonstrated MSC microvesicles induced a reversal of TGFβ-induced activation of HSC, as in 
Meier et al; however, the contents of the microvesicles were not interrogated further.  
 
Tsai et al demonstrated a concomitant rise in hepatocyte growth factor (HGF) and Met-P 
expression after MSC treatment78, which they hypothesised may modulate either MSC action or 
homing to areas of injury. In fact the HGF/c-Met signalling pathway has been shown to be critical 
to MSC homing to the liver in an acute ischaemic liver injury model in rats, as subsequently 
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confirmed by Transwell in vitro studies135. Furthermore, Ishikawa et al demonstrated the critical 
role of the HGF/c-Met pathway in the resolution of 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
(DDC)-induced hepatic fibrosis. It was found to be critical to mobilising and differentiating the 
native hepatic stem cell niche (oval cells), and for the recruitment of MMP-9-expressing mature 
macrophages136. Studies have also established that HGF promotes MMP expression in vivo, and 
also causes HSC apoptosis in vitro137.  
 
Parekkadan et al showed that human BM-MSC induced replicative arrest and apoptosis of 
activated HSC in an indirect co-culture experiment, and HGF was deemed to be the major pro-
apoptotic agent, as its neutralisation attenuated HSC apoptosis137. MSC-derived IL-10 and TNF-α 
inhibited HSC proliferation and collagen synthesis, whilst their blockage allowed HSC proliferation 
despite the presence of MSC.  Of interest, HSC-derived IL-6 stimulated IL-10 secretion by MSC. In 
vivo verification would allow for a robust evaluation of these pathways. 
 
Pan et al injected 1x106 murine BM-MSC via tail vein after mice had been subject to 4 weeks of IP 
CCl4-induced liver injury138. They demonstrated a significant decrease in fibrosis as measured by 
morphometric analysis (60% reduction of fibrosis area; p<0.05), and both collagen and αSMA 





Figure 1-2 Mechanisms by which MSCs may reduce fibrosis45 
Adapted from Haldar et al.45 
1) Alter the fate of hepatic myofibroblasts to a non-fibrogenic inactive phenotype, or by promoting their 
apoptosis. 2) Alter the macrophage phenotype to promote resolution. The ability of MSCs to alter macrophage 
fate has been documented outside the liver and needs to be explored in the setting of liver disease. 3) MSCs 
may themselves secrete MMP and contribute to the breakdown of ECM. HGF, hepatocyte graft factor; IL, 
interleukin; MMP, matrix metalloproteinase; NGF, nerve growth factor; TNF, tumour necrosis factor; TRAIL, 
TNF-related apoptosis-inducing ligand.   
 
They then went on to establish the critical role of hepatocyte-derived cytokine, delta-like 1 (Dlk1), 
in HSC activation and showed both in vivo and subsequently in vitro that MSC-derived fibroblast 
growth factor (FGF) 2 is critical in the down-regulation of hepatocyte Dlk1 expression, and 
subsequent HSC activation. This provides an insight on the indirect and amplifying paracrine 
32 
 
mechanisms by which MSC may deliver an anti-fibrotic effect. However, not all studies have shown 
MSC to have the desired inhibitory effect on HSCs. Baligar et al cultured primary HSC with 
conditioned medium from adipose tissue derived MSC, and showed both increased activation 
(expression of αSMA and collagen-1) and proliferation (Ki-67) of HSC in this environment. A 
significant increase (p<0.05) in MSC-derived TGF-β was noted in the conditioned media compared 
to the control media. An inhibitor to TGF-β receptor kinase significantly barred the MSC-CM 
induced activation of HSC, proving MSC derived TGF-β contributes to HSC activation in vitro. TGF-
β is a well-described agent of MSC-mediated immuno-regulation in settings of acute 
inflammation139,140, though its application in models of chronic liver injury is doubtful as most 
studies describe a decrease in TGF-β with MSC therapy. They injected 0.5x106 human AD-MSC in 
to the spleens of mice subjected to 8 weeks of IP CCl4-induced liver injury at week 4 of injury. The 
MSC-treated group had a significant reduction in fibrosis by CPA (5% vs. 6%; p<0.05), however 
there was no reduction (or increase) in αSMA+ staining. The authors did not investigate TGF-β or 
TIMP levels, but did report a three-fold increase in MMP-12 expression (p<0.05). As previously 
discussed, MMP-12 is expressed by restorative macrophages, so it possible that MSC exert their 
anti-fibrotic effect in this experiment by influencing macrophage polarity, though the authors did 
not investigate this further.   
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1.7. Do BM-MSC contribute to fibrosis?  
The contribution of BM-derived cells to fibrogenesis has been a contentious issue, and significant 
studies are summarised in table 1.3. In an early study, Baba et al suggested BM-derived HSC might 
co-localise with scar tissue after CCl4 injury. They transplanted 1x105 unsorted whole bone marrow 
cells from GFP transgenic mice (GFP-tg) into irradiated WT mice. Recipient mice were sacrificed 
after 8 weeks of CCl4 injury. 31.7% of isolated GFAP+ and desmin+ HSC from uninjured livers 
expressed GFP. In injured liver, αSMA-expressing cells co-localised with GFP near areas of scar, 
but this was not quantified, and a functional contribution to fibrosis was not described141.  
 
In an elegant series of gender mismatched BM reconstitution studies Russo et al showed that BM 
cells contribute to HSC, hepatic myofibroblasts, and to collagen expression using 2 models of 
murine hepatic injury (CCl4 and TAA)142. The group demonstrated BM reconstitution after they 
injected 1x106 un-sorted BM cells from male donors into age-matched female recipients. They 
used fluorescent in situ hybridisation (FISH) to reveal that 14% of HSC were of BM (male) origin in 
the absence of injury, which increased to 70% after 12 weeks of CCl4 injury. Myofibroblast numbers 
(defined by the expression of αSMA – activated HSC) increased with duration of injury to 
approximately 400 cells per unit area (10 high power fields), but the proportion of BM-derived 
myofibroblasts remained constant at around 70%, suggesting an axis of renewal from the BM. 
Using BM cells with a β-gal reporter under the control of a α2(I)collagen enhancer they 
demonstrated the presence of β-gal expressing cells around areas of scarring in the liver after 12 
weeks of CCl4 injury. In situ hybridisation for mRNA for pro(α1)I collagen and Y chromosome along 
with IHC for αSMA, confirmed collagen expression in BM-derived cells. The authors went on to 
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establish whether the BM cells functionally contributed to the fibrotic phenotype in liver injury; 
irradiated mice received BM transplants from Col-1a1rr mice, which have a mutated collagenase-
resistant collagen, and on injury wild-type mice developed extensive peri-cellular fibrosis similar 
to that seen in the Col-1a1rr mice. The phenotype of fibrosis, as measured by histopathological 
assessment and hydroxyproline assay, was markedly greater than that seen in mice receiving wild 
type (WT) BM. Notably, the proportion of myofibroblasts of BM origin from Col-1a1rr mice was 
63% compared to 49% in mice receiving BM from WT mice, suggesting that the genotype of the 
BM-derived myofibroblasts could influence their homing/engraftment to the liver as well as the 
injured organ’s fibrotic response. To determine which cells within the BM were responsible the 
authors performed a series of gender mismatched reconstitution studies demonstrating that 
marrow stromal and not haematopoietic stem cells were responsible for BM-derived 
myofibroblasts in the liver. It is not clear how similar the marrow stromal cells used in this study 
were to MSC, as data were not provided on cell surface marker expression or tri-lineage 
differentiation.  
 
The same group also published a case series of male patients who had received liver transplants 
from female donors, who had then gone on to require another transplant for cirrhosis143. 
Explanted liver tissue was analysed for Y chromosome by in-situ hybridisation together with IHC 
for HSC and myofibroblast and identified that 14-45% of myofibroblast were deemed to be of 
recipient origin. Similarly, they showed 25% of hepatic myofibroblasts found in the explant of a 
female cirrhotic patient who had previously received an HLA-matched BMT from a male donor for 




More recently, Li et al reconstituted the BM of irradiated WT mice with enhanced GFP (EGFP) 
transgenic whole BM. They defined BM-derived myofibroblasts as αSMA+ cells that also expressed 
EGFP and showed that the proportion of BM-derived myofibroblasts increased with duration of 
injury up to 80% after 6 weeks of twice-weekly IP CCl4 in C57Bl/6 mice. They then used 1.2x106 
MSC (plastic-adherent; CD90+, CD105+, CD166+, CD34-, CD45-, CD14-) from EGFP transgenic mice 
to reconstitute the BM of irradiated WT mice (with 1.08x107 whole BM from a WT donor) and 
demonstrated that after two weeks of CCl4 injury 70% of myofibroblasts were of BM-MSC origin. 
Furthermore, they showed that BM cell homing to the injured liver was sphingosine-1-phosphate 
(S1P) dependent such that blockade of the S1P receptor 3 with suramin reduced BM cell homing 
by 80%144. Notably, the effect of this blockade on fibrosis was not reported, and no direct 
contribution to fibrosis was reported in this study. Nevertheless, Kong et al repeated Li’s 
experiment using EGFP+ MSC reconstitution of irradiated BM in WT mice, and blocked the S1P 
dependent pathway with the partial S1P agonist FTY720145. In the setting of CCl4 injury, they 
demonstrated a relative reduction in the mRNA expression of αSMA (88% reduction), Colα1(I) 
(75%), Colα1(III) (60%), Tgf-β1 (60%), compared to mice untreated with FTY720. They repeated the 
experiment using SCID-beige mice (an immunodeficient mouse affecting T-, B- and NK-cell 
populations) to eliminate any signal from FTY720 action on effector leucocytes and found very 
similar results suggesting that BM-derived stromal cells contribute to liver fibrosis.   
 
Di Bonzo et al irradiated NOD/SCID mice prior to tail vein infusion with human MSC to attain BM 
reconstitution, although this was not confirmed. MSC were plastic-adherent and had a 
36 
 
characteristic CD antigen signature (CD45, CD14 (low); CD106, CD16 (med); CD29, CD90, CD44, 
CD105 (high)) with tri-lineage differentiation properties. After chronic injury with 6 weeks of CCl4 
they demonstrated 7% of liver cells were positive for human HLA-I antigens146, of which half 
exhibited a myofibroblast morphology and were either αSMA or GFAP positive146. It was unclear 
what proportion of the total HSC and myofibroblast populations were BM-derived although the 
contribution was considerably less than had been described in other papers which may reflect the 
xenogeneic nature of the study.  
 
In contrast to Russo et al who reported that it was BM stromal cells and not haematopoietic stem 
cells that contributed to liver fibrosis, Miyata et al reported a dominant role for haematopoietic 
stem cells147. They transplanted haematopoietic stem cells from transgenic EGFP mice into 
irradiated mice, and demonstrated that after 12 weeks of injury with CCl4, up to 60% of the GFP-
positive cells in the liver were myofibroblasts. Data on the percentage of HSC and myofibroblasts 
that were derived from the haematopoietic lineage was not provided.
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Functional contribution to fibrosis; Key conclusions 
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• 31.7% of isolated HSC expressed GFP in uninjured liver 
• IHC of uninjured liver showed GFP cells expressing GFAP and desmin (not αSMA) 
• GFP-cells co-localised with αSMA in injury. 
• No functional contribution to fibrosis demonstrated 
Russo142; 
2006 
Unsorted whole BM cells;  















• BM-derived HSCs defined as Y-chromosome positive and GFAP+ 
• 14% of HSCs were BM-derived in uninjured liver 
• Proportion of BM-derived HSC increased with duration of injury (70% at 12 weeks), 
yet total numbers of GFAP+ cells remained constant with increasing duration of 
injury (around 380 cells/ unit high power field area). 
• 69% of MFs (αSMA) in injury were of BM origin – this remained constant with 













• No αSMA+ cells in recovery; the proportion of GFAP+ cells was as it was before 
injury, with 16% being of BM origin; a desmin+ cell group congregated around 
residual scarring - 42% of which were of BM origin - indicating the heterogeneity 
of expression, and how this may be source-dependent 
Unsorted Whole BM cells; 
Male;   
col1a2 mice - express β-gal 
(reporter), under control of 












• Cells expressing β-gal confirmed to be of BM origin (Y-chromosome co-
localisation); more BM derived αSMA cells (226 cells / unit area) than BM-derived 
β-gal cells (161 cells / unit area) – suggesting not all αSMA cells express collagen.  
• Other: ISH for pro(α1)I together with FISH for Y-chromosome used to demonstrate 
collagen transcription in BM derived cells. 
• Both these results suggest a BM-cell derived collagen expression 
Unsorted Whole BM cells; 
Male;   
Col1α1rr mice - mutated, 
collagenase resistant 
collagen expression 
1x106 IP CCL4 







• Test mice had a more profound and characteristic peri-cellular fibrosis compared 
to mice with WT BM: Hyp - 2.5mM/mg vs. 2.0mM/mg.  
• 63% of MF were of BM origin compared to 49% in mice receiving BM from WT 
mice. This suggested that the genotype of the BM-derived MF could influence the 
injured organ’s fibrotic response. 
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• 53% of MF were of BMMSC origin 
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• 7% of cells in liver were HLA+, after 6 weeks of injury.  
• Approximately half (3.33% of total) of HLA+ cells had MF morphology and were 
either GFAP+, or αSMA+. 
• No functional contribution to fibrosis demonstrated. 






Unsorted whole BM cells; 
transgenic EGFP mice 










• EGFP+/αSMA+ co-expressing cells defined BM derived MF 
• Proportion of MF of BM origin increased with duration of injury - 80% with 6 
weeks of CCL4 injury 
BM-MSC (EGFP+ mice) + 
Whole BM (EGFP- mice) 
1.2x106 BMMSC; 
1.08x107 whole 
BM cells.  




• 70% of the MFs were BM-derived, suggesting a predominant contribution from 
BMMSC 
• Mice were injured in the presence or absence of suramin (S1P receptor 3 blocker). 
Suramin led to decreased EGFP+ cells in liver (80% relative reduction), though no 
data on how this affected liver fibrosis was offered 
MSC were PA.  
Immunophenotyping: pos – CD44, CD105, 
CD166; neg – CD34, CD45, CD14  
Kong145; 
2014  
BM-MSC (EGFP+ mice) + 
Whole BM (EGFP- mice) 
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• Mice were injured in the presence or absence of FTY720 (blocking partial S1P 
agonist). FTY720 led to relative reduction in the mRNA expression of αSMA (88% 
reduction), Colα1(I) (75%), Colα1(III) (60%), TGF-β1 (60%).  
• Similar results in ICR, and SCID-beige mice MSC were PA.  
Immunophenotyping: pos – CD44, CD105, 
CD166; neg – CD34, CD45, CD14 
Hi’yama148; 
2009  
Unsorted whole BM cells; 
transgenic mice harbouring 
tissue-specific enhancer/ 
promoter sequences of α2(I) 
collagen gene linked to 
EGFP or LUC 
5x106 cells  Mice; 
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• Activation of the Col1α2 promoter was assessed by confocal microscopic 
examination detecting EGFP signals and LUC activity by assays of liver 
homogenates.  
• After CCl4 injury or BDL only negligible contributions of the BM to collagen 
production demonstrated.  
• BM cells did localise to areas of scarring, but they did not produce collagen, and 







Unsorted whole BM cells; 
transgenic LratCre mGFP, 
mTom. LratCre faithfully 
expressed in HSC;  
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• Authors did not detect LratCre-labelled HSCs in normal liver or fibrotic livers after 
BDL or chronic CCL4.  
• HSC isolated from these mice did not express mGFP, whereas controls did show 
abundant mGFP expression.  
• These data strongly suggest the HSC population is from liver resident cells.  
• These data were in the context of other data to confirm HSC as the predominant 




Adapted from Haldar et al.45 
All studies involved BM irradiation and reconstitution with donor cells. All cell transplantation was done by tail vein injection. αSMA, alpha smooth muscle actin;  BDL, 
bile duct ligation; BM, bone marrow; BMT, BM transplant; CCl4, carbon tetrachloride;  FACS, fluorescence-activated cell sorting; (F)ISH, fluorescence in situ hybridisation; 
GFAP, glial fibrillary acidic protein; GFP, green fluorescent protein; HLA, human leukocyte antigen; HSC, hepatic stellate cell; ICR, Institute of Cancer Research; IP, 
intraperitoneal; LUC, luciferase; MF, myofibroblast; PA, plastic adherent; S1P, sphingosine-1-phosphate; SCID, severe combined immunodeficiency; TGFβ, tissue growth 




In contrast to the aforementioned studies, Higashiyama et al148 reported no role for BM-derived 
cells in the generation of liver fibrosis. In their studies BM of wild-type mice was replaced by cells 
obtained from transgenic animals harbouring tissue-specific enhancer/promoter sequences of 
α2(I) collagen gene (Colα1-2) linked to EGFP or firefly luciferase (LUC) gene. Expression of collagen 
by such cells as would occur after adoption of a myofibroblast phenotype would result in EGFP 
fluorescence or luciferase expression. After CCl4 or BDL injury, only negligible contributions of the 
bone marrow to collagen production were demonstrated in either model. BM cells did localise to 
areas of scarring, but they were not collagen producing, and did not stain for macrophage or 
Kupffer cell markers. A further novel fate-tracing study by Mederacke (using BM reconstitution of 
irradiated mice with whole BM from mTom/LratCre transgenic mice; LratCre faithfully reports 
HSCs) demonstrated that resident hepatic stellate cells were not of bone marrow origin in either 
CCl4 or BDL injury47. As with Higashiyama, BM cells (mTom+) were seen to populate scarred areas 
but the identity of these cells was not further characterised, although they did not report LratCre.  
 
Reconciling the disparate findings between these studies is challenging and possibly reflects 
differences in BM reconstitution, models of liver injury and methods used to confirm cellular 
identities. In situ hybridisation and IHC co-staining can lack sensitivity and specificity although 
confocal imaging as used by Russo et al provides greater confidence. Additionally, studies relying 
on αSMA production as a surrogate for collagen-producing cells may over-estimate the functional 
contribution of such cells to liver fibrosis as not all αSMA positive cells produce collagen149. 




1.8. Do liver resident MSCs contribute to fibrosis? 
A very recent study by Kramann et al identified a subpopulation of PDGFβ receptor (PDGFβR)-
positive pericytes that express Gli1, and that can be found in all solid organs151. Gli1+ PDGFβR+ 
cells demonstrate classical hallmarks of being MSC; they had the potential for tri-lineage 
mesenchymal differentiation regardless of their origin, and expressed CD29, Sca1, Cd44, Cd105, 
but not CD31, CD45 and CD34. The authors established that resident perivascular Gli1+ cells 
underwent proliferative expansion after injury and differentiated into myofibroblasts in vivo, the 
extent of which varied across organs. In a model of renal fibrosis (unilateral ureteric obstruction), 
45% of myofibroblasts were of Gli1 origin, whereas only 39% of αSMA+ cells were of Gli1 origin 
after a CCl4-induced hepatic fibrosis. Nevertheless, they demonstrated that a Gli1 knockout led to 
a 50% amelioration of renal fibrosis in the UUO model, although the equivalent experiment in 
liver fibrosis was not reported. Though the idea of perivascular cells contributing to fibrosis in 
different organ systems is not novel152, this was the first genetic fate-tracing experiment to 
conclusively demonstrate that a resident population of MSC can react in this way. Kramann et al 
also demonstrate that neither circulating nor BM-derived Gli+ cells contributed to the 
myofibroblast pool in kidney fibrosis by the use of both a BM transplant and a parabiosis model.  
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1.9. Aims of the research 
The contribution of endogenous MSC to hepatic fibrogenesis remains contentious due to 
conflicting reports. In contrast, there are no convincing reports of exogenous MSC contributing 
to liver fibrosis; rather, their anti-fibrotic potential makes them an attractive agent, apparently 
exploiting mechanisms that modulate inflammation, induce the degradation of ECM, and switch 
off the drivers of fibrosis (Figure 1.2). The therapeutic potential of MSCs in the regression of 
fibrosis after the cessation of injury has not yet been comprehensively investigated and is clinically 
relevant in an era of better cure rates of hepatitis C, and for cirrhotic patients with alcoholic liver 
disease who have maintained abstinence. 
 
The primary aim of this body of work is to determine the therapeutic effect of MSC therapy on 
established liver fibrosis. In order to do this, I will: 
• Delineate the time-course and ascertain the reproducibility of fibrosis regression using 
two toxin-mediated models of murine liver fibrosis 
• Characterise human UCT-MSCs provided by industry collaborators 
• Determine the effect of MSC therapy on the resolution of established liver fibrosis and on 
fibrogenesis 
• Detail the bio-distribution and persistence of peripherally intravenously injected MSCs in 
mice subject to chronic hepatic fibrosis using CryoVizTM imaging technology.  
• Ascertain any effect of MSCs on LX2 (human stellate cell line) biology in vitro in an effort 




Materials and Methods 
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2.1. Isolation of mesenchymal stromal cells from human umbilical cord 
tissue 
Orbsen Therapeutics Limited (OTL) (Galway, Ireland) provided human UCT-derived syndecan 2-
positive (S2)-cells for use. They isolated, enriched and cultured the cells for use by previously 
described methods.153 Briefly, human UCT was collected from Caesarean deliveries by Tissue 
Solutions Ltd. (Glasgow, UK) in accordance with local legal and ethical requirements. Tissue was 
transported to OTL and processed for cell isolation within 48 hours of delivery. Whole tissue was 
manually dissociated, and enzymatically digested by collagenase 1, hyaluronidase 1 and DNase 
for 2 hours at 37°C. The resulting single cell suspension was stained with CD362-APC 
(allophycocyanin) (clone 305515, 1:50 dilution; R&D systems, UK). After 30 minutes at 4°C, the 
cells were washed and suspended in magnetic-activated cell sorting (MACS) buffer (80µL/107 
cells). MACS buffer is phosphate buffered saline (PBS) with 2% heat-inactivated FCS, and 1mM of 
ethylenediaminetetraacetic acid (EDTA). Anti-APC beads (20µL/107 cells) were added to the cells 
for 15 minutes at 4°C. The stained cells were then isolated using MS columns (Miltenyi Biotec; UK). 
Each cell fraction was counted, seeded for expansion (as described in section 2.2) and 





2.2. Storage, culture, subculture and use of human MSC 
Cells were packaged and received on dry ice in 1mL cryovials containing 1x106 cells in 1mL of 
serum with 10% dimethyl sulfoxide (DMSO), and promptly stored in liquid nitrogen until needed. 
For use, cells were thawed in a 37°C water bath, and contents transferred to a 15mL conical-
bottom polypropylene tube containing 12mL of pre-warmed complete MSC culture medium at 
37°C. Complete MSC culture medium was prepared in a biological safety cabinet and consisted 
of Minimum Essential Media – alpha with GlutaMAXTM supplement (32561029; Gibco, UK) (αMEM), 
with 10% heat-inactivated FCS (F9665; Sigma-Aldrich, UK), 1% penicillin/streptomycin 
(10,000U/mL; 15140122; Gibco, UK) and 1ng/mL of recombinant human FGF (100-18B; Peprotech, 
UK)  and stored at 4°C.  
 
The suspension was then centrifuged for 5 minutes at a relative centrifugal force of 400g at 
20±5°C. The supernatant was subsequently discarded, and the pellet gently re-suspended in 5mL 
of complete MSC culture medium by flicking the bottom of the tube and using a Pasteur pipette. 
The cell suspension was then transferred to a T-175cm2 cell culture flask with a vented cap 
containing 25mL of pre-warmed complete MSC culture medium (total volume = 30mL). Cells were 
then incubated at 37°C in a hypercapnic (5% CO2) atmosphere. The flasks were inspected for 
cellular confluence and contamination daily, and the spent medium changed every 2-3 days or 
earlier if a significant pH change was indicated by the phenol red (i.e. if it turned yellow). 70-80% 
confluence could be expected at day 4 or 5, at which point the cells could be sub-cultured for 
expansion if required, or prepared for infusion. Passage 4 cells were used for all experiments. For 
either, the medium was removed, and the cells washed with 10mL of sterile PBS, twice. The cells 
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were then bathed in 10mL of pre-warmed (to 37°C) 1X TrypLETM Express Enzyme (12605010; Gibco, 
UK), and incubated for 5 minutes in a 37°C incubator. The contents of the flask were then 
examined using an inverted light microscope to ensure the cells had dislodged from the surface 
of the flask. If not, the flask contents were incubated for a further 2 minutes, and then re-examined. 
The trypsin was neutralised by adding 20mL of complete MSC culture medium to the flask, and 
the cell suspension then aspirated and transferred to a 50mL conical-bottom polypropylene tube. 
They were centrifuged for 5 minutes at a relative centrifugal force of 400g at 20±5°C. The 
supernatant was discarded, and the pellet re-suspended in 5mL of complete MSC culture medium. 
After ensuring adequate re-suspension of the cells, 20μL were mixed with an equal volume of 
0.4% trypan blue solution (15250061; Gibco, UK). 10μL of the cell suspension with trypan blue 
mixture was applied to the haemocytometer affixed with a moistened glass coverslip. Under an 
inverted light microscope using 10X objective, the live cells (unstained cells) were counted in each 
of the 4 corner sets of 16 squares using a hand tally counter: 
 
The number of viable cells was then calculated: 
The sum of viable cells in the 4 corner sets of 16 squares divided by 4 = X.  
X multiplied by 104 to give the number of cells per mL = y 
y multiplied by dilution factor with trypan blue (=2), which is then multiplied by volume of original 




The remaining suspension was then spun in a centrifuge for 5 minutes at a relative centrifugal 
force of 400g at 20±5°C. The supernatant was discarded and cell pellet re-suspended fit for 
purpose.  
• For sub-culturing cells the pellet was re-suspended in complete MSC culture medium; 
1x106 cells in suspension were then be transferred to a T-175cm2 cell culture flask 
containing pre-warmed complete medium as previously described. 
• For long-term storage of cells, they were suspended in Cryostor® cell cryopreservation 
medium CS5 (CS299; Sigma Aldrich, UK) at a density of 1x106 cells/mL, and 1mL transferred 
to 1.5mL cryovials. The cryovials were frozen at -80°C in a Mr. FrostyTM Freezing Container 
(51000001; Thermo Scientific, UK) to ensure a cooling rate of -1°C/minute, before they 
were transferred to liquid nitrogen storage.  
• For preparation of cells for injection into mice, the pellet was re-suspended in an 
appropriate volume of sterile 0.9% saline to give a final concentration of 5c/mL, where c = 
number of cells being infused per mouse. 300μL of cell suspension in saline was transferred 
to a 1.5mL Eppendorf tube, and transferred on ice to the Biomedical Services Unit (BMSU) 
(where the mice were housed). The cells were re-suspended by gentle flicking of the 
Eppendorf tube, followed by gentle mixing by the use of a 1mL pipette. 200μL (containing 
number of cells = c) of the cell suspension was then injected via lateral tail vein in a pre-
warmed mouse (37°C), using an appropriate micro-injector syringe (500µL syringe) with a 
28-gauge needle. The mice were observed for acute deterioration for 15 minutes before 
being housed for standard observations and follow up. The duration from bench (when 
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cells suspended in saline in biological safety cabinet) to mouse (when tail vein injection 
performed) was kept to less than 45 minutes.  
 
2.2.1. Preparation and storage of MSC conditioned medium 
Syndecan-2 selected MSCs at passage 4 were seeded in 6-well plates at a density of 5x104 cells 
per well and incubated as previously described in 2mL of MSC complete culture medium without 
FGF supplementation. The media were changed every 48 hours, or earlier in the event of a media 
colour change. Cells were grown to a confluence of 60-80%, which typically required 2-4 days 
before the spent media was exchanged for fresh Dulbecco’s Minimum Essential Media with 
GlutaMAXTM supplement (11584456; Gibco, UK) (DMEM) with 10% FCS. After 24 hours, the media 
were collected via aspiration, transferred to a 50mL conical-bottom polypropylene tube and 
centrifuged for 5 minutes at a relative centrifugal force of 400g at 20±5°C. The supernatant was 
then carefully aspirated, and diluted in fresh MSC culture medium (without FGF) as required, and 
stored as 1mL aliquots in 1.5mL Eppendorf tubes at -80°C for later use. On the day of use, the 
conditioned media were thawed at 37°C, and used. Unused conditioned media were discarded 






2.3. Characterisation of MSC 
2.3.1. Characterisation of MSCs by flow cytometry 
MSCs were cultured to passage 3 in complete medium as described, dislodged with trypsin, and 
suspended to a concentration of 1x107 cells/ mL of flow cytometry (FACS) buffer (same as MACS 
buffer). The BD StemflowTM Human MSC Analysis Kit (562245; BD biosciences, UK) was set up as 
per manufacturer’s instructions. 1x106 cells in 100µL of FACS buffer were added to FACS tubes, 
and antibodies were added as described in Table 2.1. The cells were incubated for 30 minutes at 
4°C, shielded from light 
 
On completion, the samples were washed twice in 2mL of ice-cold FACS buffer and centrifuged 
for 5 minutes at a relative centrifugal force of 400g at 4°C. The resulting pellets were stained with 
a live-dead marker (conjugated with APC Cy7; 1µL in 1000µL PBS): incubating in 100µL for 30 
minutes at 4°C shielded from light. The samples were then washed twice as already described, 
and resuspended in 500µL of FACS buffer, passed through a 50µm filter before analysing on a 

















As per BD StemflowTM Human MSC Analysis Kit manufacturer’s instructions. Volumes of antibodies were added to 
1x106 cells in 100µL of FACS buffer. 
 
MSCs from OTL were also examined for their expression of S2/CD362. MSC from each batch 
received were cultured to passage 3, washed and suspended to a density of 1x105 cells/ 100µL of 
FACS buffer. 1x105 cells were loaded per well of a 96-well plate. 2µL of the human CD362 APC-
conjugated antibody (FAB2965A; R&D systems, UK) were added to each of the test wells. An 
unstained control and an appropriate isotype control were used – 1µl of APC-conjugated 
monoclonal rat IgG2b (IC013A; R&D systems, UK). The cells were left to incubate for 30 minutes 




Single colour compensation CD90 FITC 5µL 
Single colour compensation CD44 PE 5µL 
Single colour compensation CD105 PerCP-Cy 5.5 5µL 
Single colour compensation CD73 APC 5µL 
Live-dead single colour 
compensation 
Live-dead APC Cy7 1µL 
    
Unstained control Unstained - - 
Positive and negative isotype 
control cocktails, 
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at 4°C shielded from light, then washed twice in FACS buffer, and finally suspended in 500µL of 
FACS buffer before analysing.  
 
2.3.2. Characterisation of MSC by adipogenic differentiation 
2.3.2.1. Preparing adipogenic differentiation medium 
Complete adipogenic medium was a product of the StemPro® Adipocyte Differentiation Kit 
(A1007001; Gibco, UK), whereby 90mL of StemPro® Adipocyte Differentiation Basal Medium was 
added to 10mL of StemPro® Adipocyte Supplement and gentamycin (15750060; Gibco, UK) at a 
concentration of 5µg/mL. 
 
2.3.2.2. Stimulating adipogenic differentiation 
MSC were seeded at passage 3 in a 12-well tissue culture plate at a density of 5x104 cells/well, in 
complete MSC culture medium (2mL/well) and cultured as described in section 2.2. At 70-80% 
confluence, the spent media were removed, and the cells washed in a working volume of sterile 
PBS, before replacing with pre-warmed complete adipogenesis differentiation medium. The cells 
were checked daily for differentiation, and evidence of fat vacuoles. The spent media were 
aspirated and discarded every 3 days, and replaced with complete adipogenesis differentiation 
medium. The culture continued for 14 days before the cells were washed twice in sterile PBS and 
fixed in 2mL of 10% neutral-buffered formalin. Following 30 minutes of incubation at room 
temperature, the cells were washed twice in sterile PBS, and stored at 4°C bathed in PBS until such 
time as to perform Oil Red O staining.  
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2.3.2.3. Oil Red O staining  
Oil Red O (00625; Sigma Aldrich, UK) was dissolved in 99% isopropanol at a concentration of 3g/L 
to make a stock solution. A working solution was made on the day of staining by diluting the stock 
solution in distilled water (1.5:1) and filtering through Whatman paper (WHA10010155, Aldrich, 
UK). Fixed cells were washed in PBS. 2mL of 60% isopropanol was added to each well. After 5 
minutes, the isopropanol was aspirated and discarded, and 2mL of the freshly-prepared oil red O 
working solution was added to each well. After 15 minutes, the working solution was discarded, 
and the cells were washed twice in distilled water to ensure the water runs clear. 2mL of filtered 
25% Mayer’s haematoxylin (008011; ThermoFisher Scientific, UK) was added as a nuclear 
counterstain to the wells. After 5 minutes, the counterstain was aspirated and discarded. The cells 
were washed with warm tap water, and the plate/wells kept wet to ensure the integrity of the lipid 
vacuoles. The cells were then visualised using a phase contrast inverted light microscope at 10X 
and 20X magnification.  
 
2.3.3. Characterisation of MSC by chondrogenic differentiation 
2.3.3.1. Preparing chondrogenic differentiation medium 
An “incomplete” and “complete” chondrogenic media were prepared from the Human 
Mesenchymal Stromal Cell differentiation BulletKitTM – chondrogenic (PT-3003; Lonza, USA). An 
incomplete chondrogenic medium was prepared by adding SingleQuotsTM of dexamethasone, 
ascorbate, insulin-transferrin-selenium supplement, gentamycin, amphotericin-B, sodium 
pyruvate, proline and L-glutamine to 185mL of chondrogenic differentiation basal medium. 
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Complete chondrogenic medium was made on the day of intended use by adding recombinant 
human TGFβ3 (100-36E, Peprotech, USA) to incomplete medium at a concentration of 10ng/mL. 
 
2.3.3.2. Stimulating chondrogenic differentiation 
At passage 4, 2.5x105 MSC in complete MSC culture medium were transferred to a 15mL conical-
bottom polypropylene tube and washed in sterile PBS, by gentle resuspension and centrifuging 
at a relative centrifugal force of 150g at 20±5°C for 5 minutes. The cells were then washed in 
incomplete chondrogenic medium, and the supernatant discarded from the resultant pellet. The 
cells were resuspended in 500µL of freshly-made complete chondrogenic medium, and left to 
incubate at 37°C in a hypercapnic (5% CO2) atmosphere. The lids of the tubes were not fully 
tightened to allow gas exchange. A pellet was allowed to form, and the cells were left undisturbed 
for 48 hours. The spent medium was aspirated and discarded every 3 days, and replaced with 
freshly made complete chondrogenic medium; the bottom of the tube was gently agitated / 
flicked every 2-3 days to ensure the pellet remained free-floating. After 28 days of culture, the 
spent medium was fully aspirated, and the pellet embedded in PolyFreeze Tissue Freezing Medium 
(SHH0026; Sigma, UK), and snap-frozen in liquid nitrogen. The pellet was stored in a -80°C freezer, 
until cryo-sectioning to a thickness of 4µm.  
 
2.3.3.3. Toluidine Blue staining  
0.1% toluidine blue solution was prepared in acetic acid–sodium acetate buffer solution (pH 4.0). 
The buffer solution was prepared and pH balanced by adding 8.47mL of glacial acetic acid 
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(10060000; Fisher Scientific, UK) to 1.53mL of sodium acetate (S2889; Sigma-Aldrich, UK) solution 
(from anhydrous). Frozen sections were cut to 4μm thickness and fixed onto X-tra® glass 
microscope slides (3800050; Leica, UK). The slides were defrosted for 30 minutes. A wax boundary 
was drawn around the tissue on the slide. 200µL of 0.1% toluidine blue solution was applied to 
the sample. After 2 minutes, the slides were rinsed in tap water until it was running clear. The 
slides were serially dehydrated in 99% ethanol thrice, followed by clearing in xylene thrice. Each 
rinse was undertaken for 3 minutes. The slides were mounted with coverslips using non-aqueous 
DPX mounting medium (1005790500, EMD Millipore, UK).  
 
2.3.4. Characterisation of MSC by osteogenic differentiation 
2.3.4.1. Preparing osteogenic differentiation medium 
Complete osteogenic medium was a product of the StemPro® Osteogenesis Differentiation Kit 
(A1007201; Gibco, UK), whereby 90mL of StemPro® Osteocyte Differentiation Basal Medium was 
added to 10mL of StemPro® Osteocyte Supplement and gentamycin (15750060; Gibco, UK) at a 
concentration of 5µg/mL. 
 
2.3.4.2. Stimulating osteogenic differentiation 
MSC were seeded at passage 3 in a 12-well tissue culture plate at a density of 1x104 cells/well, in 
complete MSC culture medium (2mL/well) and cultured as described in section 2.2. At 60-70% 
confluence, the spent media were removed, and the cells washed in a working volume of sterile 
PBS, before replacing with pre-warmed complete osteogenesis differentiation medium. The cells 
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were checked daily for differentiation, and contamination. The spent media were aspirated and 
discarded every 3 days, and replaced with fresh complete osteogenesis differentiation medium. 
The culture continued for 14 days before the cells were washed twice in sterile PBS and fixed in 
2mL of 10% neutral-buffered formalin. Following 30 minutes of incubation at room temperature, 
the cells were washed twice in water.   
 
2.3.4.3. Alizarin Red-S staining  
1% Alizarin Red S solution was prepared by diluting 1g of Alizarin Red S powder (A5533; Sigma-
Aldrich, UK) in 100mL of distilled water, and pH adjusted to 4.1-4.3 using sodium hydroxide 
solution. The solution was filtered as previously described prior to use. Formalin-fixed cells in a 
12-well plate as detailed in section 2.3.4.2 were washed in water. 0.5mL of the 1% Alizarin Red S 
solution was added to each well, and the plate left to agitate on a gently shaking platform for 30 
minutes. The staining solution was then removed, and the wells washed in water and left to air 





2.4. Animal Husbandry 
Male C57Bl/6 mice were purchased from Charles River UK Ltd. (Margate, UK) and acquired at an 
age of 7-9 weeks. They were housed and cared for at the University of Birmingham Biomedical 
Services Unit (Birmingham, UK) by standard care protocols. All procedures on the animals were 
carried out in accordance with the Animals (Scientific Procedures) Act 1986, UK, under project 
licence 70/7707 (care of Professor Philip Newsome) and underwent ethical review prior to 
approval and enactment. Male C57Bl/6 mice, aged between 8-10 weeks  were used for the 
experiments. Mice were clinically assessed and weighed at least weekly throughout experiments. 
A 10% decrease in weight was deemed significant and warranted the mouse to be excluded from 
further injury and thus the experiment. Other signs of clinical distress were assessed during the 
standard observation period. If mice were found to be suffering and the situation deemed 
unsalvageable, the mice were euthanised. Otherwise, mice would be euthanised per protocol as 
scheduled by the experimental design (see relevant results sections)  
56 
 
2.5. Inducing toxin-mediated hepatic injury and fibrosis  
2.5.1. Carbon tetrachloride 
Protocols of chronic hepatic injury by CCl4 have been conducted at the University of Birmingham 
BMSU previously154; a feasibility experiment was therefore not required. 
 
CCl4 (289116; Sigma-Aldrich, UK) was diluted 1:3 with mineral oil (M8410; Sigma, UK) in sterile 
conditions (biological safety cabinet), and transported to the BMSU in an autoclaved glass 
container. The mice were subject to twice-a-week IP injections of this solution at a dose of either 
1 or 2μL/g body weight (b/w) for 6 weeks (12 doses in total), by the use of an appropriate syringe 
and a 28-30-gauge single-use needle. The mice were clinically assessed and weighed prior to 
every injection to instruct correct dosing. They were closely observed for any signs of acute clinical 
deterioration for 15 minutes after injection, before being housed for standard observations and 
follow up.  
 
2.5.2. Thioacetamide 
Protocols of chronic hepatic injury by TAA have not been conducted at the University of 
Birmingham BMSU previously. As such, small-scale feasibility studies were conducted to 
determine the safety of the proposed protocols. TAA (163678; Sigma-Aldrich, UK) was diluted in 
sterile UV treated water to a final concentration of 20mg/mL in a biological safety cabinet (stock 




2.5.2.1. Intraperitoneal thioacetamide 
The stock solution was transported to the BMSU in an autoclaved glass container. Mice were 
subject to IP injection of TAA (150mg/kg bodyweight) by the use of an appropriate syringe and a 
28-30-gauge single-use needle155–157. Following 15 minutes of close observation, the mice were 
housed for standard observations and follow up.  
 
2.5.2.2. Oral thioacetamide 
The mice were housed and provided chow as per usual BMSU protocols, but their drinking water 
was substituted for TAA solution. Mice were given TAA in 1:5 diluted fruit squash (Robinson’s 
orange and pineapple, single strength, no added sugar) at a dose of 100mg/L for 3 days, and then 
300mg/L for 3 days, followed by 600mg/L for the rest of the duration (up to 16 weeks) (diluted 
from stock of 20mg/mL). Mice were weighed and clinically assessed for signs of distress daily (see 
Section 2.4 for exclusion criteria). The drinking bottles were weighed daily to determine adequate 
oral liquid intake.  
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2.6. Investigating the therapeutic effect of MSCs in vivo 
The therapeutic effects of MSCs on the resolution of established fibrosis, or fibrogenesis were 
examined by injecting MSCs at different time points. These details are described in the 
experimental design sections of the results chapters. MSCs or a matched volume of their carrier 
(sterile 0.9% saline) were injected into the tail veins of experimental mice as described in section 




2.7. Mouse euthanasia; tissue and blood collection for analysis 
Upon completion of an experiment, blood and tissue were collected from mice by the following 
methods: 
o Blood and serum: Cardiac puncture under terminal anaesthesia by isoflurane. Up to 
1000μL of blood was aspirated through a 25-gauge needle with an appropriate syringe 
and collected in a 1.5mL Eppendorf tube. The mice were immediately euthanised by 
cervical dislocation, and death confirmed. The clotted blood was centrifuged at 10,000 
rpm for 10 minutes. The serum supernatant was aspirated and re-centrifuged under the 
same settings to clarify the supernatant from any cell debris. The serum was then collected 
and stored at -80°C.  
• Liver: Abdominal contents were exposed by sleeve laparotomy and reflection. For cases 
intended for flow-cytometric (and not hydroxyproline) analysis the inferior vena cava was 
cannulated with a 26-gauge needle to flush the liver with 10mL of PBS. Swelling and pallor 
of the liver would confirm adequate flushing. The portal vein was cut to allow the flushed 
contents to escape the circulation.  The liver was subsequently surgically dissected from 
the abdomen, and the gallbladder rejected.  
o The left lobe of the liver was placed in 10% neutral buffered formalin – for formalin-
fixed paraffin embedding OR placed in RPMI 1640 Medium, GlutaMAXTM 
Supplement, HEPES (RPMI) with 2% FCS (7240021; Gibco, UK) for flow cytometry.  
The other lobes were snap-frozen on liquid nitrogen: 




o The right lobe was used for hepatic hydroxyproline assay 





2.8. Flow cytometry analysis for myeloid cells 
2.8.1. Isolation of immune cells from mouse liver 
The left lobe of experimental mouse livers was collected in RPMI with 2% FCS as described in 
section 2.7 from the BMSU on ice. Upon return to the laboratory, all processing was undertaken 
in a biological safety cabinet. The liver tissue was manually homogenised using a sterile plunger 
in an appropriately sized vessel (6-well plate). The homogenised tissue was then passed through 
a 70µm cell strainer with RPMI/2%FCS in to a 15mL conical-bottom polypropylene tube, which 
was topped up with RPMI/2%FCS and centrifuged at 2000 RPM at 4°C for 5 minutes. The 
supernatant was discarded, and the pellet was resuspended in 5mL of RPMI/2%FCS. The cell 
suspension was then gently layered upon 7mL of cold (4°C) Optiprep solution in a 15mL conical-
bottom polypropylene tube and centrifuged at a relative centrifugal force of 1000g at 20°C for 25 
minutes, with the brakes off. Optiprep solution was made by diluting 1 unit of OptiPrepTM Density 
Gradient Medium (D1556; Sigma, UK) in 2.75 units of PBS. The resulting band of cells at the 
interface between the RPMI and the Optiprep solution was aspirated using a sterile Pasteur pipette 
and transferred to a 15mL conical-bottom polypropylene tube, and washed in RPMI/2%FCS by 
centrifugation at 2000 RPM at 4°C for 5 minutes. The supernatant was then discarded, and the 
pellet resuspended and washed in FACS buffer. The resulting pellet was then re-suspended in 




2.8.2. Isolation of immune cells from mouse blood 
Upon terminal anaesthesia, blood was collected from experimental mice by cardiac puncture as 
described in section 2.7. 200µL of blood was collected in EDTA collection tubes (459036; Grenier 
Bio-One Ltd, UK). The blood was incubated at room temperature in an equal volume of 1X RBC 
lysis buffer (00-4333-57; eBioscience, Invitrogen, UK) for 5 minutes. The reaction was stopped by 
adding 20mL of PBS and centrifuged at 2000 RPM for 5 minutes. The pellet was then twice washed 
in FACS buffer by centrifugation, before re-suspending in 300µL of FACS buffer.  
 
2.8.3. Antibody staining 
200µL of the each cell suspension samples were loaded to a well of a 96-well plate. The plate was 
centrifuged at a relative centrifugal force of 1700g with brakes attenuated to a setting of 3 on a 
Harrier benchtop 15/80 centrifuge. The supernatant from each well was discarded. The cells were 
incubated with 100µL of APC CY7-conjugated live/dead stain (1:1000 concentration) for 30 
minutes at 4°C, protected from light. The cells were then twice washed with FACS buffer, before 
adding 60µL of the myeloid primary antibody mixture to each test well, mixed, and left to incubate 
at 4°C, protected from light for 30 minutes. The cells were then twice washed in FACS buffer and 
fixed for 20 minutes in 200µL of 3% formalin (37% formaldehyde (F1635, Sigma, UK)) at room 
temperature. Cells were then twice washed and subsequently re-suspended in 200µL of FACS 
buffer before analysing on a Cyan ADP flow cytometer (Beckman Coulter, UK).  
 




The primary myeloid antibody mixture was prepared as described in Table 2.2. The dilution factors 
had been pre-optimised by others in the Newsome laboratory.  
 






Antibodies to isolate and analyse myeloid cells from mouse liver and serum cells. 60µL of cell suspension were 
incubated in a primary antibody panel as described in this table for 30 minutes at 4°C, protected from light. Single 
colour staining of cells and IMC staining of cells were done using the same dilution factors as described in the table.  
 
FlowJo 8.7 for Mac (Ashland, Oregon, USA) was used to analyse the data. The software’s in-built 
compensation matrix (Compensation Wizard) was used to compensate for the different 
fluorochromes. Data was analysed and represented as cells/mg of liver tissue or per 100µL of 
blood.  
Antibody Cat#, supplier Isotype (IMC Source) Fluorescence  
tag 
Dilution factor Antibody  
volume 
CD11b 53-0122-80, eBioscience Rat IgG2b  
(400633, BioLegend) 
FITC 100 0.6µL 
Ly6c 128031, BioLegend Rat IgG2c  
(400725, BioLegend) 
BV 421 20 3µL 
CD45 45-0451-82, eBioscience Rat IgG2b  
(400631, BioLegend) 
PerCP-Cy 5.5 200 0.3µL 
Gr1 108411, BioLegend Rat IgG2b  
(400611, BioLegend) 
APC 100 0.6µL 
CD11c 117318, BioLegend Armenian hamster IgG 
(400921, BioLegend) 
PE-Cy7 100 0.6µL 
CD3 100233, BioLegend Rat IgG2b  
(400547, BioLegend) 
BV 510 20 3µL 
F4/80 123109, BioLegend Rat IgG2a  
(400507, BioLegend) 
PE 20 3µL 
PBS / well 48.9µL 
Total vol / well 60µL 
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2.8.4. Gating strategies for myeloid cells 
 
Figure 2-1: Flow cytometry gating strategy for myeloid cell populations 
Cells of myeloid origin were isolated from mouse liver and blood and analysed by flow cytometry. A generous 
gate was selected by forward scatter (FSc) and side scatter (SSc). Singlets were selected by gating FSc by pulse 
width. Live cells (not taking up the live-dead marker) were selected, and cells were subsequently gated as 
CD45+ (leucocytes), CD3- (non-lymphoid). CD11b+/CD11c- cells select out myeloid non-DC cells. F4/80+ 
cells select out the macrophages (and eosinophils), and the Gr1+/F4/80- population select out neutrophils. 
The F4/80 cells with high side scatter likely represent eosinophils, whereas the low side scatter cells are 
macrophages that can be subdivided by their Ly6c expression. Ly6chi cells represent pro-fibrogenic 




2.9.  Liver biochemical tests 
100μL of serum (from each mouse) was analysed for alanine aminotransferase (ALT), measured by 
an Olympus AU400 analyser (OLY-AU400; Beckman Coulter, USA) at the clinical biochemistry 
laboratory of the Birmingham Women’s Hospital (Birmingham, UK) as a surrogate for on-going 




2.10. Hepatic hydroxyproline assay 
The hydroxyproline assay is a biochemical surrogate measure of collagen content of a tissue, 
which assumes that collagen is nearly unique as a protein that contains the amino acid 
hydroxyproline.  
 
2.10.1. Preparation of Chloramine-T solution 
A buffer was prepared by mixing 25g citric acid monohydrate (C1909; Sigma-Aldrich, UK), 6mL of 
glacial acetic acid (10060000; Fisher Scientific, UK), 60g of sodium acetate trihydrate (236500; 
Sigma-Aldrich, UK), 17g of sodium chloride (S9888-M; EMD Millipore, UK), and dissolving in water 
to a total volume of 500mL. The buffer was corrected to pH 4 and stored at 4oC until required. 
Chloramine-T solution was prepared by dissolving 1.75g of sodium N-chloro-p-
toluenesulfonamide (402869; Sigma Aldrich, UK) in 10mL of distilled water, 10mL of 2-propanol 
(I9516; Sigma, UK), 80mL of buffer and 500mL of distilled water. The solution was adjusted to pH 
6.  
 
2.10.2. Preparation of Ehrlich’s solution 
Ehrlich’s solution was prepared by dissolving 7.5g of p-dimethylaminobenzaldehyde (S156477; 
Sigma Aldrich, UK) in 30mL of 2-propanol (I9516; Sigma, UK) and 13mL of 60% perchloric acid 




2.10.3. Preparation of hydroxyproline standards 
The hydroxyproline standards deliver a “standard curve” of absorbance values against which to 
determine the hydroxyproline content of the test samples. 25mg of trans-4-hydroxy-L-proline 
(H54409; Aldrich, UK) was dissolved in 250mL of 0.001N hydrochloric acid (13-1683; SAJ, UK) to 
make stock solution of 100μg/mL. To make standards, we diluted stock solution to 4, 2, 1, 0.5, 
0.25, and 0μg in 50μL of distilled water.  
 
2.10.4. The hydroxyproline assay 
50-100mg of the right lobe of the liver was used for this assessment. The wet weight of each 
sample was noted, before it was transferred to a 1.5mL Eppendorf tube containing 0.5mL of ice-
cold double distilled water. The tissue was then manually homogenised using a hand-held pellet 
pestle (Z359971; Sigma, UK), before a further 0.5mL of ice-cold distilled water was added to the 
sample. 125μL of 3.05N trichloroacetic acid solution (T0699; Sigma, UK) was added to the sample 
before being left to incubate on ice at 4°C for 30 minutes. The sample was centrifuged at 15,000 
rpm for 5 minutes at 20±5°C. The supernatant was discarded from each sample, and the resultant 
pellet extracted with a fresh non-plugged glass Pasteur pipette (612-1701; VWR, UK) and 
transferred to a 12x75mm borosilicate Schott® culture tube (Z620246-50EA; Aldrich, UK). 500μL 
of 6N hydrochloric acid (13-1683; SAJ, UK) was then added to each tube, and a screw lock lid with 
rubber insert was applied tightly. Each tube and lid were checked for defects prior to use to ensure 
there was no escape of hydrochloric acid gas from the subsequent step. The samples were left at 
120°C for 16 hours to allow hydrolysis, before the lids were removed, and the samples were left 
for a further 48 hours at 80°C for complete desiccation. The samples were then removed from the 
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oven and left to cool to room temperature. The desiccated precipitate was suspended in 500μL of 
distilled water with the aid of a long glass Pasteur pipette (612-1701; VWR, UK), and mixed using 
a laboratory bench-top vortex mixer. The mixture was then added to the top chamber of a sterile 
1.5mL Costar® Spin-X® polypropylene centrifuge tube with a 0.45μm nylon filter membrane 
(CLS8163; Corning, UK). The tubes were centrifuged at 15,000 rpm for 5 minutes. 50μL of the 
filtered solution was then transferred to a clean 2mL clear borosilicate tube with solid top rubber 
lined cap (224721; DWK, UK). The hydroxyproline standards were prepared as described in section 
2.10.3 to run alongside the test samples. 950μL of double-distilled water was added to each 
sample in the tubes. 500μL of chloramine-T solution (section 2.10.1) was added to each sample, 
lids applied, and mixed by use of a laboratory bench-top vortex mixer. After 20 minutes at room 
temperature, 500μL of Ehrlich’s solution (section 2.10.2) was added to each sample, mixed by 
vortex, and left at 65°C for 15 minutes in a pre-warmed oven. Samples were then passively cooled 
to room temperature. 200μL of each sample were loaded to a clear, flat-bottom 96-well plate in 
triplicates. A plate reader (micro-well plate colorimeter) was then used to measure light 





2.11. Preparing slides from formalin-fixed paraffin embedded tissue for 
staining 
Formalin-fixed tissue (left lobe of liver) was prepared in tissue cassettes and embedded in paraffin 
wax to form tissue blocks that were stored at room temperature. The formalin-fixed paraffin 
embedded (FFPE) tissue blocks were cut at a thickness of 3μm onto X-tra® glass microscope slides 
(3800050; Leica, UK) using a heated water bath and stored at room temperature until subsequently 
required. The slides were de-waxed by serial rinsing in xylene thrice, followed by 99% ethanol 
thrice, and rehydrated in water twice. Each rinse/wash was undertaken for 3 minutes.  
 
2.11.1. Haematoxylin and eosin staining 
Following dewaxing, dehydrating and washing, slides were placed in Harris haematoxylin stain 
(PRC/R/51; PFM Medical, UK) for 4 minutes, then in water for 2 minutes, and differentiated in 1% 
acid alcohol for 30 seconds. They were then washed in water for 2 minutes, then Scott’s Tap Water 
(PRC/R/76; PFM Medical, UK) for 30 seconds and then in water again for a further 2 minutes before 
being stained in 1% aqueous eosin (PRC/11/1; PFM Medical, UK) for 1 minute. The slides were 
then washed in water for 4 minutes before being serially dehydrated in 99% ethanol for 3 minutes 
thrice, followed by clearing in xylene for 3 minutes thrice. The slides were mounted with coverslips 




2.11.2. Immunohistochemistry (IHC) 
Paraffin embedded sections on glass slides were prepared, cleared, dehydrated and washed as 
described in section 2.11. A wax pen was used to draw a boundary around the sections on each 
slide, and the slides placed in a rocking humidified chamber for all subsequent steps. Endogenous 
peroxidase activity was blocked by treating sections with 150μL of Dako REAL peroxidase blocking 
solution (S202386-2; Agilent, UK) for 20 minutes. Slides were then serially washed for 5 minutes 
at a time with 0.1% Tween-20 (P2287; Sigma, UK) in BioUltra tris-buffered saline, pH 7.6 (94158; 
Sigma, UK) (TBS-T), twice. Antigen retrieval was performed by immersing the slides in the pre-
warmed solution of pH-adjusted buffer and heating at high power in a microwave oven for 15 
minutes. The slides were retrieved after 20 minutes of passive cooling to room temperature, and 
washed in TBS-T, twice. Non-specific antibody binding was blocked by applying 150μL of 2X 
casein buffer solution (10X casein buffer (SP-5020; Vector laboratories, UK) diluted in TBS) to the 
sections for 20 minutes. This was replaced with 200µL of primary antibody, diluted to the required 
concentration as described in Table 2.3. After an hour, the sections were washed in TBS-T, twice, 
before adding the appropriate ImmPRESSTM horseradish peroxidase conjugated secondary 
antibody (Vector laboratories, UK). After 30 minutes, the slides were twice washed with TBS-T. 
200µL of ImmPACT DAB peroxidaseTM substrate (SK-4105; Vector laboratories, UK) was added to 
the sections for up to 90 seconds, or until a colour change was noted in the positive control, 
before washing rapidly in water. For sections that were counterstained, 200µL of filtered 1:4 
diluted Mayer’s haematoxylin (008011; Thermo Fisher, UK) was used for 15 seconds before serial 
washing in a warm, and then cold water bath for 2 minutes with agitation. The slides were 
dehydrated, cleared, washed and mounted with a coverslip as described in section 2.11.1.  The 
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IHC experiments were performed with isotype controls, no primary antibody controls and negative 
tissue controls for each antibody.  
 
Table 2-3: Antibodies for immunohistochemistry  
 
2.11.3. Picrosirius red staining 
Formalin-fixed paraffin embedded sections cut to 8μm onto glass slides were used. The slides 
were prepared, cleared, dehydrated and washed as described in section 2.11. A wax pen was used 
to draw a boundary around the sections on each slide, and the slides placed in a humidified 
chamber. Sections were moistened with distilled water prior to applying 200μL of 0.5% 
polymolybdic acid (HT153; Sigma, UK), for 5 minutes. The slides were transferred to a metal slide 
rack and bathed in PSR solution at room temperature on a rocking plate for 90 minutes. The PSR 
solution was made by dissolving 100mg of Direct Red 80 (365548; Sigma Aldrich, UK) in 100mL of 
saturated picric acid (P6744; Sigma, UK). The slide rack was then removed from the PSR solution, 




Conc. Clonality Host; 
isotype 
Target Diluent;  
dilution 
Secondary;  





pH 8 0.5mg/mL mono Rat;  
IgG2b, κ 
mouse TBS;  
1/200 
Anti-rat, 













from goat;  
MP-7404 
αSMA Abcam, UK;  
ab5694 
pH 8 0.2mg/mL poly Rabbit; 
IgG 


















and serially rinsed with agitation in 2 baths of acidified water (0.5% glacial acetic acid (10060000; 
Fisher Scientific, UK)) for 30 seconds, a bath of 0.1% (w/v in acidified water) fast green FCF (F7252; 
Sigma, UK) for 1 minute, 2 further baths of acidified water for 30 seconds, 3 baths of fresh 99% 
ethanol for 30 seconds, before finally being transferred to xylene. After 5 minutes, the slides were 
mounted with coverslips using non-aqueous DPX mounting medium (1005790500, EMD Millipore, 
UK). 
 
2.11.4. Digitising slide images for analysis 
Physical slides were converted to virtual slides by the use of an automated slide scanner (Axio 
Scan.Z1; Zeiss, Germany). A fixed acquisition protocol was designed and used on designated 








The .czi files containing the whole section were opened in the aforementioned Zen image 
processing software, and images magnified to ensure adequate detail was obvious, and colour 
contrast adjusted uniformly amongst a batch of slides. The visible image on the screen was 
Camera Hitachi HV F202 
Objective 20x  
Pixel resolution 0.22µm/pixel 
Contrasting technique Transmitted light brightfield 
Z stack Yes 
Compression Lossless 
Stitching Online 
File format .czi 
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captured and saved in a .png format; further images from the same slide were acquired to ensure 
at least 80% of each entire slide / section was captured. 
2.11.5. Morphometric analysis of PSR and IHC stained liver tissue sections 
The .png file was opened in Image J (NIH/LOCI, University of Wisconsin, USA) software, and 
converted to an RGB stack image. The image was then set to the green channel for PSR stained 
slides, and the blue channel for DAB, and AEC stained slides. An automatic threshold was utilised 
and adjusted to ensure no aberrant positive areas were demarcated. Areas of the slide that were 
dead space (e.g. biliary trunk) were removed from analysis using the lasso tool. The positive area 
was then calculated by the software as a % area of the working field. An arithmetic mean of the 




2.12. In vivo localisation of MSC after IV injection 
At passage 4, the required number of MSCs were collected (106 MSC / mouse + 2x106 for flow 
cytometry) in complete MSC culture medium at a suspension concentration of 1x107 cells/mL to 
undertake the experiment as designed (detailed in Chapter 6). The Qtracker® 605nm cell labeling 
kit (Q25001MP; Life technologies, Invitrogen, UK) was used to label the MSCs in culture with 
fluorescent nanocrystals. 1µL of Component A and Component B of the kit were mixed in a 1.5mL 
Eppendorf tube and incubated for 5 minutes at 20±5°C. 200µL of complete MSC culture medium 
was added to the labelling solution and mixed by vortex for 30 seconds. 100µL of the cell 
suspension (containing 1x106 cells) was added to the labelling solution and incubated at 37°C in 
a hypercapnic environment for 1 hour. The cells were then washed in sterile saline twice. 1x106 
cells were tested for nanocrystal uptake and fluorescence on a Cyan ADP flow cytometer (Beckman 
Coulter, UK), against unstained cells. Labelled cells were otherwise prepared for injection into mice 
as described in section 2.2, injected into mice as described in section 2.6, and the mice euthanised 
by CO2 inhalation. The carcasses were submerged and embedded in PolyFreeze Tissue Freezing 
Medium (SHH0026; Sigma, UK), and rapidly frozen on a bed of dry ice. They were then stored at 
-80°C until shipment to BioInVision Inc. in Cleveland, USA. BioInVision Inc. use CryoVizTM cryo-
imaging technology to detect, spatially map and quantify fluorescent units (in this case, 
QuantumDot® labelled MSCs) at a microscopic resolution within a macroscopic (whole mouse) 
field of view. The technology and software rendered three-dimensional maps of the fluorescent 
cells in the mice, quantified the number of cells in whole organs, and two-dimensional virtual 
sections for analysis.  
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2.12.1. Flow cytometric analysis of QuantumDot® labelled cells 
To determine the fidelity of uptake of the fluorescent nanocrystals, labelled cells were washed and 





2.13. In vitro methodology 
2.13.1. Storage, culture and subculture of LX2 cells 
The immortalised human hepatic stellate cell line, LX2, was obtained from Dr Scott Friedman 
(Mount Sinai School of Medicine, New York, USA) and stored by Dr Emma Shepherd (Centre for 
Liver and Gastrointestinal Research, University of Birmingham, Birmingham, UK), in our 
laboratories. Cells were stored in liquid nitrogen at a concentration of 1x106 in 1mL of serum with 
10% DMSO.  
 
Low-serum LX2 medium was used for cell culturing. It was prepared in a biological safety cabinet 
and consisted of DMEM with GlutaMAXTM supplement (11584456; Gibco, UK) with 2% heat-
inactivated FCS (F9665; Sigma-Aldrich, UK), 1% penicillin/streptomycin (10,000U/mL; 15140122; 
Gibco, UK) and stored at 4°C. 
 
For use, cells were transported from liquid nitrogen to the working laboratory on dry ice. The cells 
were then rapidly thawed in a 37°C water bath, and contents transferred to a 15mL conical-bottom 
polypropylene tube containing 12mL of pre-warmed complete low-serum LX2 culture medium at 
37°C. The suspension was then centrifuged for 5 minutes at a relative centrifugal force of 400g at 
20±5°C. The supernatant was subsequently discarded, and the pellet gently re-suspended in 8mL 
of complete low-serum LX2 culture medium by flicking the bottom of the tube and using a Pasteur 
pipette. The cell suspension was then transferred to 4 T-75cm2 cell culture flasks (2.5x105 cells / 
flask) with a vented cap containing 15mL of pre-warmed complete low-serum LX2 culture medium 
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(total volume = 20mL / flask). Cells were incubated at 37°C in a hypercapnic (5% CO2) atmosphere. 
They were inspected for confluence and contamination daily, and the medium changed every 2 
days or earlier if a significant pH change was indicated by the phenol red (i.e. if it turned yellow). 
70%-80% confluence could be expected at day 3, at which point the cells could be sub-cultured 
for expansion if required or prepared for seeding into multi-well plates for further analysis. For 
either, the medium was removed, and the cells washed with 10mL of sterile PBS, twice. The cells 
were then bathed in 7mL of pre-warmed (to 37°C) 1X TrypLETM Express Enzyme (12605010; Gibco, 
UK), and incubated for 5 minutes in a 37°C incubator. The contents of the flask were then 
examined using an inverted light microscope to ensure the cells had dislodged from the surface 
of the flask. If not, the flask was kept on incubation for a further 2 minutes. The trypsin was 
neutralised by adding 15mL of complete medium (containing serum) to the flask, and the cell 
suspension then aspirated and transferred to a 50mL conical-bottom polypropylene tube. They 
were spun for 5 minutes at a relative centrifugal force of 400g at 20±5°C. The supernatant was 
subsequently discarded, and the pellet re-suspended in 5mL of complete medium. After ensuring 
adequate re-suspension, live cell numbers were calculated using a haemocytometer as described 
in section 2.2. 
 
The remaining suspension was then spun for 5 minutes at a relative centrifugal force of 400g at 




• For sub-culturing cells the pellet was re-suspended in complete low-serum LX2 culture 
medium; 2.5x105 cells in suspension were transferred to T-75cm2 cell culture flasks as 
previously described.   
• For long-term storage of cells, they were suspended in Cryostor® cell cryopreservation 
medium CS5 (CS299; Sigma Aldrich, UK) at a density of 1x106 cells/mL, and 1mL transferred 
to 1.5mL cryovials. The cryovials were frozen at -80°C in a Mr. FrostyTM Freezing Container 
(51000001; Thermo Scientific, UK) to ensure a cooling rate of -1°C/minute, before they 
were transferred to liquid nitrogen storage.  
 
2.13.2. Immunocytochemistry 
LX2 cells were cultured as already described and seeded to 24-well plates with cover glass inserts 
at a density of 3x104 cells per well.  
 
LX2 cells were seeded in complete low-serum culture medium for 8 hours, and serum starved 
(supplemented with 0.1% bovine serum albumin (15260037, Gibco, UK) (BSA)) for 24 hours before 
exchanging the media for the test- or control-media. After 48 hours, the cells were washed in PBS 
twice before fixing in 10% neutral buffered formalin for 10 minutes. The cells were washed in ice-
cold PBS and the plate stored at 4°C with 2mL of PBS in each well until such time that the cells 
were stained.  
 
For staining, the PBS was removed, and the cells gently washed in PBS for 5 minutes. Cells were 
permeabilised in 0.1% Triton-X 100 (X100; Sigma-Aldrich, UK) in PBS for 10 minutes, before 
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washing twice for 5 minutes at a time with 0.1% Tween-20 (P2287; Sigma, UK) in PBS (PBS-T). 
Non-specific antibody binding was blocked by incubating the cells in 200µL of 2X casein buffer 
solution (10X casein buffer (SP-5020; Vector laboratories, UK) diluted in TBS) for 20 minutes. 200µL 
of primary antibody diluted in PBS to the required concentration as described in Table 2.4, was 
then added to the cells for 1 hour at room temperature. After washing twice in PBS-T, the 
appropriate ImmPRESSTM horse radish peroxidase conjugated secondary antibody (Vector 
laboratories, UK) was added to the cells. After 30 minutes, the slides were washed twice with PBS-
T. 200µL of AEC horseradish peroxidase substrate (SK-4200; Vector laboratories, UK) was added 
to the sections for up to 25 minutes, or until a colour change was noted in the positive control, 
before washing in water. The cells were then counterstained in 200µL of filtered 1:4 diluted Mayer’s 
haematoxylin (008011; Thermo Fisher, UK) for 15 seconds before serial washing in a warm, and 
then cold-water bath for 2 minutes, until the water was running clear. The cover glass inserts were 
carefully removed, and mounted to microscope slides (3800050; Leica, UK) by using VectaMount 
AQ aqueous mounting medium (H-5501; Vector laboratories, UK). The immunocytochemistry 
(ICC) experiments were performed with isotype controls. 
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Table 2-4: Antibodies for immunocytochemistry 
 
2.13.2.1. Quantifying positively stained cells 
Physical slides were converted to virtual slides by the use of an automated slide scanner and 
processed for analysis as described earlier. The .png file was then be opened in Image J software. 
All available cells (up to a maximum of 500) (nuclei stained by Mayer’s haematoxylin) in serial high 
power fields were counted, and all positively stained cells were separately recorded. The % of 
positively stained cells was used to estimate the total positive staining on the whole slide.  
 
Antibody Supplier;  
cat # 
Conc. Clonality Host;  
isotype 
Target Diluent;  
dilution 
Secondary;  
cat #  
Vimentin  
(EPR3776) 
abcam, UK;  
ab92547 
0.5mg/mL mono Rabbit;  
IgG 
















αSMA abcam, UK;  
ab5694 
0.2mg/mL poly Rabbit; 
IgG 





Isotype control abcam, UK; 
ab37415 













0.2mg/mL mono Mouse; 
IgG1, κ 

















Isotype control Invitrogen, 
UK; 
14-4714-81 









2.13.3. Senescence associated β-galactosidase assay 
Senescent cells display increased senescence-associated expression of β-galactosidase (SA-β-gal) 
activity. A senescence detection kit (ab65351; abcam, UK) was used to detect senescence in LX2 
cells in 12-well plates. 
 
5x104 LX2 cells were seeded per well in complete low-serum culture medium for 8 hours. After 
confirmation of adherence to the bottom of the wells by microscopy, the cells were serum starved 
and supplemented with 0.1% BSA for 24 hours. They were then gently washed twice with sterile 
PBS, before adding 3mL of either control or test media.  
 
After 36-48 hours (at 70-80% confluence), the spent media were removed from the wells, and the 
cells washed with PBS. The cells were fixed with 0.5mL (470µL staining solution + 5µl staining 
supplement + 25µl of X-gal solution (20mg/mL) in DMSO) of supplied fixative solution for 15 
minutes at room temperature, and then washed twice in PBS. 0.5mL of the supplied staining 
solution mixture was added to each well and incubated at 37°C (normal CO2 atmosphere), shielded 
from light for 12 hours. The cells were then observed under a light microscope to determine blue 
(positive) colour development and photographed using a digital camera. The images (saved as 
.jpeg files) were used for qualitative analysis.  
 
2.13.4. Cell proliferation assay 
The CyQUANT® Cell Proliferation Assay Kit (C7026; Thermo Scientific, UK) was used to determine 




It utilises a fluorescent green dye that exhibits enhancement when bound to cellular nucleic acids. 
Frozen cells are thawed and lysed in the presence of a solution containing the green dye, and the 
fluorescence is measured using a microplate reader.  
 
 5x103 LX2 cells were seeded into wells of 5 identically designed flat-bottomed clear 96-well plate, 
and incubated in complete low-serum LX2 culture medium for 8 hours. The cells were serum 
starved and supplemented with 0.1% BSA. The medium was exchanged for test or control medium 
after 24 hours (time zero), and plates were serially frozen at 0, 24, 36, 48 and 72 hours.  
 
The reagent (herein described as Cy-solution) was prepared as per manufacturer’s 
recommendation but modified to detect up to 1x105 cells in a 200µL volume. Subsequently, the 
plates were thawed at room temperature, and 200µL of the Cy-solution was added to each well, 
alongside standard curve samples. After 5 minutes of incubation, shielded from the light, the 
sample reading of fluorescence were measured using a fluorescence microplate reader with filters 
appropriate for 480nm excitation and 520nm emission maxima.  
 
2.13.4.1. CyQUANT® standard curve 
A reference standard curve was created to convert sample fluorescence values in to absolute LX2 
cell numbers. LX2 cells were cultured in complete culture media, detached, and collected as a 
pellet as previously described. Cells were washed in sterile PBS twice, and suspended to a density 
of 106 cells / mL of PBS. The cell suspension was then divided in to aliquots of 1mL in 1.5mL 
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Eppendorf tubes, and centrifuged at 1,500 rpm for 5 minutes. The supernatant was discarded, and 
the pellet was frozen at -80°C.  
 
At the time of analysis, the pellet was thawed at room temperature, and re-suspended in 1mL of 
the Cy-solution by vortexing. A dilution series was generated in a 96-well plate (flat-bottom, clear) 
using the Cy-solution as the diluent to make dilutions corresponding to cell numbers of 5x103 to 
1x105, ensuring to include a sample with no cells as a negative control. As with the test samples, 
the standard curve samples were analysed in technical triplicates. After 5 minutes of incubation, 
shielded from light, the fluorescence was measured on a microplate reader as described.  
 
2.13.5. Cell apoptosis assay 
The induction of apoptosis in LX2 cells was assessed in different culture conditions by the use of 
an Annexin-V apoptosis detection kit (ab14085; abcam, UK). 3x105 cells were seeded in to wells of 
a 6-well plate in complete low-serum LX2 culture medium. After 8 hours, the cells were serum 
starved and supplemented with 0.1% BSA for 24 hours. The media were then exchanged for test 
and control media (5mL per well) as required for 48 hours. A positive control was designed, 
whereby cells were cultured in compete medium for 44 hours, and then gliotoxin (G9893; Sigma, 
Aldrich, UK) was added at a concentration of 6nM for the final 4 hours. Upon completion of 24 
hours, the media were collected from each well in 15mL conical-bottom polypropylene tubes, and 
the remaining adherent cells were detached with trypsin as previously described. Enzymatic 
activity was neutralised with one volume of serum-containing medium, and the cells transferred 
to the same corresponding polypropylene tubes. The cells were collected by centrifugation (400g 
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for 5 minutes), the supernatant discarded, and the cells suspended in warm PBS, counted, pelleted, 
and re-suspended to a density of 1-5x105 cells in 500µL of 1X binding buffer supplied in the kit in 
a 1.5mL Eppendorf tube. 5µL each of Annexin V-FITC and propidium iodide were added to each 
cell suspension and incubated at room temperature for 5 minutes shielded from light, before 




2.14. Quantitative PCR 
2.14.1. RNA extraction from mouse liver tissue 
The RNeasy Mini Kit (74104; Qiagen, UK) was used to extract RNA from murine hepatic tissue. All 
instruments and general consumables were pre-treated in an ultraviolet light box for 20 minutes 
prior to use. 20-30mg of the caudate or quadrate lobe of the sample mouse liver was 
homogenised in a sterile GentleMACS M tube (130-093-236; Miltenyi Biotec, UK) containing 600μL 
of RLT buffer supplemented with 10μL/mL of 2-β-mercaptoethanol (M6250; Aldrich, UK). Samples 
were then mechanically homogenised and disrupted in a GentleMACS Dissociator (130-093-235; 
Miltenyi Biotec, UK) using program RNA.01_01. Following centrifugation for 1 minute at 2,000 
rpm, the homogenate was transferred to a 1.5mL Eppendorf tube, and centrifuged for 3 minutes 
at 13,000 rpm. The supernatant was aspirated (the debris discarded) and mixed with one volume 
(600μL) of 70% ethanol. The sample was then transferred to the upper chamber of a RNeasy Spin 
Column and centrifuged at 13,000 rpm for 20 seconds. The flow-through was discarded from the 
lower collection tube. 350μL of RW1 buffer was added to the upper chamber of the spin column 
and centrifuged at 13,000 rpm for 20 seconds. The flow-through was discarded. 80μL of RNase-
free DNase solution (79254; Qiagen, UK) was carefully added to the silica membrane of the spin 
column. After 15 minutes, 350μL of RW1 buffer was added to the upper chamber of the spin 
column and centrifuged at 13,000 rpm for 20 seconds. The flow-through was discarded. 500μL of 
RPE buffer was then added to the upper chamber of the spin column and centrifuged at 13,000 
rpm for 20 seconds. This was then repeated, with the flow through being discarded on each 
occasion. The spin column was then transferred to a new collection tube and centrifuged for 2 
86 
 
minutes at 13,000 rpm. Upon completion, the spin column was transferred to a nuclease-free 
1.5mL Eppendorf tube, and 50μL of sterile pre-warmed nuclease-free water (12994; Qiagen, UK) 
was added to the spin column membrane and centrifuged at 13,000 rpm for 1 minute. The eluate 
was then replaced on to the spin column membrane and re-centrifuged at 13,000 rpm. The spin 
column was then discarded, leaving the eluate (RNA) for analysis and use. The concentration of 
the RNA was determined by measuring the absorbance at 260nm in a spectrophotometer. The 
purity was estimated by measuring the ratio of readings at 260nm and 280nm (target value 
1.9±0.1), and at 260nm and 230nm (target value 2.1±0.1). In the event that the RNA was not an 
adequate purity, it was discarded, and the extraction process was repeated.  
 
2.14.2. RNA extraction from LX2 cells 
A washed pellet of 1-5x106 cells was disrupted in 600µL RLT buffer and homogenised by passing 
the disrupted lysate through a blunted 21-gauge needle attached to a sterile plastic syringe 10 
times. Otherwise the protocol was as described in the section above. 
 
2.14.3. cDNA synthesis 
All instruments and general consumables were pre-treated in an ultraviolet light box for 20 
minutes prior to use. 2µg of RNA from each sample was made up to a total volume 10.5μL with 
sterile nuclease-free water in a 0.2mL DNase- and RNase-free PCR microtube (Z374873; Sigma, 
UK). 0.5μL of random primers (C1181; Promega, UK) and 1μL of 10mM-each dNTP mix 
(R0192Thermo Scientific, UK) were then added to each sample, and the sample tubes transferred 
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to a pre-heated thermo-cycler plate and incubated for 5 minutes at 65°C. The sample tubes were 
quickly chilled on ice, and the contents of the tubes collected to the bottom by brief 
centrifugation. 4μL of 5x First Strand Buffer (18064; Invitrogen, UK), 2μL of 0.1M dithiothreitol 
(18064; Invitrogen, UK) and 1μl of nuclease free water was added and mixed to each sample. The 
samples were left to incubate for 2 minutes at 25°C. Finally, 1μL of SuperScriptTM II reverse 
transcriptase (18064; Invitrogen, UK) was added to each sample, and mixed gently. Samples were 
incubated at 42°C for 50 minutes, and then the reaction was inactivated by heating at 70°C for 15 
minutes. The samples were then stored at -20°C until ready for use.   
 
2.14.4. Real time quantitative polymerase chain reaction (qPCR) 
All instruments and general consumables were pre-treated in an ultraviolet light box for 20 
minutes prior to use. LightCycler® 384 multi-well plates (04729749001; Roche, UK) were used, and 
samples were prepared on ice. Samples were made up in a final volume of 10µL containing 5μL 
of TaqMan® minor groove binder gene probe (Table 2.5) with a 5’ FAM reporter dye (4331182, 
4351372; Thermo Fisher, UK), 0.3μL of 2X reaction TaqMan® Universal PCR Master Mix II (4304437; 
Applied Biosystems, UK), 4.2μL of nuclease free water and 0.5μL of cDNA. Each sample and gene 
were tested in technical triplicate. No-RNA, and no-cDNA samples were used as negative controls. 
Samples were collected to the bottom of the wells by centrifugation at 1,500 rpm for 1 minute 
and sealed using the supplied sealing foil (04729757001; Roche, UK). The samples were processed 
using a LightCycler® 480 Instrument II (05015243001; Roche, UK). The PCR acquisition programme 
consisted of polymerase activation (95°C for 10 minutes), then denaturing and annealing over 40 
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cycles (95°C for 15 seconds, 60°C for 1 minute), with the fluorescence being recorded at the end 
of each cycle.  
 
The amplification curves for each reaction were analysed against their technical replicates; sample 
results with obvious errors (high background noise, or no discernible curve) were discarded. A 
threshold to analyse cycling threshold (Ct) was manually set in the bottom third of the log-linear 
exponential phase, above any background noise, and kept constant per plate. Relative differences 
between samples were determined using the ΔΔCt method / 2-ΔΔCt 158, whereby: 
• ΔCt (sample) = Ct (target gene) – Ct (housekeeping gene) 
• ΔΔCt = ΔCt (test sample) – ΔCt (control)  




Table 2-5: Probes for qPCR 
 
Mouse gene probes TaqMan® ID Species Assignment 
Tgfb1;  
transforming growth factor, beta 1 
Mm01178820_m1 Human target 
Col1a1;  
collagen, type I, alpha 1 
Mm00801666_g1 Human target 
Col3a1;  
collagen, type III, alpha 1 
Mm00802331_m1 Human target 
Acta2; 
Actin, alpha 2 smooth muscle 
Mm00725412_s1 Human target 
Mmp2; 
Matrix metallopeptidase 2 
Mm00439498_m1 Human target 
Mmp9; 
Matrix metallopeptidase 9 
Mm00442991_m1 Human target 
Timp1; 
Tissue inhibitor of metalloproteinase 1 
Mm00441818_m1 Human target 
Actb; 
Actin, beta 
Mm02619580_g1 Human reference 
Human gene probes TaqMan® ID Species Assignment 
COL1A1;  
collagen type I, alpha 1 
Hs00164004_m1 Human target 
ACTA2;  
actin, alpha 2 smooth muscle 
Hs00426835_g1 Human target 
PPARG;  
peroxisome proliferator activated receptor gamma 
Hs01115513_m1 Human target 
PDGFRB;  
platelet derived growth factor receptor beta 
Hs01019589_m1 Human target 
SRSF4;  
serine and arginine rich splicing factor 4 




Data were analysed using GraphPad Prism version 8.1.0 for Windows (San Diego, California, USA). 
Data sets were tested for normality by the Shapiro-Wilk test. Non-parametric data were 
summarised using median and 95% confidence interval (CI) and compared using the Mann-
Whitney test. Parametric data were summarised using the mean and standard deviation and 
compared using the unpaired Student’s-t test. Power calculations were conducted to determine 
the necessary sample size for the intervention experiments to achieve a change of 25% of PCR 
CPA to a statistical power of 90% with a specific α error of 0.05. The data was presumed to be 









3.1. Background and context 
The over-arching aim of this body of work is to examine the therapeutic effect of a putative anti-
fibrotic agent – namely mesenchymal stromal cells – in the setting of established liver fibrosis. 
Animal models remain the gold standard of pre-clinical fibrosis research owing to their reported 
discrimination to the complex interplay between the multiple cell types and pathways that govern 
fibrosis in vivo.  
 
3.1.1. An ideal model to test the effect of a therapeutic agent on established liver 
fibrosis 
A model, by definition will differ from the original against which it is compared. An ideal model 
should have fidelity, by which the overall proportionate difference is minimal, and discrimination, 
by which the extent the model reproduces a particular property of the original is conserved159. 
Such models may not be readily accessible. Therefore, a pragmatic approach is to accept low 
fidelity, under the assumption of high discrimination – in this case, for fibrosis. Though the field 
accepts that the fibrogenic pathways for many of the available rodent models do not have human 
counterparts, the final scar is comparable, and results from experiments that examine effects on 
the scar may be translatable to human disease160. Rodent models are practical due to their fast 
reproductive cycle, ease of manipulation and ease of pathway targeting owing to an in-depth 
understanding of their biology, and a perceived reproducibility of injury using standard protocols. 
Moreover, they are “tried and tested”, and the wealth of published available data provides 




The intended beneficiaries of this project are those with persistent fibrosis or cirrhosis after the 
cessation of injury (i.e. patients with treated viral hepatitis, abstinent patients with ARLD, etc.). 
Therefore, I chose models in which the injury could be easily stopped once fibrosis was 
established, with a view to treating a persistent residual scar in the absence of on-going injury: 
chemically induced fibrosis models, CCl4 and TAA. For the purposes of my intervention 
experiments, it was critical to describe the depth of fibrosis at peak injury, the resolution of fibrosis 
after cessation of injury, and the reproducibility / variability of both.  
 
Figure 3-1 Schematic of ideal fibrosis model for planned anti-fibrotic intervention 
Chemical-induced fibrosis models should deliver a peak fibrosis that is easily measurable by standard fibrosis 
readouts. The scar should persist after the cessation of injury, and only resolve slowly (blue recovery period, 
yellow box depicts the limits of any ongoing inflammation or hepatocyte damage after injury cessation). Under 
identical injury and maintenance environments, the injury and recovery should be reproducible, with little 
variance. These conditions would allow intervention (green arrow) to be instigated in the absence of ongoing 




3.1.2. CCl4-induced hepatotoxicity 
CCl4 hepatotoxicity is the best-characterised murine fibrosis model161, with significant fibrosis, or 
even cirrhosis with 6-8 weeks on injury (dependent on genetic strain and dosing regimen)162.  
 
None of the reported effects by which CCl4 is thought to be hepatotoxic are likely to act in 
isolation163. CCl4 requires metabolic activation in the liver by cytochrome P450; the toxicity of the 
resulting trichloromethyl radical, CCl3*, results from both primary interaction with critical target 
molecules (e.g. nucleic acids, proteins, lipids), and secondary interactions via a prior alteration 
process such as lipid peroxidation or ROS formation.  
• CCl4-mediated hypomethylation of RNA can impede protein synthesis, and 
hypomethylation of phospholipids can impede lipoprotein secretion – both processes 
affect cellular integrity and function.  
• CCl3* reacts with oxygen to form the highly reactive trichloromethylperoxy radical 
CCl3OO*. This drives lipid peroxidation, which in turn destroys phospholipid-associated 
polyunsaturated fatty acids. The permeability of cellular and intracellular organelle 
membranes is compromised, with loss of calcium sequestration and cellular 
homeostasis164.  
• CCl3*-mediated fatty acid breakdown also releases reactive aldehydes, which can inhibit 




These processes contribute to cellular damage via either apoptosis or necrosis predominantly in 
zone 3. Moreover, at the molecular level, CCl4 activates cytokines that drive apoptosis (TNFα) and 
fibrosis (TGFβ).  
 
The culmination of these multiple injury modes is a four-phase progressive fibrotic injury: 1) acute 
injury, 2) initiation of fibrosis, 3) advanced fibrosis, 4) resolution after injury is ceased. The first 
phase is characterised by hepatocyte damage and Kupffer cell activation, both of which recruit 
inflammatory mediators of the tissue-injury response including macrophages, NK cells, 
neutrophils and lymphocytes and activate myofibroblasts. Within 2-3 weeks of iterative injury, 
fibrosis ensues, which progresses to bridge (central-central, followed by central-portal) after 6-8 
weeks162. A number of investigators have shown the natural regression of fibrosis after cessation 
of injury, but the time course of this seems to vary, and is less-well characterised161,162,165.  
 
3.1.3. TAA-induced hepatotoxicity 
Like the CCl4 model, TAA-induced fibrosis follows a multiphasic fibrogenic pathway which is 
propagated by inflammation, and resolves when the hepatotoxic insult is removed. It is frequently 
applied to verify findings obtained in other models (like the CCl4 model).  
 
However, unlike the CCl4 model, the mechanisms by which TAA induces hepatotoxicity and fibrosis 
are less-well characterised. TAA is first oxidised to TAA-S,S-oxide by the cytochrome P450 pathway 
or by FAD-containing monooxygenases. This in turn leads to oxidative stress, lipid peroxidation 
and glutathione depletion. The result of these include centrilobular cellular injury and the fibrosis 
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progression166. Moreover, TAA-S,S-oxide, covalently binds to cellular proteins and lipids, which 
has a multitude of cytopathic downstream effects including enzyme inhibition, dysfunctional 
protein folding, and aberrant mitochondrial chaperone function167.  
 
The resulting fibrosis is often more pronounced than seen in CCl4, and microscopy reveals 
hepatocyte vacuolization, a mixed inflammatory infiltrate involving portal tracts, with ductal 
proliferation and portal-portal and portal-central bridging. Other differences with CCl4 model 
include a prolonged latency period between drug exposure and the development of fibrosis. 
However, published data suggests that the fibrosis does not resolve quite as readily as with the 
CCl4 model, thus providing a more stable substrate on which to test an anti-fibrotic agent167.  
 
3.1.4. Choice of genetic background 
Both CCl4 and TAA-induced hepatotoxicity is strain dependent. Though BALB/c mice are more 
sensitive to fibrosis, I chose to experiment with C57Bl/6 mice as they afforded greater scope for 






3.2. Aims of the chapter 
The aims of the work in this chapter were to:  
• establish two models of chemical-induced liver fibrosis 
• determine the safety of the models 
• establish the reproducibility and variance of peak fibrosis 
• determine the time course and variance of fibrosis resolution of both models 
• examine the duration of continued inflammation and hepatocyte damage after final injury 






3.3. Establishing models of liver fibrosis and resolution: CCl4 
3.3.1. Fibrosis and resolution model: Low dose CCl4  
 
Figure 3-2: Schematic of IP CCl4 chronic hepatic injury (low dose) and resolution 
Age-matched male C57Bl/6 mice were injected IP (dashed vertical arrows) with CCl4 diluted in mineral oil (1:3) 
at a dose of 1μl/g 12 times over 6 weeks (twice per week). Six mice were euthanised on each of indicated 
recovery time points (blue circles) after the last IP injection for tissue and serum analysis. 
 
I undertook a time course experiment to delineate peak fibrosis and natural resolution after injury 
cessation using a modified version of a previously established protocol at the University of 
Birmingham liver laboratories (Figure 3.2)154. All mice survived the protocol, with none showing 






Figure 3-3: Mouse weight changes; IP CCl4 chronic hepatic injury (low dose) 
Mice in experiment described in Figure 3.2 were weighed and assessed for signs of distress prior to each IP 
dose of CCl4. Summary bars: Standard deviation and mean value. 
 
The peak fibrosis as shown in figure 3.4 (panel A), was readily reproducible across the test mice, 
but with a wide range, which was evident in both the PSR (peak CPA, median 2.14%, interquartile 
range (IQR) 0.60%) and Hyp outputs (peak Hyp, median 276µg/g, IQR 381µg/g) (Figure 3.5). There 
was clear evidence of natural resolution over the 21 days after injury cessation (nadir PSR median 
1.33%, IQR 0.91%; nadir median Hyp 229 µg/g, IQR 101µg/g), but the fibrosis persisted above the 
levels of the control injections with mineral oil (Figure 3.4, panel F) (median PSR 0.47%, IQR 0.33%, 
p=0.004; median Hyp 122µg/g, IQR 47µg/g, p=0.002).  
 


























Figure 3-4: Staining of collagen deposition by PSR; IP CCl4 chronic hepatic injury 
(low dose) and resolution 
Mice were euthanised for tissue analysis on days 1 (A), 4 (B), 7 (C), 14 (D) and 21 (E) of recovery after chronic 
hepatic injury as described in Figure 3.2. Paraffin-embedded tissue (left hepatic lobe) cut to a thickness of 
8µm were stained for collagen by picrosirius red (PSR) and fast green as described in section 2.11.3. Red areas 
demarcate collagen. Figure F shows PSR staining from a mouse subject to iterative IP injections of mineral oil 






Figure 3-5: Quantitative analysis of collagen deposition; IP CCl4 chronic hepatic 
injury (low dose), and resolution 
Morphometric analysis of collagen proportionate area (CPA) following picrosirius red (PSR) staining of 
paraffin-embedded sections as described in Figure 3.4 (A). The caudate & quadrate lobes were used for 
hepatic hydroxyproline assay (B) (section 2.10). Summary bars: 95% confidence interval and median value. The 
Mann-Whitney test was used to compare values in the injured mice euthanised at different time points against 




3.3.2. Fibrosis and resolution model: High dose CCl4  
As the protocol was well tolerated, I undertook another time course experiment (Figure 3.6) with 
a view to achieving a greater peak fibrosis, thereby allowing a more established scar on which an 




Figure 3-6: Schematic of IP CCl4 chronic hepatic injury (high dose) and resolution 
Age-matched male C57Bl/6 mice were twice injected IP with CCl4 diluted in mineral oil (1:3) at a dose of 1μ
l/g (dashed vertical arrows), followed by 10 injections of 2µl/g (blocked vertical arrows) over 6 weeks (twice 
per week). Ten mice were euthanised at the indicated time points (blue circles) after the last IP injection for 
tissue and serum analysis. 
 






Figure 3-7: Mouse weight changes; IP CCl4 chronic hepatic injury (high dose) 
Mice subject to chronic hepatic injury as described in Figure 3.6 were weighed and assessed for signs of 
distress prior to each IP dose of CCl4 (A) or mineral oil (B). Summary bars: standard deviation and mean value. 
 
The fibrosis as measured by median PSR CPA (Figure 3.8, panel A & 3.9) was markedly higher than 
that achieved with the lower dose protocol at peak (2.85%, IQR 0.97%, p=0.011), and nadir (1.79%, 
IQR 0.72%, p=0.042).  The hydroxyproline assay yielded crude results to suggest that fibrosis was 
greater in the mice injured with a higher dose, though the difference did not reach statistical 
significance (peak, 385 µg/g, IQR 179µg/g, p=0.368; nadir, 266µg/g, IQR 89µg/g, p=0.427) owing 





Figure 3-8: Staining of collagen deposition by PSR; IP CCl4 chronic hepatic injury 
(high dose), and resolution 
Mice were euthanised for tissue analysis on days 1 (A), 4 (B), 7 (C), 14 (D) and 21 (E) of recovery after chronic 
hepatic injury as described in Figure 3.6. Paraffin-embedded tissue (left hepatic lobe) cut to a thickness of 
8µm were stained for collagen by picrosirius red (PSR) and fast green as described in section 2.11.3. Red areas 
demarcate collagen. Figure F shows PSR staining from a mouse subject to iterative IP injections of mineral oil 






Figure 3-9: Quantitative analysis of collagen deposition; IP CCl4 chronic hepatic 
injury (high dose), and resolution 
Morphometric analysis of collagen proportionate area (CPA) following picrosirius red (PSR) staining of 
paraffin-embedded sections as described in Figure 3.8 after chronic hepatic injury as described in Figure 3.6 
(A). The caudate and quadrate lobes of the extracted livers were used for hepatic hydroxyproline assay (B) as 
described in section 2.10. Summary bars: 95% confidence interval and median value. The Mann-Whitney test 
was used to compare values in the injured mice euthanised at different time points against uninjured control 





Figure 3-10: Gross histopathological assessment of hepatic tissue by H&E staining; 
IP CCl4 chronic hepatic injury (high dose), and resolution 
Mice were euthanised for tissue analysis on days 1 (A), 4 (B), 7 (C), 14 (D) and 21 (E) of recovery after chronic 
hepatic injury as described in Figure 3.6. Paraffin-embedded sections (left hepatic lobe) cut to a thickness of 
3µm were stained with H&E to assess overall morphological changes. Figure F shows H&E staining from a 
mouse subject to iterative IP injections of mineral oil (control). Scale bar (–) measures 200µm. 
 
Gross morphometric analysis of the liver tissue by H&E (Figure 3.10), shows relatively healthy 
lobules with periportal mild inflammation (Panels A & B) which dissipated with time from last 




Figure 3-11: Staining for activated myofibroblasts by αSMA; IP CCl4 chronic 
hepatic injury (high dose), and resolution 
Mice were euthanised for tissue analysis on days 1 (A), 4 (B), 7 (C), 14 (D) and 21 (E) of recovery after chronic 
injury as described in Fig 3.6. Paraffin-embedded sections (left hepatic lobe) cut to 3µm thickness were stained 
for alpha smooth muscle actin (αSMA) as described in section 2.11.2. Figure F shows αSMA staining from a 
mouse subject to iterative IP injections of mineral oil (control). Dark areas indicate positive staining. Scale bar 





The higher dose protocol yielded a greater fibrotic residue without compromising feasibility or 
mouse safety. Similarly, the higher-dose protocol demonstrated a clear persistence of scar-
associated myofibroblasts expressing αSMA for 7 days after injury cessation (median 3.10%, IQR 
1.06%; UC median 0.46%, IQR 0.12%, p<0.001) (Figure 3.11 & 3.12). They were visibly diminished 
from the 14th day of resolution onwards, despite a persistent scar. It is noteworthy that there was 
a significant statistical difference of the αSMA-stained areas between each of the injured cohorts 
and the uninjured controls. However, as stated, the difference in magnitude of positive area 
between the injured and uninjured mice was negligible beyond the 7th day of recovery (Day 14, 
median 0.90%, IQR 0.22% vs UC, p<0.001; Day 21, median 0.67%, IQR 0.33% vs UC, p=0.003).  
 
The expression of a panel of fibrosis-related genes were examined (Figure 3.13). The expression 
of each of the genes was significantly elevated at peak injury (day 1 of recovery) (Table 3.1), and 
the expression of all diminished with time from injury cessation. The expression of Col3a1 (median 
2.07-fold, IQR 1.63-fold, p=0.005), Mmp2 (median 2.62-fold, IQR 1.12-fold, p=0.003), and Timp1 
(median 2.45-fold, IQR 1.48-fold, p=0.004) were still significantly elevated on day 21 of recovery 
compared to the uninjured control. The expression of Col1a1, Tgfb1 and Mmp9 diminished to the 
levels of the uninjured control by day 14 of recovery.  
 
Figure 3-12: Quantitative analysis of 
myofibroblast activation; IP CCl4 chronic 
hepatic injury (high dose), and 
resolution 
 
Morphometric analysis of positive-stained areas 
following αSMA (alpha smooth muscle actin) staining 
of paraffin-embedded sections as described in Figure 
3.11 after chronic hepatic injury as described in Figure 
3.6.  Summary bars: 95% confidence interval and 
median value.  The Mann-Whitney test was used to 
compare values in the injured mice euthanised at 
different time points against uninjured control (UC) 





Figure 3-13: Gene expression analysis by qPCR of fibrosis-associated genes; IP CCl4 
chronic hepatic injury (high dose), and resolution 
Mice were euthanised for tissue analysis on days 1, 4, 7, 14 and 21 of recovery after chronic injury as described 
in Fig 3.6. Expression of fibrosis-associated genes (A: Acta2, B: Col1a1, C: Col3a1, D: Tgfb1, E: Mmp2, F: Mmp9, 
G: Timp1) was assessed by qPCR of homogenised and disrupted hepatic tissues (caudate and quadrate lobes) 
as described in section 2.14. Summary bars: 95% confidence interval and median value.  The Mann-Whitney 
test was used to compare values in the injured mice euthanised at different time points against uninjured 
control (UC) mice; p<0.05 (*) were deemed statistically significant. Acta2, actin; Col1a1, collagen-1; Col3a1, 
collagen-3; Mmp, matrix metalloproteinase; Timp1, tissue inhibitor of matrix metalloproteinase-1; Tgfb1, 
transforming growth factor beta-1.   
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3.3.3. Determining period of continued inflammation and hepatocyte injury after 
toxin-cessation: High dose CCl4 model 
 
Figure 3-14: Assessment of inflammatory infiltrate by CD45 staining; IP CCl4 
chronic hepatic injury (high dose), and resolution 
Mice were euthanised for tissue analysis on days 1 (A), 4 (B), 7 (C), 14 (D) and 21 (E) of recovery after chronic 
hepatic injury as described in Figure 3.6. Paraffin-embedded sections (left hepatic lobe) cut to a thickness of 
3µm were stained for CD45 as described in section 2.11.2. Figure F shows staining from a mouse subject to 
iterative IP injections of mineral oil (control). Sections were counterstained with haematoxylin to demarcate 
background nuclei. Brown areas indicate positive staining. Scale bar (–) measures 200µm. Examples of the 







IHC for CD45 facilitated qualitative and quantitative assessment of inflammatory cell infiltrate 
(Figure 3.14 & 3.15). This demonstrated an increase in inflammatory cell density concentrated 
around the portal tracts; this was most prominent at 24 hours (Panel A; median positive area 
4.98%, IQR 1.34% vs. UC 2.64%, IQR 0.44%, p<0.001) after the last CCl4 injection, but still obvious 
on day 4 (Panel B; area 4.72%, IQR 1.32% vs. UC, p<0.001) of recovery. By day 7 and beyond, the 
infiltrate has dispersed from the portal areas, though the morphometric analysis of positive-
stained area was significantly elevated above the uninjured control until day 14 (day 7, area 3.66%, 
IQR 1.41%, p=0.012; day 14 area, 3.27%, IQR 0.85%, p=0.019).  
 
ALT is a serum marker of hepatocyte damage or membrane instability (Figure 3.16). Serum ALT 
was significantly raised for the first 24 hours after injury cessation (median 776IU/L, IQR 514IU/L 
vs UC median 15IU/L, IQR 15IU/L, p<0.001), and was only marginally raised by the 4th day (median 








Figure 3-15: Quantitative analysis of 
inflammatory infiltrate by CD45 
staining; IP CCl4 chronic hepatic 
injury (high dose), and resolution 
 
Morphometric analysis of positive-stained areas 
following CD45 staining of paraffin-embedded 
sections as described in Figure 3.14. Summary 
bars: 95% confidence interval and median value. 
The Mann-Whitney test was used to compare 
values in the injured mice euthanised at different 
time points against uninjured control (UC) mice; 





Figure 3-16: Serum ALT as a marker of 
hepatocyte injury; IP CCl4 chronic 
hepatic injury (high dose), and 
resolution 
 
Sera from each euthanised mouse as described in 
Figure 3.6 were analysed for ALT as a surrogate for 
hepatocyte injury or cell membrane instability using 
a clinical biochemistry analyser. Summary bars: 95% 
confidence interval and median value. ALT, alanine 
aminotransferase; IU, international units. The 
Mann-Whitney test was used to compare values in 
the injured mice euthanised at different time points 
against uninjured control (UC) mice; p<0.05 (*) 





3.4. Establishing models of liver fibrosis and resolution: TAA 
The Birmingham Biomedical Services Unit (BMSU) and our laboratory have some experience of 
using CCl4 as both an acute and chronic hepatotoxic agent154. However, the TAA model had not 
been utilised prior; as such, experimentation required early low-volume feasibility and safety 
experiments before embarking on establishing a fibrosis and resolution model.  
 
3.4.1. Feasibility and safety of IP TAA protocol 
 
Figure 3-17: IP TAA chronic hepatic injury feasibility experiment 
Age-matched male C57Bl/6 mice were injected IP with 150mg/kg TAA diluted in mineral oil, with a plan to 
euthanise two mice at each of the indicated time points (blue circles) for tissue and serum analysis (A). 
However, the experiment was prematurely terminated 24 hours after the first IP injection of three mice due to 
evidence of severe physical distress in the mice. The mice were euthanised after cardiac puncture under 
terminal anaesthesia. H&E staining of paraffin-embedded tissue (B, C; left hepatic lobe) showed continuous 
peri-centrilobular necrosis (eosinophilic hot pink areas) surrounding islands of surviving peri-portal 
hepatocytes (star). Scale bar (–) measures 200µm. 
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A feasibility experiment was conducted to examine the safety and efficacy of a chronic model of 
hepatic injury by the iterative delivery of IP TAA. A protocol was produced by reference to peer-
reviewed and published standard operating procedures and a literature search53,60,167,169. The 
protocol was submitted as an amendment to our project licence and ratified by the Birmingham 
BMSU and named animal care and welfare officer (NACWO). We trialled a conservative starting 
dose of 150mg/kg, with a plan to titrate over 6 weeks depending on physical response40 (Figure 
3.17, panel A). 24 hours after the initial dose, the mice were observed to be obtunded, lacking a 
postural righting response and showing clear signs of physical distress with tachypnoea and 
grimacing. Under the advice of the supervising NACWO, the mice were sacrificed after cardiac 
puncture under terminal anaesthesia, and tissue was collected post-mortem for analysis. Serum 
transaminase levels for all three mice were over 4000IU/L, suggesting massive hepatic injury. H&E 
staining (panels B & C) showed a widespread and profound zonal necrosis, with islands of 
surviving hepatocytes around portal tracts. As a consequence of this catastrophic hepatic necrosis, 




3.4.3. Feasibility and safety of oral TAA protocol 
 
Figure 3-18: Schematic of oral TAA chronic hepatic injury - feasibility experiment 
Age-matched male C57Bl/6 mice were subject to hepatic injury by substituting their drinking water with TAA 
diluted in fruit squash (1:5) to be taken ad libitum. A starting dose of 100mg/L (three days - green block) was 
sequentially increased to 300mg/L (three days - yellow block) and 600mg/L (pink block) for the remainder of 
the 12-week experiment. Two mice were euthanised on each of indicated time points (blue circles) during 
injury for tissue and serum analysis. 
 
 
Figure 3-19: Mouse weight changes; oral TAA chronic hepatic injury model – 
feasibility experiment 
Mice were weighed and assessed for signs of distress every week whilst on oral TAA as described in Figure 
3.18. Summary bars: range and mean value. 
 

























An experiment to examine the feasibility and safety of an oral TAA-induced hepatic fibrosis model 
followed. An externally validated operating protocol was acquired from Professor Henderson’s 
laboratory and modified (MRC Centre for Inflammation Research, Edinburgh, UK)60. Ten mice were 
subject to the protocol as described in section 2.5.3.2, and depicted in figure 3.18. Mice were 
weighed and examined for signs of distress daily for two weeks, every 48 hours for another two 
weeks, and bi-weekly thereafter. The mice were noted to lose weight in the first four weeks but 
never below the threshold of 80% of their starting weight, before regaining and maintaining an 
acceptable weight for the remainder of the injury period (Figure 3.19). Despite the initial weight 
loss, the mice did not exhibit signs of distress, and were healthy throughout. All mice survived 
until their intended euthanasia date. 
 
Nevertheless, there were evidence of significant hepatic injury by week 4 as evidenced by bridging 
necrosis between portal tracts, and hepatocyte vacuolization on H&E staining (Figure 3.20, Panel 
A)167. By week 10 and 12, the areas of necrosis were being replaced by pale pink bands of thick 
fibrosis (Panels C – E). IHC for CD45 cells reflected the area of cellular damage, but the infiltrate 
was comparatively modest, and seemed to increase with the fibrotic burden in weeks 10 and 12 
of injury (Figure 3.21 & Figure 3.22, Panel A). As has been previously published, hepatocyte 
damage was persistent throughout but the ALT rise was modest (<100IU/L for 10 weeks, upper 






Figure 3-20: Gross histopathological assessment of hepatic tissue by H&E 
staining; oral TAA chronic hepatic injury - feasibility experiment 
Mice were euthanised for tissue analysis after 4 (A), 6 (B), 8 (C), 10 (D) and 12 (E) weeks of chronic hepatic 
injury as described in Figure 3.18. Paraffin-embedded sections (left hepatic lobe) cut to a thickness of 3µm 
were stained with H&E to assess overall morphological changes. Scale bar (–) measures 200µm. Examples of 




Fibrosis occurred in a dose / duration dependent manner (Figure 3.23 & 3.24), and manifested as 
thick septa of portal-portal bridging surrounding islands / nodules or apparently normal tissue by 
weeks 10 and 12. Deposition of collagen as revealed by PSR was temporally congruent with scar-
associated myofibroblast activation as evidenced αSMA IHC (Figure 3.25), and the increased 
expression of fibrosis related genes (Figure 3.26). The model was deemed not only to be safe and 
feasible, but delivered a significant scar by week 12, that resembled early cirrhosis. Allied fibrosis 
outputs also increased, affording good reason to pursue a time-course experiment to delineate 




Figure 3-21: Assessment of inflammatory infiltrate by CD45 staining; oral TAA 
chronic hepatic injury - feasibility experiment 
Mice were euthanised for tissue analysis after 4 (A), 6 (B), 8 (C), 10 (D) and 12 (E) of chronic hepatic injury as 
described in Figure 3.18. Paraffin-embedded sections (left hepatic lobe) cut to a thickness of 3µm were stained 
for CD45 as described in section 2.11.2. Dark areas indicate positive staining. Scale bar (–) measures 200µm. 







Figure 3-22: Quantitative analysis of inflammatory infiltrate 
by CD45 staining and hepatocyte injury by serum ALT 
measurements; oral TAA - feasibility experiment 
 
 
Morphometric analysis of positive-stained 
areas following CD45 staining as described 
in Figure 3.21. Sera from each euthanised 
mouse after chronic hepatic injury as 
described in Figure 3.18 were analysed for 
alanine aminotransferase (ALT) as a 
surrogate for hepatocyte injury or cell 
membrane instability using a clinical 




Figure 3-23: Staining of collagen deposition by PSR; oral TAA chronic hepatic 
injury - feasibility experiment 
Mice were euthanised for tissue analysis after 4 (A), 6 (B), 8 (C), 10 (D) and 12 (E) weeks of chronic hepatic 
injury as described in Figure 3.18. Paraffin-embedded tissue (left hepatic lobe) cut to a thickness of 8µm were 
stained for collagen by picrosirius red (PSR) and fast green as described in section 2.11.3. Red areas demarcate 






Figure 3-24: Quantitative analysis of collagen deposition; oral TAA chronic 
hepatic injury - feasibility experiment 
Morphometric analysis of collagen proportionate area (CPA) following picrosirius red (PSR) staining of 
paraffin-embedded sections as described in Figure 3.23 after chronic hepatic injury as described in Figure 
3.18 (A). The caudate and quadrate lobes of the extracted livers were used for hepatic hydroxyproline assay 






Figure 3-25: Staining for activated myofibroblasts by αSMA; oral TAA chronic 
hepatic injury - feasibility experiment 
Mice were euthanised for tissue analysis after 4 (A), 6 (B), 8 (C), 10 (D) and 12 (E) weeks of chronic hepatic 
injury as described in Figure 3.18. Paraffin-embedded sections (left hepatic lobe) cut to a thickness of 3µm 
were stained for alpha smooth muscle actin (αSMA) as described in section 2.11.2. Dark areas indicate positive 
staining. Scale bar (–) measures 200µm. Morphometric analysis of positive-stained areas is graphically 
represented in Figure F. Summary bars: range and mean value.  Examples of the centrilobular vein (#) and 





Figure 3-26: Gene expression analysis by qPCR of fibrosis-associated genes; oral 
TAA chronic hepatic injury - feasibility experiment 
Mice were euthanised for tissue analysis after 4, 6, 8, 10 and 12 weeks of chronic hepatic injury as described 
in Figure 3.18. Expression of fibrosis-associated genes (A: Acta2, B: Col1a1, C: Col3a1, D: Tgfb1, E: Mmp2, F: 
Mmp9, G: Timp1) was assessed by qPCR of homogenised and disrupted hepatic tissues (caudate and quadrate 
lobes) as described in section 2.14. Summary bars: range and mean value. Acta2, actin; Col1a1, collagen-1; 
Col3a1, collagen-3; Mmp, matrix metalloproteinase; Timp1, tissue inhibitor of matrix metalloproteinase-1; 
Tgfb1, transforming growth factor beta-1 
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3.4.4. Fibrosis and resolution model: oral TAA  
 
Figure 3-27: Schematic of oral TAA chronic hepatic injury model and resolution 
Mice were subject to hepatic injury as described in Figure 3.18 by substituting their drinking water with TAA 
diluted in fruit squash (1:5), at increasing concentrations. The TAA was replaced by standard drinking water 
after 16 weeks.  Ten mice were euthanised on each of indicated recovery time points (blue circles) for tissue 
and serum analysis. 
 
 
Figure 3-28: Mouse weight changes; oral TAA chronic hepatic injury model and 
resolution 
Mice were weighed and assessed for signs of distress every week whilst on oral TAA (Fig 3.27) (A), or on fruit 






For the purposes of the time course experiment we extended the injury for 16 weeks with the 
intent of depositing a resolute scar (Figure 3.27).  As in the feasibility experiment, all mice survived 




Figure 3-29: Staining of collagen deposition by PSR; oral TAA chronic hepatic 
injury model and resolution 
Mice were euthanised for tissue analysis after 1 (A), 4 (B), 7 (C), 14 (D), 28 (E) and 42 (F) days of recovery 
following 16 weeks of chronic hepatic injury as described in Figure 3.27. Paraffin-embedded tissue (left hepatic 
lobe) cut to a thickness of 8µm were stained for collagen by picrosirius red (PSR) and fast green as described 
in section 2.11.3. Figure G shows staining from a mouse euthanised after drinking fruit squash without TAA 
for 16 weeks, and normal drinking water for 1 day (control). Red areas demarcate collagen. Scale bar (–) 




The model resulted in a reproducible thick scar (Figure 3.29 & 3.30), which continued to progress 
and reach peak fibrosis 4 days after injury cessation (median PSR 10.39%, IQR 2.82%; median Hyp 
529µg/g, IQR 125µg/g). The scar was resolute and persisted for 42 days after cessation of injury 
(median PSR 6.32%, IQR 7.63%; median Hyp 284µg/g, IQR 77µg/g). However, the persistence of 
fibrosis was not consistent after 42 days of recovery, with a wide range of residual scar as measures 
by PSR.  
 
αSMA-expressing scar associated myofibroblasts persisted for 14 days (median area 3.17%, IQR  
1.85% vs. UC median 0.11%, IQR 0.10%, p<0.001), after which the expression diminished to the 
 
Figure 3-30: Quantitative analysis of collagen deposition; oral TAA chronic 
hepatic injury model and resolution 
Morphometric analysis of collagen proportionate area (CPA) following picrosirius red (PSR) staining of 
paraffin-embedded sections as described in Figure 3.29 (A). The caudate and quadrate lobes of the extracted 
livers were used for hepatic hydroxyproline assay (B) as described in section 2.10. Summary bars: 95% 
confidence interval and median value.  The Mann-Whitney test was used to compare values in the injured 




levels seen in uninjured controls (day 28 median area 0.15%, IQR  0.23%, p=0.09) (Figure 3.31 & 
3.32).  
 
Figure 3-31: Staining for activated myofibroblasts by αSMA; oral TAA chronic 
hepatic injury model and resolution 
Mice were euthanised for tissue analysis after 1 (A), 4 (B), 7 (C), 14 (D), 28 (E) and 42 (F) days of recovery 
following 16 weeks of chronic hepatic injury as described in Figure 3.27. Paraffin-embedded sections (left 
hepatic lobe) cut to a thickness of 3µm were stained for alpha smooth muscle actin (αSMA) as described in 
section 2.11.2. Figure G shows αSMA staining from a mouse euthanised after drinking fruit squash without 
TAA for 16 weeks, and normal drinking water for 1 day (control). Dark areas indicate positive staining. Scale 






Figure 3-32: Quantitative analysis of 
myofibroblast activation; oral TAA chronic 
hepatic injury model and resolution 
 
Morphometric analysis of positive-stained areas following 
alpha smooth muscle actin (αSMA) staining of paraffin-
embedded sections as described in Figure 3.31. Summary 
bars: 95% confidence interval and median value. UC, 
uninjured control 
The resolution of the expression of fibrosis-related genes is described in figure 3.33. The 
expression of all the genes were elevated throughout the 42 days of recovery, except for Acta2 
(the expression on day 4 and 28 of recovery were not statistically different to the UC). The 
expression of Col1a1, Col3a1, Tgfb1, Mmp2, and Timp1 peaked within the first week of recovery 
before diminishing to a lower level elevation (Table 3.1). By comparison, the expression of Acta2 
and Mmp9 persisted around 2-3 fold that of the uninjured control cohort throughout recovery. 
The difference between the expression at day 1 and day 42 of recovery were statistically 




Figure 3-33: Gene expression analysis by qPCR of fibrosis-associated genes; oral 
TAA chronic hepatic injury model and resolution 
Mice were euthanised for tissue analysis after 1, 4, 7, 14, 28 and 42 days of recovery following 16 weeks of 
chronic hepatic injury as described in Figure 3.27. Expression of fibrosis-associated genes (A: Acta2, B: Col1a1, 
C: Col3a1, D: Tgfb1, E: Mmp2, F: Mmp9, G: Timp1) was assessed by qPCR of homogenised and disrupted 
hepatic tissues (caudate and quadrate lobes) as described in section 2.14. Summary bars: 95% confidence 
interval and median value. The Mann-Whitney test was used to compare values in the injured mice euthanised 
at different time points against uninjured control (UC) mice; p<0.05 (*) were deemed statistically significant. 
Acta2, actin; Col1a1, collagen-1; Col3a1, collagen-3; Mmp, matrix metalloproteinase; Timp1, tissue inhibitor 




3.4.5. Determining the profile of inflammation and hepatocyte injury after toxin-
cessation: oral TAA model 
 
 
Figure 3-34: Assessment of inflammatory infiltrate by CD45 staining; oral TAA 
chronic hepatic injury model and resolution 
Mice were euthanised for tissue analysis after 1 (A), 4 (B), 7 (C), 14 (D), 28 (E) and 42 (F) days of recovery 
following 16 weeks of chronic hepatic injury as described in Figure 3.27. Paraffin-embedded sections (left 
hepatic lobe) cut to a thickness of 3µm were stained for CD45 as described in section 2.11.2. Figure G shows 
CD45 staining from a mouse euthanised after drinking fruit squash without TAA for 16 weeks, and normal 
drinking water for 1 day (control). Dark areas indicate positive staining. Scale bar (–) measures 200µm. 





Figure 3-35: Quantitative analysis of inflammatory infiltrate by CD45 staining 
and hepatocyte injury by serum ALT measurements; oral TAA chronic hepatic 
injury model and resolution 
Morphometric analysis of positive-stained areas following CD45 staining of paraffin-embedded sections as 
described in Figure 3.34. Sera from each euthanised mouse as described in Figure 3.27 were analysed for ALT 
as a surrogate for hepatocyte injury or cell membrane instability using a clinical biochemistry analyser. ALT, 
alanine aminotransferase; IU, international units. The Mann-Whitney test was used to compare values in the 
injured mice euthanised at different time points against uninjured control (UC) mice; p<0.05 (*) were deemed 
statistically significant. 
 
The inflammatory infiltrate settled along the fibrotic scar and around the portal tracts (Figure 3.34). 
The infiltrate progressively dispersed and partially diminished (Figure 3.35, panel A) through the 
first week of recovery. By day 14 the level of inflammatory infiltrate equated to the uninjured 
controls (p=0.248). Serum ALT was modestly elevated at the cessation of injury (median ALT 
117IU/L, compared to 776IU/L in the CCl4 after the 1st day of recovery) reflecting the persistent 
low-level hepatocyte damage observed in the feasibility study (Figure 3.35, panel B). The low-level 
rise of serum ALT remained significantly elevated after 42 days of recovery. However, the median 
values fell below the clinical upper limit of normal (50IU/L) by the 14th day of recovery (median 




3.5.1. Feasibility and safety 
The IP CCl4 chronic hepatic injury model has already been established and used at the Birmingham 
BMSU170. Nevertheless, the study confirmed that it could be completed safely, at a higher dose 
than previously trialled. The 16-week oral TAA model was introduced to the Birmingham BMSU 
following a small volume feasibility experiment over 12 weeks. The mice were healthy throughout, 
with no dropouts or deaths over the 16-week injury period.  
 
However, IP TAA, used at previously published safe doses to induce liver fibrosis171, caused a 
catastrophic hepatic injury as a consequence of widespread acute zonal necrosis after a single 
dose. I considered trialling the IP route again at a lower dose172, but it was deemed more 
reasonable to trial the oral regimen which had proven safety and efficacy at another UK institute60.  
 
3.5.2. Peak fibrosis and resolution 
CPA after PSR staining is, on balance, a better test than hepatic hydroxyproline for quantifying 
extant tissue ECM, in that it provides a direct and accurate representation of microscopically visible 
collagen deposition, which has been shown to have excellent clinical prognostic value173. 
Moreover, bias was minimised in this study by using a slide-scanner to measure the CPA across 
the largest lobe of liver (>80% of available area) to ensure fidelity to standardised guidelines 




Peak fibrosis as measured by CPA in both the CCl4 and the TAA models were comparable to 
published data60,154,165. TAA delivered a greater fibrotic scar than the CCl4 model (Table 3.1). The 
fibrosis persisted to the investigated recovery time points in both but was more pronounced in 
the TAA model. The decrease of the mRNA expression of fibrosis-related genes in resolution is in 
the same order of magnitude as has been published in similar models of fibrosis165,172. The findings 
as summarised in table 3.1 would suggest the chronic TAA model to be a better fit to the “ideal” 
scenario as graphically described in figure 3.1, but both were nevertheless suitable to test the 






Table 3-1: Summary comparison of fibrosis at peak and after recovery in the IP 
CCl4 and oral TAA model 
 
 
Differences in fibrosis readouts at peak, and after a designated duration of recovery after last hepatic injury in the CCl4 
and TAA models. Comparisons between outputs were undertaken by a Mann-Whitney test (nonparametric) and 
deemed statistically significant if p<0.05 (bold). Bold italics were assigned to statistically significant differences 
whereby CCl4 > TAA. αSMA, alpha smooth muscle actin; Acta2, actin; Col1a1, collagen 1; Col3a1, collagen 3; IQR, 
interquartile range; Mmp, matrix metalloproteinase; Tgfb1, transforming growth factor 1; Timp1, tissue inhibitor of 




 Peak After recovery 









% CPA of PSR 
(median, IQR; %) 
2.85, 0.97 10.39, 2.82 <0.001 1.79, 0.72 7.27, 1.02 <0.001 
Hepatic hydroxyproline 
(median, IQR; µg/g liver) 
385, 179 529, 125 0.005 266, 89 397, 155 0.002 
% area αSMA staining 
(median, IQR; %) 
4.37, 1.43 7.54, 0.87 <0.001 0.62, 0.33 0.15, 0.23 <0.001 
PCR: Acta2 
(median, IQR; fold) 
1.74, 1.23 1.09, 1.12 0.123 0.94, 0.58 1.88, 1.66 0.043 
PCR: Col1a1 
(median, IQR; fold) 
5.58, 5.43 22.92, 17.88 <0.001 1.48, 0.75 4.19, 17.88 <0.001 
PCR: Col3a1 
(median, IQR; fold) 
5.60, 4.15 8.46, 8.56 0.035 2.07, 1.63 3.05, 2.69 0.190 
PCR Tgfb1 
(median, IQR; fold) 
3.10, 2.84 6.14, 1.43 <0.001 1.04, 0.58 4.21, 3.50 <0.001 
PCR: Mmp2 
(median, IQR; fold) 
8.10, 3.70 14.33, 15.66 0.007 2.62, 1.12 5.38, 5.19 0.009 
PCR: Mmp9 
(median, IQR; fold) 
2.67, 2.34 3.92, 2.91 0.393 1.30, 1.26 2.15, 4.88 0.105 
PCR: Timp1 
(median, IQR; fold) 
7.71, 6.36 30.31, 19.08 <0.001 2.45, 1.48 14.50, 34.88 <0.001 
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3.5.3. Defining a time frame for intervention 
The data was used to inform the timing of the intervention (MSCs) in the primary experiment (in 
Chapter 5) in the absence of continuing evidence of active hepatocyte injury and inflammatory 
reaction. This scenario was chosen to ensure any observed therapeutic effect on fibrosis was 
independent of a dampening of immune-mediated injury and was primarily anti-fibrotic. 
Furthermore, it was thought to be analogous (though imperfectly so) to the intended beneficiaries 
– patients with persistent fibrosis or cirrhosis in the absence of ongoing aetiological injury (i.e. 
abstinent patients with ARLD, treated viral hepatitis related cirrhosis, controlled autoimmune 
hepatitis, etc.).  
 
ALT had near normalised by day 4, and CD45 cell infiltration had dispersed from the portal tracts, 
and dissipated to low levels by day 7 in the chronic CCl4 model. As such, day 7 of recovery was 
deemed an appropriate time point to intervene on established fibrosis in the CCl4 model.  
 
Day 14 of recovery was selected as an appropriate intervention time point for the chronic TAA 
model, based on CD45-positive cells dissipating to levels equivalent to the uninjured controls, and 
serum ALT level normalisation.  
 
3.5.4. Variation in fibrosis despite identical injury  
One of that the major shortcoming of both models is an inadequate reproducibility of fibrosis as 
primarily measured by CPA and Hyp at peak and during resolution. Though the vagaries of the 
Hyp assay could attribute to some of the variance (as described in Section 2.10), the CPA assay 
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was a representation of what could be microscopically seen, and bias was limited by using an 
automated slide scanner and measuring CPA from >80% of each paraffin section of the largest 
lobe of the liver. Moreover, the variance was also evident in the PCR of fibrosis-related genes. 
 
Age and sex-matched mice were bought from a common supplier and the experimental 
conditions including the timing of dosing for mice were identical for each experiment. As for the 
CCl4 model, the study employed an IP weight-based dosing strategy that is preferred by many 
investigators for excellent reproducibility, ease of performance and safety162. Whereas some 
investigators have abandoned the IP route of administration due to peritoneal adhesions, I found 
minimal complications in any of the mice at the time of tissue extraction165. Moreover, having 
previously completed a similar IP-dosed chronic injury model, the experiment was not a victim of 
my own personal learning curve154. It was not possible to accurately determine whether the mice 
took comparable doses of TAA ad libitum throughout their 16-week injury period. However the 
model is well established and preferred by other laboratories60,167. Moreover, the mice self-
governed their intake and maintained good hydration throughout, and a very narrow variation on 
weight over the 16-week period suggesting their fluid intake was appropriate for their needs 
(Figure 3.28). Nevertheless, I concede a variation in dosing may have contributed to the variation 
in fibrosis in the oral TAA model.  
 
Having controlled for obvious variables, the variation may be attributable to natural inter-mouse 
differences that other investigators and experiments would also be subject to. It is difficult to 
ascertain the true reproducibility of fibrosis in the available published data, as few clearly represent 
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the variance of their data, and fewer still undertake power calculations to necessitate such 
granularity. Furthermore, investigators rarely employ identical injury strategies. Scholten’s 
standard operating manual for the CCl4 model have used their internal data to approximate a 25% 
variance within each group of Col1 mRNA expression, but have not declared the expected variance 
for other outputs162. Trautwein’s guidelines for in vivo pre-clinical experimentation suggested 
group sizes of 8-15 but did not qualify on what measured output or power this was based. 
Nevertheless, for the purposes of this study, it was necessary to base sample size calculation on a 
change in established fibrosis – extant ECM. We elected to use CPA based on the earlier discussion 
about representative sampling and limitation of bias.  
 
Table 3-2: Sample size calculations for intervention experiment based on time 











Sample size calculations based on peak fibrosis and resolution data to achieve a ∆ of 25% to a statistical power of 90% 
with a specific α error probability of 0.05. The data was presumed to be parametrically distributed for the purposes of 
the calculation and a two-tailed test was performed. CPA, collagen proportionate area; PSR, picrosirius red 
 
Mr James Hodson (Statistician at the Institute of Translational Medicine, University Hospital 
Birmingham, UK) checked and verified the sample size calculations. 
 









Mean (%) 2.92 1.87 10.55 7.56 
Standard deviation 0.62 0.44 2.64 1.73 




In summary, the work in this chapter has established the safety and feasibility of 2 hepatic fibrosis 
and resolution models, 1) 12 IP injections of CCl4 over 6 weeks, followed by 3 weeks of recovery, 
2) 16 weeks of oral TAA in drinking squash given ad libitum followed by up to 6 weeks of recovery. 
The results also highlighted the potential toxicity of IP TAA.  
 
Fibrosis attenuated with recovery but persisted to the final investigated recovery time points in 
both models. Fibrosis was variably reproducible despite identical injury conditions, which in turn 
informed the sample size for subsequent intervention experiments as described in Chapter 5. 
Moreover, delineation of changes to the inflammatory cell infiltrate and serum ALT informed an 









4.1. Background and context 
MSCs were classically defined as BM cells that adhered to plastic75. This yielded heterogeneous 
unsorted cells that varied both phenotypically and functionally from batch to batch, rendering it 
difficult to establish a true picture of efficacy and comparability. To rectify this, the ISCT agreed 
standards by which to uniformly characterise MSCs81,82. Further to their ability to adhere to plastic, 
MSCs needed to readily transdifferentiate down different mesodermal lineages and express CD73, 
CD90 and CD105, but not express CD14, CD34, CD45 and class-II MHC.  
 
Pre-clinical experimentation with MSCs should report their isolation techniques, enrichment, cell 
surface marker profiles with respect to the aforementioned ISCT guidance, mesogenic 
differentiation174,175, and cell preparation information45. This will inform the translatability of in 
vitro and in vivo studies to clinical trials.  
 
I have chosen to use human MSCs for this study with a view to shortening the bridge to translate 
any pre-clinical findings to clinical application. Furthermore, our laboratory has close professional 
links with commercial partners, OTL (Galway, Ireland), who have developed a novel method to 
isolate and purify MSCs for use in human therapy. OTL allogeneic MSC therapies are currently 
being trialled for a number of clinical conditions including autoimmune hepatitis and primary 
sclerosing cholangitis (MERLIN, ClinicalTrials.gov identifier: NCT02997878). They have kindly 
provided MSCs for this body of work. 
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4.1.1. Mesenchymal stromal cell selection by prospective enrichment 
To date, MSC isolation from tissue has relied on their functional capacity to adhere to tissue 
culture plastic. According, the mononuclear cells are left to incubate for 10-14 days in which time 
the MSCs will attach and form colonies at a recognised frequency of 1/80,000. At 10-14 days these 
colony forming units are harvested by trypsin digest and re-plated in serum-rich or platelet lysate-
rich media at a density of up to 8,000 MSCs per cm2. These MSCs proliferate in vitro until sufficient 
cell numbers are obtained to permit biochemical and cytological assessment. This plastic adherent 
MSC isolation technique was developed in the 1960s and has several limitations75. The co-
expansion of other adherent cells standardly delivers a very impure population and low yield: only 
~1/80,000 BM-MNC plated are MSC. This is reflected in guidelines from the European Medicines 
Agency Committee for Advanced Therapies, including a proposal for rigorous and prospective 
characterisation in order to deliver a purer, more defined cell population176,177, to supplement 
existing standards.  
 
Even at the time of publication, the ISCT definition for characterising MSCs was recognised as 
being limited because CD 105, CD73 and CD90 are expressed on many different cells, and 
selecting on these grounds still yielded intra-population heterogeneity178. Prospective isolation 
was seen as a step towards greater precision in isolating a purer MSC population179. It relies on 
the identification, and subsequent isolation and enrichment of the MSCs by their expression of a 
discriminatory cell surface antigen. However, identifying a single cell surface marker to 
discriminate MSCs from other mononuclear cells has proved challenging. Attempts to advance 
prospective isolation of MSC began in the late 1980s when Simmons and Torok-Storb identified 
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the first reagent that was used to prospectively isolate MSC from BM, an IgM antibody called 
Stro1180. However, the Stro1 antigen was never identified, and proved to be poorly discriminatory 
for MSCs amongst other mononuclear cells. McGonagle and Jones identified antibodies to CD271 
as a marker to capture all MSC from human BM181. Likewise, two groups in Germany and Australia 
identified two different antibodies that bind and isolate the same antigen on all MSC within human 
BM. Bühring and colleagues identified an antibody to tissue non-specific alkaline phosphatase 
(ALP) called W8B2182 whereas Gronthos identified the antibody, Stro3 that also binds ALP183. Anti-
Stro-3 (or W8B2) antibody-coated magnetic bead reagents can be used to positively select cells 
displaying the ALP surface antigen. This magnetic assisted cellular sorting (MACS) approach can 
process a high number (109) of BM-MNC in a few hours, but the resulting product output is still a 
heterogeneous mixture of cells because of the single parameter (one antibody/one-bead) 
selection. That said, MACS separation of BM-MSC using anti-CD271 or anti-ALP antibodies 
(W8B2/Stro3) can enrich the MSC/MNC ratio to from 1:80,000 seen in PA-MSC preparations to 
~1:300184. This MACS-based prospective isolation of Stro3+MSC is a proprietary method used by 
Mesoblast (Australia) to manufacture their MSC therapeutics, NeoFuse™ and Revascor™. The 
Mesoblast Stro3 technology represents the only commercial advanced MSC prospective isolation 
technology and is protected by Mesoblast intellectual property filings. A plotted summary of the 
progress of isolation techniques has been reviewed elsewhere185.  
 
OTL have identified CD362/Syndecan-2 (S2) as a cell surface marker that can be used to 
prospectively isolate MSC from different tissues, that is conserved across species. In collaboration 
with Miltenyi Biotec, OTL has developed a Good Medical Practice (GMP)-grade anti-S2 antibody 
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that is bound to Miltenyi proprietary Microbead technology. This anti-S2-microbead reagent is 
proprietary technology that permits MACS-based enrichment of S2-MSC using the Miltenyi 
CliniMACS Prodigy device from several adult tissues. It provides a 300-fold enrichment of S2-MSC 
over other current MSC isolation technologies (Data from OTL, Ireland).  
 
4.1.2. Umbilical-cord tissue derived mesenchymal stromal cells 
Umbilical cord tissue is an attractive source of MSCs and has many practical advantages over other 
potential sources. Procurement from UCT removes the risk and morbidity of donors undergoing 
BM harvest or procurement from other tissue. Furthermore, the abundance of potential donors 
extends the translational potential of pre-clinical work. UCT is obtained from donors of roughly 
similar age. This may confer a favourable batch variability profile. Data from OTL indicates 
homogeneity with less than 10% variability on CCL2 secretion and less than 5% variability in IL-6 
secretion in contrast to the 50% difference in CCL2 secretion and 40% variability in IL-6 secretion 
observed with plastic adherent BM MSC. Other investigators have found human UCT-MSC to 
persist longer in mouse models than human BM MSCs186.  
 
OTL has developed an enriched S2-MSC isolated from human UCT, ORBCEL-CTM. ORBCEL-CTM has 
a narrow batch variability profile, greater proliferative capacity and enhanced immunomodulation 
compared to bone marrow derived cells in different pre-clinical experimental models (data from 





Syndecan-2 has a role in prospective isolation of MSCs and is of undoubted commercial value to 
OTL, but its biological significance on MSCs is less certain. In vitro and in vivo data using S2-
selected MSCs from OTL have shown them to influence inflammatory processes more effectively 
than unselected MSCs. These include their effect on the hepatic inflammatory infiltrate and 
modifying macrophage polarity in a mouse model of biliary injury. Preliminary data in our 
laboratory suggest S2-MSC may be biologically distinct from un-enriched MSC in their ability to 
suppress CD4 T-cell proliferation in vitro (personal communication with Dr. Ashnila Janmohamed, 
2018, Newsome laboratory, University of Birmingham). However, it is unclear whether S2 is a 
participant in the biological processes or whether it is an inert bystander. There are no published 
data investigating this yet.  
 
Syndecans are a family of four members of transmembrane heparin sulfate proteoglycans found 
in mammalian cells187. Since their discovery in 1989, there has been a relative paucity of data to 
explain what their exact functions in disease and health are. They reportedly perform a wide range 
of tasks, with some investigators theorising that they may be intrinsically disordered proteins that 
lack a unique tertiary structure in isolation, but acquire it only after interacting with a partner, 
thereby enabling them to activate disparate intracellular and extracellular pathways188. S2 interacts 
with ECM and has a role in matrix interactions and assembly at the cell surface, cell-signalling and 
migration. S2 may be crucial during embryonic neurogenesis and angiogenesis189, and may play 
a part in the pathogenesis of colorectal and lung cancer190–192. There are data to suggest S2 may 
have a role in fibrosis, yet in keeping with the pleiotropic nature of syndecans, it is unclear whether 
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the effect if pro-193–195 or anti-fibrotic196,197. Moreover, cleaved/shed S2 and membrane-bound S2 
may have contrasting functions194, reflecting a possible role in context-dependent homeostasis.  
 
Nevertheless, for this study, the primary function of syndecan-2 is as a cell surface marker of MSCs 
that facilitate the prospective enrichment of MSCs by the project’s industry collaborators, OTL.  
 
OTL generously provided human UCT-derived MSCs as described in section 2.1, and undertook 
the S2 enrichment process by their own proprietary technology. This project used S2-selected 
(D1/S2) and unselected MSCs (D1/US) from a matched donor (from herein described as donor 1 
(D1)), and S2-selected MSCs (D2/S2) from another donor (donor 2 (D2)).  
 
4.2. Aims of the chapter 
The aims of the work in this chapter were to: 
• Characterise S2-selected MSCs from two different donors, and unselected MSC from a 
matched donor by ISCT guidelines 
• Evaluate the expression of S2 from donor-matched S2-selected and unselected MSCs 




4.3. Morphology and plastic adherence of MSCs 
 
 
Figure 4-1: Bright field image of human UCT-derived MSCs 
S2-selected MSCs plated on un-coated plastic. The image is representative of S2-selected and unselected 
MSCs from different donors. Scale bar (–) measures 100µm.  
 
D1/S2, D1/US, and D2/S2 MSCs were all plastic adherent under standard culture conditions as 
described in section 2.2. MSCs spread their processes and exhibited a classic “fibroblast-like” 
morphological phenotype within 6 hours of seeding on uncoated plastic (Figure 4.1). Between 
passages 1-4, the cells reached confluence from a seeding density of 30-50% within 4-5 days 





Figure 4-2: Bright field images of human UCT-derived MSCs at different 
confluences 
MSCs plated on un-coated plastic at 30% (A), 40% (B), 50% (C), 60% (D), 70-80% (E), and 90-100% (F) 




4.4.  The mesogenic process – mesodermal differentiation of MSCs 
 
Figure 4-3: Tri-lineage differentiation of human UCT-derived MSCs  
Adipogenic (Section 2.3.2, panels A, B, C), osteogenic (Section 2.3.4, panels D, E, F) and chondrogenic (Section 
2.3.3, panels G, H, I) differentiation was stimulated in human UCT-derived MSCs from donor 1 (D1/S2+, 
syndecan-2 selected: panels A, D, G; D1/US, unselected: panels B, E, H) and donor 2 (D2/S2+, syndecan-2 
selected: panels C, F, I). Lipid vacuoles in plastic-adherent MSCs were confirmed by Oil Red O staining (A, B, 
C). 1% Alizarin Red S solution was used to stain and confirm osteogenesis on plastic-adherent MSCs (D, E, F). 
Chondrogenesis was confirmed by staining frozen sections of the chondrocyte bullet with 0.1% toluidine blue 
(G, H, I). Black scale bar measures 20µm, green scale bar measures 100 µm, red scale bar measures 500µm. 
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Both selected (D1 and D2) and unselected MSCs (D1) underwent the mesogenic process when 
appropriately stimulated in vitro as described in Figure 4.3. There were no qualitative differences 




4.5. Cell-surface marker analysis 
 
Figure 4-4: Flow-cytometric analysis of human UCT-derived MSCs by the 
expression of MSC-defining markers 
Syndecan-2-selected MSCs from Donor 1 (green histogram) and 2 (blue histogram), and unselected MSCs 
from Donor 1 (red histogram) were labelled and prepared for flow cytometry using a the BD StemflowTM 
Human MSC Analysis Kit as described in section 2.3.1. MSCs were shown to not express CD45, CD34, CD11b, 
CD19 and HLA-DR (PE fluorochrome) (A). They did express CD90 (FITC-conjugated, panel B), CD105 (PerCP-
CyTM5.5- conjugated, panel C) and CD73 (APC-conjugated, panel D). Differences between test histograms and 
control histograms was calculated using the absolute Overton subtraction method. There were no statistically 
significant differences in the expression of MSC markers between donors, and between syndecan-2 selected 
and unselected MSCs. 
 
All the MSCs expressed the requisite cell surface markers to satisfy the ISCT guidance. There were 
no statistically significant differences in the expression of specific markers between the MSC 






Figure 4-5: Flow-cytometric analysis of syndecan-2 expression in human UCT-
derived MSCs by their mode of selection and cellular confluence in-vitro 
MSCs were selected by an appropriate flow cytometry gate (A). S2-selected (B-D) and unselected (E) MSCs 
were either labelled with APC-conjugated S2 antibody (blue, orange and green), or an IMC (red histogram). 
S2 expression on MSCs increased with in-vitro cellular confluence (B-D). Differences between test histograms 
and control histograms was calculated using the absolute Overton subtraction method. There was a significant 
difference in S2-expression in MSCs enriched by S2-MACS (C), and unselected MSCs (E) at 70-80% confluence 
(Student’s t, p<0.001). Cellular confluence had a significant effect on cell-surface S2 expression (Panels B-D, 
ordinary one-way ANOVA, p<0.001).  
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A flow-cytometric comparison of S2 expression between MSCs that had either undergone S2-
selection (Section 2.1, Panel C, mean 19.2%) or not (Panel E, mean 7.7%) revealed a significant 
enrichment of S2-expressing MSCs in the cells that had undergone the MACS cellular sorting 
process (Student’s t-test, p<0.001). The MSCs were from the same donor (D1) and matched for in 
vitro cellular confluence at the time of removal from culture.  
 
Cellular confluence had a significant effect on cell-surface S2 expression, with a statistically greater 
expression noted at higher confluences (50-60% confluence; 16.7%, 70-80% confluence, 19.2%; 




4.6.1. The characterisation of MSCs 
We confirmed that the MSCs we subsequently used in our in vivo and in vitro experiments reached 
the minimum threshold to be characterised as MSCs as decreed by the ISCT. The results were 
consistent between different donors, and the OTL proprietary MACS-enrichment process does not 
affect the baseline defining characteristics of the cells. We also confirmed that the MACS-
enrichment process certainly selects an S2-enriched population, and we went on to investigate 
whether the enriched MSCs (S2-selected MSCs, S2-MSC), were functionally distinct in their ability 
to affect fibrosis in Chapters 5. 
 
4.6.2. Moving goal posts – finessing the characterisation of MSCs 
The 2006 ISCT MSC minimum characterisation guidelines did not incorporate their 
immunomodulatory properties. In 2014, the committee published a proposal to stimulate the field 
to discuss the incorporation of immunological/functional features to the baseline definitive 
characterisation of MSCs for clinical use198. It should follow, that immunological characterisation 
of MSCs be expected for pre-clinical experimentation as well. Primary to the proposals were 
incorporating functional potency assays (qPCR / protein based assays of secretome / flow 
cytometric analysis)  to provide mechanistic insights on clinical response198,199. Interrogating the 
IDO response was proposed as an assay to describe the immunomodulatory potency of MSCs. 
Colleagues in the Newsome laboratory have pursued this line of interrogation using the OTL 
human UCT-MSCs, including T-cell suppression assays, which further adds to the fuller 
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characterisation of the cells used in this study (personal communication, Dr. Ashnila Janmohamed, 
2018, Newsome laboratory, University of Birmingham). However, functional assays need to be 
function-specific; although the ISCT have proposed assays for the well-characterised 
immunomodulatory effects of MSCs, assays to reflect poorly characterised functions such as 
fibrolysis will require more exploration.  
 
4.6.3. The effect of in vitro confluence on MSC biology 
MSCs clearly increase their expression of cell surface S2 with increasing confluence; the biological 
relevance of this remains unclear. Published data suggests that other phenotypic characteristics 
of MSCs are unchanged at different cellular confluences200.  Other investigators have found that 
increasing confluence, especially when close to 100%, may affect some biological functions (pro-
angiogenesis), whilst sparing others (immunomodulation)201. Nevertheless, one cannot escape the 
potential confounding nature of changing S2 expression with confluence, especially in the 
absence of knowledge of what S2 actually does on MSCs. The issue of ensuring a fixed confluence 
for different experiments highlights the need for controlling other potential confounders when 
preparing MSCs (or any cellular therapy) in vitro. Other members of the Newsome laboratory have 
explored the utility of controlling cellular passage (Alfaifi M, 2018, PhD thesis, University of 





In summary, human UCT-derived MSCs donated by OTL from different donors were fully 
characterised as MSCs by ISCT guidelines. The proprietary MACS process by which S2 cells are 
enriched certainly increases the relative number of cells expressing S2. In vitro confluence also has 
a significant effect on S2 expression on MSCs. It is unclear whether these confluence-related 
changes affect MSC function, but the findings focus the investigator’s requirement to ensure cells 
are harvested from culture at a set confluence, and that in-vitro culture conditions do not divagate 






The therapeutic effect of 
systemic human UCT-MSC 




5.1. Background and context 
The overall aim of this body of work is to examine the therapeutic effect of mesenchymal stromal 
cells on liver fibrosis.  
 
Healthcare systems in the western world have made progress in arresting the primary disease 
aetiology for a number of the major causes of liver cirrhosis. Improving public health and 
preventative measures tackle ARLD and NASH and effective antiviral therapy can control or cure 
hepatitis B and C respectively3. However, though some patients experience a reversal of their liver 
fibrosis upon stopping the iterative aetiological injury, others, often those with more advanced 
disease, can be left with a resistant hepatic scar, and the sequelae that follow including the risk of 
hepatocellular carcinoma, decompensation and death. It is for these patients that an anti-fibrotic 
agent may be most impactful.  
 
Chapter 1 discusses the existing published data that explores the therapeutic effect of MSC on 
liver fibrosis. The pre-clinical data (Table 1.2) have been blighted by being underpowered, using 
poorly defined populations of MSCs, and at times failing to apply appropriate methodological 
rigour. However, the over-arching conclusions have been that MSCs seem to prevent fibrogenesis, 
but it remains unclear if they act to resolve established fibrosis45. Thus, MSCs given during injury 
seem to lessen the fibrotic response, but there remains equipoise as to whether MSCs given after 
fibrosis enhance resolution. The preclinical data sits alongside a body of published MSC clinical 
trial data (Table 1.1), including four randomised clinical trials, one of which explored the use of 
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MSC in abstinent patients with ARLD, in whom autologous MSCs given via the hepatic artery 
decreased fibrosis and biochemical surrogate scores of disease severity (MELD score)100.  
 
To model the clinical scenario of established liver fibrosis without continuing active injury, I 
established two models of toxin-induced liver fibrosis as described in Chapter 3. Both models 
delivered an appreciable scar, which persisted upon cessation of injury. The oral TAA model 
produced a more profound and persistent scar than the IP CCl4 model. However, the wide natural 
variation in the fibrosis as measured by PSR CPA morphometric analysis necessitates sample sizes 
of 20 in the treatment and control groups to discern a 25% decrease in fibrosis (Table 3.2) in either 
model.  The data identified a time point at which there were no evidence of significant continuing 
hepatic injury or inflammation in both models.  
 
S2-selected UCT-MSC are prospectively enriched MSCs that are already under assessment for the 
treatment of inflammatory liver disease (autoimmune hepatitis and primary sclerosing cholangitis) 
in a Phase 2a clinical trial (MERLIN: http://fp7merlin.eu/project/). Chapter 4 described the ISCT 
characterisation of the MSCs that were donated for the interventional aspects of this study by 
OTL, and the need to control for cellular confluence at the point of detachment from in vitro 
expansion.  
 
Three trial arms were tested against controls in this chapter. These included S2-selected MSCs 
from 2 different donors (D1/S2+; D2/S2+), thereby examining whether any effects (or absence 
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thereof) were donor-specific. Donor matched MSCs that had not undergone the S2 enrichment 
process were also tested (D1/US), to assess whether effects were consequent on S2 selection.  
 
5.2. Aims of the chapter 
The aims of the work in this chapter were to:  
• Examine the effect of systemic human UCT-MSC therapy on fibrosis resolution in the 
absence of ongoing hepatic injury or inflammation in 2 murine models 
• To also examine the effect of systemic human UCT-MSC therapy on fibrogenesis  
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5.3. Intervention to enhance fibrosis resolution in the absence of ongoing 
hepatocyte injury or inflammation 
5.3.1. The effect of human UCT-MSCs on established CCl4-induced liver fibrosis 
 
Figure 5-1: Schematic of experiment to explore the effect of MSC therapy on the 
resolution of established liver fibrosis using the IP CCl4 chronic hepatic injury 
model: Experiment 1 
Age-matched male C57Bl/6 mice were twice injected with CCl4 diluted in mineral oil (1:3) at a dose of 1µl/g 
bodyweight (dashed vertical arrows) IP, followed by 10 injections at a dose of 2µl/g bodyweight (blocked 
vertical arrows) over 6 weeks. Mice were injected with 0.75x106 MSCs in 200µL of sterile 0.9% saline carrier 
(test) or just carrier (control)  by tail-vein on days 6 and 8 of recovery (total dose = 1.5x106 cells) – EXPERIMENT 
1.  Mice were euthanised on day 21 of recovery (after last IP injection) for tissue and serum analysis. Syndecan-
2-selected MSC were tested from two donors (D1/S2+ and D2/S2+), and unselected MSC from donor 1 
(D1/US) (N=20 each test arm, N=20 control arm). Primary analyses in this experiment were between the each 
of the test arms and the control arm. 
 
The time course experiments delineating peak hepatic fibrosis and resolution following 6 weeks 
of high dose IP CCl4 (Section 3.3.2), revealed that hepatic inflammatory cells as  assessed by CD45 
IHC, had dispersed from portal areas and hepatocyte damage as measured by serum ALT had 
normalised by day 7 of recovery. As such, intervention was given as 2 doses at day 6 and 8 (Figure 
5.1). A dose of 0.75x106 MSC was selected as a maximum for a single bolus due to mice on 
occasion suffering immediate post injection fatal thromboembolic phenomena (cerebrovascular 
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event or pulmonary embolus) using doses above this threshold (preliminary tests – results not 
shown). A total of 1.5x106 MSCs was chosen to be similar to doses that have been trialled in mice 
before in chronic models (Table 1.2), and was cumulatively greater than doses trialled in acute 
liver injury models in the Newsome laboratory202.  
 
The time point for assessment was chosen based on the time-course experiments that showed 
persistent scar at day 21 of recovery. Moreover, natural resolution takes days (as shown in Chapter 
3), and any therapeutic enhancement would likely require days to manifest – therefore a 14 day 






Figure 5-2: Analysis of collagen deposition in Experiment 1 
Following injury, mice were injected with MSCs (donor 1, S2-selected [D1/S2+] - A; donor 1, unselected 
[D1/US] – B; donor 2, S2-selected [D2/S2+] – C) or control (D) as described in Figure 5.1 and euthanised on 
day 21 of recovery. Paraffin-embedded tissue were stained for collagen by PSR and fast green as described in 
section 2.11.3. Red areas demarcate collagen. Scale bar (–) measures 200µm. Morphometric analysis of 
collagen proportionate area (CPA) (E) and assessment of hepatic hydroxyproline (F) as described in section 
2.10 allowed comparison between the treatment groups and the control group by the use of the unpaired 
Student’s t-test (E) and Mann-Whitney test (F); p<0.05 was deemed significant. Summary bars: standard 
deviation and mean value for figure E; 95% CI and median value for figure F 
 
Human UCT-MSCs had no significant effect on the resolution of IP CCl4-induced liver fibrosis when 
administered in the absence of ongoing hepatic injury or inflammation (Figure 5.2). By day 21 of 
recovery, αSMA-positive scar-associated myofibroblasts were inactivated in natural resolution 
(Figure 3.11, 3.12), and the results in Figure 5.3 and Panel A of Figure 5.4 suggest MSC 




Figure 5-3: Analysis of myofibroblast activation in Experiment 1 
Following injury, mice were injected with MSCs (donor 1, S2-selected [D1/S2+] - A; donor 1, unselected 
[D1/US] – B; donor 2, S2-selected [D2/S2+] – C) or control (D) as described in Figure 5.1 and euthanised on 
day 21 of recovery. Paraffin-embedded tissue were stained for αSMA as described in section 2.11.2. Dark areas 
indicate positive staining. Scale bar (–) measures 200µm. Morphometric analysis of positive stained area (E) 
allowed quantitative comparison between treatment groups and the control group by the use of the unpaired 
Student’s t-test; p<0.05 was deemed significant. Summary bars: standard deviation and mean value 
 
Overall, MSC intervention had little effect on the expression of fibrosis-related gene mRNA 
expression (Figure 5.4). However, S2-selected MSCs (but not unselected MSCs) from 2 donors 
increased the expression of Col1a1, Col3a1 and Tgfβ1. The significance of these isolated adverse 
findings is questionable without any lasting effect on myofibroblast activation or gross scar 




Figure 5-4: Gene expression analysis by qPCR of fibrosis-associated genes in 
Experiment 1 
Following injury, mice were injected with MSCs (donor 1, S2-selected [D1/S2+]; donor 1, unselected [D1/US]; 
donor 2, S2-selected [D2/S2+]) or control as described in Figure 5.1 and euthanised on day 21 of recovery. 
Expression of fibrosis-associated genes (A: Acta2, B: Col1a1, C: Col3a1, D: Tgfb1, E: Mmp2, F: Mmp9, G: Timp1 
versus. Housekeeping gene Gapdh) were assessed by qPCR of hepatic tissues as described in section 2.14. 
The Mann-Whitney test was used to compare expression in treatment groups and control group; p<0.05 was 




In knowledge of the immunomodulatory effect of MSC, I went on to examine whether the MSC 
administration had any effect on the myeloid inflammatory infiltrate. Members of the Newsome 
laboratory using the same MSCs had shown an MSC-induced change of macrophage polarity in 
a murine biliary injury model, which may have relevance to fibrotic pathways202.  
 
 
Figure 5-5: Analysis of inflammatory infiltrate by CD45 staining and hepatocyte 
injury by serum ALT measurements and in Experiment 1 
Following injury, mice were injected with MSCs (donor 1, S2-selected [D1/S2+] - A; donor 1, unselected 
[D1/US] – B; donor 2, S2-selected [D2/S2+] – C) or control (D) as described in Figure 5.1 and euthanised on 
day 21 of recovery. Paraffin-embedded sections were stained for CD45 for assessment of inflammatory-cell 
infiltrate as described in section 2.11.2. Dark areas indicate positive staining. Scale bar (–) measures 200µm. 
Morphometric analyses of positive stained area were used for quantitative comparisons (E). Sera from each 
euthanised mouse were analysed for ALT as a surrogate for hepatocyte injury or cell membrane instability (F). 
The unpaired Student’s t-test was used to compare values in treatment groups and control group; p<0.05 was 





Figure 5-6: Flow cytometric analysis of myeloid cells from hepatic tissue and sera 
in Experiment 1 
Following injury, mice were injected with MSCs or control as described in Figure 5.1 and euthanised on day 
21 of recovery. Hepatic tissue and sera were processed for flow cytometric analysis as described in section 
2.8. The gating strategy as described in section 2.8.4 was used to determine the number of myeloid cells 
(CD11b+, CD11c-), neutrophils (CD11b+, CD11c-, F4/80-, Gr+), macrophages/monocytes (CD11b+, CD11c-, 
F4/80+), fibrogenic macrophages (CD11b+, CD11c-, F4/80+, Ly6chi), and restorative macrophages (CD11b+, 
CD11c-, F4/80+, Ly6clo). The unpaired Student’s t-test was used to compare mean values the treatment and 
control groups; p<0.05 was deemed significant. Summary bars: standard deviation and mean value 
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MSC administration had no significant measured effect on surrogates on hepatocyte injury (ALT 
– Figure 5.5, Panel F), the gross inflammatory infiltrate (Figure 5.5, Panel E), or myeloid 






5.3.2. The effect of human UCT-MSCs on established TAA-induced liver fibrosis 
 
Figure 5-7: Schematic of experiment to explore the effect of MSC therapy on the 
resolution of established liver fibrosis using the oral TAA chronic hepatic injury 
model: Experiment 2 
Age-matched male C57Bl/6 mice were subject to hepatic injury by substituting their drinking water with TAA 
diluted in fruit squash (1:5) to be taken ad libitum. A starting dose of 100mg/L (three days - green block) was 
sequentially increased to 300mg/L (three days - yellow block) and 600mg/L (pink block). The TAA solution 
was replaced by standard drinking water after 16 weeks. Mice were injected with 0.75x106 S2-selected MSCs 
(from a single donor) in 200uL of sterile 0.9% saline carrier (test, N = 20) or just carrier (control, N = 20) by 
tail-vein on days 13 and 15 of recovery (total dose = 1.5x106 cells) – EXPERIMENT 2.  Mice were euthanised 
on day 28 of recovery (after oral TAA removed) for tissue and serum analysis. Primary analyses in this 
experiment were between the test arm and the control arm. 
 
The time point at which inflammation and hepatic injury had settled after the cessation of oral 
TAA (protocol as described in Section 3.4.4), was determined after examination of fibrosis and 
resolution time course experiments (Figure 3.35). As such, intervention was given as 2 doses at 
day 13 and 15 (Figure 5.7) of recovery following oral TAA-induced hepatic fibrosis, when the ALT 
had normalised and the CD45 inflammatory infiltrate had dispersed. A persistent scar was evident 
to day 42 of natural recovery (Figure 3.30); however, there was a wide variation in the 
morphometric analysis of CPA by PSR staining at day 42, which was not evident at day 28 of 
recovery. Moreover, as explained in section 5.3.1, 14 days was deemed long enough for MSCs to 
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have an effect on fibrosis resolution. As such, day 28 of recovery was chosen as the time point for 
assessment of the effect of MSC administration.  
 
 
Figure 5-8: Analysis of collagen deposition in Experiment 2 
Following injury, mice were injected with S2-selected MSCs from a single donor (A) or control (B) as described 
in Figure 5.7 and euthanised on day 28 of recovery. Paraffin-embedded tissue were stained for collagen by 
PSR and fast green as described in section 2.11.3. Red areas demarcate collagen. Scale bar (–) measures 
200µm. Morphometric analysis of collagen proportionate area (CPA) (C) and assessment of hepatic 
hydroxyproline (D) as described in section 2.10 allowed comparison between the treatment group and control 
group by the unpaired Student’s t-test (C) and Mann-Whitney test (D); p<0.05 was deemed significant. 





Human UCT-MSCs had no significant effect on the resolution of oral TAA-induced liver fibrosis 
when administered in the absence of ongoing hepatic injury or inflammation (Figure 5.8). 
Moreover, as was seen in the IP CCl4 model, MSC administration had no effect on αSMA expression 
(Figure 5.9 and Panel A of Figure 5.10), and had no effect on the mRNA expression of other 
fibrosis-related genes (Figure 5.10).  
 
 
Figure 5-9: Analysis of myofibroblast activation in Experiment 2 
Following injury, mice were injected with S2-selected MSCs from a single donor (A) or control (B) as described 
in Figure 5.7 and euthanised on day 28 of recovery. Paraffin-embedded tissue were stained for αSMA as 
described in section 2.11.2. Dark areas indicate positive staining. Scale bar (–) measures 200µm. Morphometric 
analysis of positive stained area (C) allowed quantitative comparison between the treatment group and 
control group by the unpaired Student’s t-test; p<0.05 was deemed significant. Summary bars: standard 






Figure 5-10: Gene expression analysis by qPCR of fibrosis-associated genes in 
Experiment 2 
Following injury, mice were injected with S2-selected MSCs from a single donor or control as described in 
Figure 5.7 and euthanised on day 28 of recovery. Expression of fibrosis-associated genes (A: Acta2, B: Col1a1, 
C: Col3a1, D: Tgfb1, E: Mmp2, F: Mmp9, G: Timp1 versus. housekeeping gene Gapdh) was assessed by qPCR 
of hepatic tissues as described in section 2.14. Comparison between the treatment group and control group 






Figure 5-11: Analysis of inflammatory infiltrate by CD45 staining and hepatocyte 
injury by serum ALT measurements and in Experiment 2 
Following injury, mice were injected with S2-selected MSCs from a single donor (A) or control (B) as described 
in Figure 5.7 and euthanised on day 28 of recovery. Paraffin-embedded sections were stained for CD45 for 
assessment of inflammatory-cell infiltrate as described in section 2.11.2. Dark areas indicate positive staining. 
Scale bar (–) measures 200µm. Morphometric analyses of positive stained area were used for quantitative 
comparisons (C). Sera from each euthanised mouse were analysed for ALT as a surrogate for hepatocyte injury 
or cell membrane instability (D). Comparison between the treatment group and control group was done by 
the unpaired Student’s t-test; p<0.05 was deemed significant. Summary bars: standard deviation and mean 
value.  
 
As in the IP CCl4 model, MSC administration in the absence of ongoing hepatic injury had no 
measured effect on surrogates on hepatocyte injury (ALT – Figure 5.11, Panel D), and the gross 
inflammatory infiltrate (Figure 5.11, Panel C).   
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5.4. Intervention to enhance fibrosis resolution in the presence of ongoing 
hepatocyte injury or inflammation 
Human UCT-MSC therapy did not resolve established fibrosis in the setting of a no ongoing 
hepatic injury or inflammation in either the IP CCl4 or oral TAA model. 
 
 
Figure 5-12: Schematic of experiment to explore the effect of MSC therapy on the 
resolution of established liver fibrosis in the presence of on-going inflammation 
using the IP CCl4 chronic hepatic injury model: Experiment 3 
Age-matched male C57Bl/6 mice were twice injected with CCl4 diluted in mineral oil (1:3) at a dose of 1μl/g 
bodyweight (dashed vertical arrows) IP, followed by 10 injections at a dose of 2µl/g bodyweight (blocked 
vertical arrows) over 6 weeks. Mice were injected with 0.75x106 S2-selected MSCs (from a single donor) in 200uL 
of sterile 0.9% saline carrier (test, N = 20) or just carrier (control, N = 20) by tail-vein on days 1 and 3 of recovery 
(total dose = 1.5x106 cells) – EXPERIMENT 3. Mice were euthanised on day 21 of recovery (after last IP injection) 
for tissue and serum analysis. Primary analyses in this experiment were between the test arm and the control 
arm. 
 
There are evidence to suggest that MSCs require in vivo interaction with an inflammatory milieu 
(licencing) to effect a function203. This is particularly true for MSC-mediated immunomodulation 
in the setting of graft-versus host disease, where MSCs have a clear benefit when given in severe 
steroid-refractory disease, but not in more quiescent disease204,205. Therefore, I subsequently 
sought to examine whether the timing of therapy may influence outcome. I used the shorter 6-
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week IP CCl4 protocol rather than the longer 16-week oral TAA protocol, and administered MSC 
therapy after injury had ceased, but at a time when there was still residual hepatocyte injury and 
hepatic inflammation; days 1 & 3 of recovery (Figure 5.12). 
 
 
Figure 5-13: Analysis of collagen deposition in Experiment 3 
Following injury, mice were injected S2-selected MSCs from a single donor (A) or control (B) as described in 
Figure 5.12 and euthanised on day 21 of recovery. Paraffin-embedded tissue were stained for collagen by PSR 
as described in section 2.11.3. Red areas demarcate collagen. Scale bar (–) measures 200µm. Morphometric 
analysis of collagen proportionate area (CPA) (C) and assessment of hepatic hydroxyproline (D) as described 
in section 2.10 allowed comparison between the treatment groups and the control group by the use of the 





Figure 5-14: Analysis of myofibroblast activation in Experiment 3 
Following injury, mice were injected with S2-selected MSCs from a single donor (A) or control (B) as described 
in Figure 5.12 and euthanised on day 21 of recovery. Paraffin-embedded tissue were stained for αSMA as 
described in section 2.11.2. Dark areas indicate positive staining. Scale bar (–) measures 200µm. Morphometric 
analysis of positive stained area (C) allowed comparison between treatment groups and the control group by 
the use of the unpaired Student’s t-test; p<0.05 were deemed significant. Summary bars: standard deviation 





Figure 5-15: Gene expression analysis by qPCR of fibrosis-associated genes in 
Experiment 3 
Following injury, mice were injected with S2-selected MSCs from a single donor or control as described in 
Figure 5.12 and euthanised on day 21 of recovery. Expression of fibrosis-associated genes (A: Acta2, B: Col1a1, 
C: Col3a1, D: Tgfb1, E: Mmp2, F: Mmp9, G: Timp1 versus. housekeeping gene Gapdh) were assessed by qPCR 
of hepatic tissues as described in section 2.14. The Mann-Whitney test was used to compare expression in 




Changing the timing of MSC administration did not change the effect of their administration. 
Human UCT-MSCs had no significant effect on the resolution of IP CCl4-induced liver fibrosis when 
administered in the setting of ongoing hepatic injury and inflammation, whether measured by 
extant collagen (Figure 5.13), myofibroblast activation (Figure 5.14) or the expression of fibrosis-
related genes (Figure 5.15).   
 
 
Figure 5-16: Analysis of inflammatory infiltrate by CD45 staining and hepatocyte 
injury by serum ALT measurements and in Experiment 3 
Following injury, mice were injected with S2-selected MSCs from a single donor (A) or control (B) as described 
in Figure 5.12 and euthanised on day 21 of recovery. Paraffin-embedded sections were stained for CD45 for 
assessment of inflammatory-cell infiltrate as described in section 2.11.2. Dark areas indicate positive staining. 
Scale bar (–) measures 200µm. Morphometric analyses of positive stained area were used for quantitative 
comparisons (C). Sera from each euthanised mouse were analysed for ALT as a surrogate for hepatocyte injury 
or cell membrane instability (D). The unpaired Student’s t-test was used to compare expression in treatment 
groups and control group; p<0.05 was deemed significant and *-marked. Summary bars: standard deviation 






Figure 5-17: Flow cytometric analysis of myeloid cells from hepatic tissue and sera 
in Experiment 3 
Following injury, mice were injected with MSCs or control as described in Figure 5.12 and euthanised on day 
21 of recovery. Hepatic tissue and sera were processed for flow cytometric analysis as described in section 
2.8. The gating strategy as described in section 2.8.4 was used to determine the number of myeloid cells 
(CD11b+, CD11c-), neutrophils (CD11b+, CD11c-, F4/80-, Gr+), macrophages/monocytes (CD11b+, CD11c-, 
F4/80+), fibrogenic macrophages (CD11b+, CD11c-, F4/80+, Ly6chi), and restorative macrophages (CD11b+, 
CD11c-, F4/80+, Ly6clo). The unpaired Student’s t-test was used to compare mean values the treatment and 
control groups; p<0.05 was deemed significant. Summary bars: standard deviation and mean value 
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Moreover, MSC administration had no significant effect on hepatic inflammation as measured by 
CD45 IHC (Figure 5.16, Panel A-C), or flow cytometry of myeloid inflammatory substrates (Figure 
5.17). A statistically significantly raised ALT in the MSC treatment arm (Figure 5.16, Panel D) is 
unlikely to be biologically significant as the mean values and range are still under the upper limit 
of normal (ALT upper limit of normal = 50IU/L). Moreover, a qualitative comparative assessment 
of the H&E staining between the treatment and control arms yielded no significant differences 






5.5. Intervention to reduce fibrogenesis during ongoing hepatic injury 
Human UCT-MSC therapy did not resolve established fibrosis in the presence or absence of 
ongoing inflammation and hepatocyte injury in either the IP CCl4 or oral TAA model.  
 
The published data overwhelmingly suggests MSCs given during the fibrogenic process (whilst 
injury is ongoing) can reduce the final burden of fibrosis. This has been shown in multiple rodent 
fibrosis models, and using both syngeneic and xenogeneic (including human) MSCs (Table 1.2).  
 
As such, I sought to examine whether intervening during injury can reduce fibrosis in both the IP 
CCl4 (Figure 5.18) and oral TAA models (Figure 5.24) in a statistically powered experiment.  
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5.5.1. The effect of human UCT-MSCs during CCl4-induced liver fibrosis 
 
Figure 5-18: Schematic of experiment to explore the effect of MSC therapy on 
fibrogenesis using the IP CCl4 chronic hepatic injury model: Experiment 4 
Age-matched male C57Bl/6 mice were twice injected with CCl4 diluted in mineral oil (1:3) at a dose of 1μl/g 
bodyweight (dashed vertical arrows) IP, followed by 10 injections at a dose of 2µl/g bodyweight (blocked 
vertical arrows) over 6 weeks. Mice were injected with 0.75x106 MSCs in 200uL of sterile 0.9% saline carrier 
(test) or just carrier (control, N = 20) by tail-vein 24 hours after the 5th and 10th IP injections (total dose = 
1.5x106 cells) – EXPERIMENT 4. Mice were euthanised 24 hours after the last IP injection for tissue and serum 
analysis. Syndecan-2-selected MSC were tested from two donors (D1/S2+ and D2/S2+), and unselected MSC 
from donor 1 (D1/US) (N=20 each test arm). Primary analyses in this experiment were between the test arms 






Figure 5-19: Analysis of collagen deposition in Experiment 4 
During injury, mice were injected with MSCs (donor 1, S2-selected [D1/S2+] - A; donor 1, unselected [D1/US] 
– B; donor 2, S2-selected [D2/S2+] – C) or control (D) as described in Figure 5.1 and euthanised on day 21 of 
recovery. Paraffin-embedded tissue were stained for collagen by PSR and fast green as described in section 
2.11.3. Red areas demarcate collagen. Scale bar (–) measures 200µm. Morphometric analysis of collagen 
proportionate area (CPA) (E) and assessment of hepatic hydroxyproline (F) as described in section 2.10 allowed 
comparison between the treatment groups and the control group by the use of the unpaired Student’s t-test 
(E) and Mann-Whitney test (F); p<0.05 was deemed significant. Summary bars: standard deviation and mean 
value for figure E; 95% CI and median value for figure F 
 
Human UCT-MSCs had no significant effect on the fibrogenesis of IP CCl4-induced liver fibrosis, 
whether measured by extant collagen (Figure 5.19), myofibroblast activation (Figure 5.20) or the 




Figure 5-20: Analysis of myofibroblast activation in Experiment 4 
During injury, mice were injected with MSCs (donor 1, S2-selected [D1/S2+] - A; donor 1, unselected [D1/US] 
– B; donor 2, S2-selected [D2/S2+] – C) or control (D) as described in Figure 5.18 and euthanised 24 hours 
after the last IP injection. Paraffin-embedded tissue were stained for αSMA as described in section 2.11.2. Dark 
areas indicate positive staining. Scale bar (–) measures 200µm. Morphometric analysis of positive stained area 
(E) allowed comparison between the treatment group and control group by the unpaired Student’s t-test; 






Figure 5-21: Gene expression analysis by qPCR of fibrosis-associated genes in 
Experiment 4 
During injury, mice were injected with MSCs (donor 1, S2-selected [D1/S2+]; donor 1, unselected [D1/US]; 
donor 2, S2-selected [D2/S2+]) or control as described in Figure 5.18 and euthanised 24 hours after the last 
IP injection. Expression of fibrosis-associated genes (A: Acta2, B: Col1a1, C: Col3a1, D: Tgfb1, E: Mmp2, F: 
Mmp9, G: Timp1 versus housekeeping gene Gapdh) was assessed by qPCR of hepatic tissues as described in 
section 2.14. The Mann-Whitney test was used to compare expression in treatment groups and control group; 





Figure 5-22: Analysis of inflammatory infiltrate by CD45 staining and hepatocyte 
injury by serum ALT measurements and in Experiment 4 
During injury, mice were injected with MSCs (donor 1, S2-selected [D1/S2+] - A; donor 1, unselected [D1/US] 
– B; donor 2, S2-selected [D2/S2+] – C) or control (D) as described in Figure 5.18 and euthanised 24 hours 
after the last IP injection. Paraffin-embedded sections were stained for CD45 for assessment of inflammatory-
cell infiltrate as described in section 2.11.2. Dark areas indicate positive staining. Scale bar (–) measures 200µm. 
Morphometric analyses of positive stained area were used for quantitative comparisons (E). Sera from each 
euthanised mouse were analysed for ALT as a surrogate for hepatocyte injury or cell membrane instability (F). 
The unpaired Student’s t-test was used to compare expression in treatment groups and control group; p<0.05 
was deemed significant. Summary bars: standard deviation and mean value 
 
MSC administration resulted in a higher serum ALT than control saline administration (Figure 5.29, 
Panel F). The effect was independent of MSC donor or the S2 selection process. There were no 
obvious qualitative differences in the gross morphological pathology between the treatment and 




Figure 5-23: Flow cytometric analysis of myeloid cells from hepatic tissue and sera 
in Experiment 4 
Following injury, mice were injected with MSCs or control as described in Figure 5.18 and euthanised on day 
21 of recovery. Hepatic tissue and sera were processed for flow cytometric analysis as described in section 
2.8. The gating strategy as described in section 2.8.4 was used to determine the number of myeloid cells 
(CD11b+, CD11c-), neutrophils (CD11b+, CD11c-, F4/80-, Gr+), macrophages/monocytes (CD11b+, CD11c-, 
F4/80+), fibrogenic macrophages (CD11b+, CD11c-, F4/80+, Ly6chi), and restorative macrophages (CD11b+, 
CD11c-, F4/80+, Ly6clo). The Mann-Whitney was used to compare mean values the treatment and control 
groups; p<0.05 was deemed significant. Summary bars: 95% CI and median value 
186 
 
An evaluation of the gross inflammatory infiltrate by CD45 IHC (Figure 5.22, Panels A-E) showed 
a dense peri-portal and scar-associated infiltrate with a statistically significant elevation CD45 
stained area in mice injected with S2-selected MSCs from donor 2, but not the other treatment 
groups. The effect was small, and a statistical evaluation of inter-treatment arm differences yielded 
no significant variance (one-way ANOVA >0.05). A subsequent analysis of myeloid inflammatory 










5.5.3. The effect of human UCT-MSCs during TAA-induced liver fibrosis 
 
Figure 5-24: Schematic of experiment to explore the effect of MSC therapy on 
fibrogenesis using the oral TAA chronic hepatic injury model: Experiment 5 
Age-matched male C57Bl/6 mice were subject to hepatic injury by substituting their drinking water with TAA 
diluted in fruit squash (1:5) to be taken ad libitum. A starting dose of 100mg/L (three days - green block) was 
sequentially increased to 300mg/L (three days - yellow block) and 600mg/L (pink block). The TAA solution 
was replaced by standard drinking water after 14 weeks. Mice were injected with 0.75x106 S2-selected MSCs 
(from a single donor) in 200uL of sterile 0.9% saline carrier (test, N = 20) or just carrier (control, N = 20) by 
tail-vein after 4, 7 and 10 weeks of injury (total dose = 2.25x106 cells) – EXPERIMENT 5.  Mice were euthanised 
24 hours after TAA was removed for tissue and serum analysis. Primary analyses in this experiment were 
between the test arm and the control arm. 
 
The oral-TAA protocol was shortened for the purposes of testing the effect of MSC administration 
during continuing injury. The feasibility experiment for the model (Figure 3.23), demonstrated that 
fibrosis was not evident at week 4 of the protocol, and significant fibrosis and myofibroblast 
activation only manifest from week 12.  As such, we selected an injury duration of 14 weeks to 
ensure the uninterrupted protocol could deliver a significant scar. We chose to start intervention 
at a time when there was no significant fibrosis, but there was evidence of hepatic injury (week 4, 
ref H&E staining Figure 3.20). We delivered three MSC doses to ensure any effect they have was 
not lost with continuing injury over the 14-week protocol. Therefore, a greater total dose of MSCs 
was given in the treatment arm in experiment 5, compared to the other intervention experiments 




Figure 5-25: Analysis of collagen deposition in Experiment 5 
During injury, mice were injected with S2-selected MSCs from a single donor (A) or control (B) as described 
in Figure 5.24 and euthanised 24 hours after TAA was removed. Paraffin-embedded tissue were stained for 
collagen by PSR and fast green. Red areas demarcate collagen. Scale bar (–) measures 200µm. Morphometric 
analysis of collagen proportionate area (CPA) (C) and assessment of hepatic hydroxyproline (D) as described 
in section 2.10 allowed comparison between the treatment group and control group by the use of the 





Figure 5-26: Analysis of myofibroblast activation in Experiment 5 
During injury, mice were injected with S2-selected MSCs from a single donor (A) or control (B) as described 
in Figure 5.24 and euthanised 24 hours after TAA was removed. Paraffin-embedded tissue were stained for 
αSMA. Dark areas indicate positive staining. Scale bar (–) measures 200µm. Morphometric analysis of positive 
stained area (C) allowed comparison between the treatment group and control group by the unpaired 





Figure 5-27: Gene expression analysis by qPCR of fibrosis-associated genes in 
Experiment 5 
During injury, mice were injected with S2-selected MSCs from a single donor or control as described in Figure 
5.24 and euthanised 24 hours after TAA was removed. Expression of fibrosis-associated genes (A: Acta2, B: 
Col1a1, C: Col3a1, D: Tgfb1, E: Mmp2, F: Mmp9, G: Timp1 versus housekeeping gene Gapdh) was assessed by 
qPCR of hepatic tissues as described in section 2.14. The Mann-Whitney-test was used to compare expression 





Much like intervention during the chronic IP CCl4 protocol in experiment 4, MSCs had no effect 
on fibroplasia when given during oral TAA-induced fibrosis (Figure 5.25-5.27).  
 
 
Figure 5-28: Analysis of inflammatory infiltrate by CD45 staining and hepatocyte 
injury by serum ALT measurements and in Experiment 5 
During injury, mice were injected with S2-selected MSCs from a single donor (A) or control (B) as described 
in Figure 5.24 and euthanised 24 hours after TAA was removed. Paraffin-embedded sections were stained for 
CD45 for assessment of inflammatory-cell infiltrate as described in section 2.11.2. Dark areas indicate positive 
staining. Scale bar (–) measures 200µm. Morphometric analyses of positive stained area were used for 
quantitative comparisons (C). Sera from each euthanised mouse were analysed for ALT as a surrogate for 
hepatocyte injury or cell membrane instability (D). The unpaired Student’s t-test was used to compare 
expression in treatment groups and control group; p<0.05 was deemed significant. Summary bars: standard 
deviation and mean value 
 
Moreover, MSC administration during oral TAA induced injury had no effect on serum ALT, or 




The work in this chapter has comprehensively demonstrated that human UCT-MSCs given via tail-
vein in two well-characterised murine models of liver fibrosis has no effect of fibrosis as measured 
by extant collagen, the expression of αSMA as a marker of activated myofibroblasts, and fibrosis-
related gene expression. The experiments were statistically powered to show a meaningful 
difference in the most reliable output measure of extant ECM – morphometric analysis of collagen 
proportionate area. As such, the data is robust, and the methodology reflects standardised 
guidelines that have been proposed to overcome the shortfalls of much of the published data in 
the field (Table 5.1) 73,162,206:  
 
Table 5-1: Application of standardised guidelines to improve reliability of 
outputs from animal experimentation to explore liver fibrosis 
Guidance73,206 Action in this study 
Selection of animals of defined adult age and sex Male C57Bl/6 mice aged 8-10 weeks at injury onset 
Group sizes of 8-15 Group sizes of 20 based on variance noted on preliminary 
data (Chapter 3, Table 3.2) 
Optimised route and dose of toxin application Route of application chosen based on translatability of 
peripheral systemic injection – discussed further in Chapter 
6 
Analysis of liver samples of sufficient size (5-10%) Hyp assay performed using 100µg sample (approximately 
7.5% of total mouse liver weight) 
Representative morphometric analysis Use of slide scanner to acquire images of whole of left lobe 
of liver – using >80% of each available image to almost 
nullify image selection bias.  
Use of representative spectrum of quantitative fibrosis and 
fibrolysis readouts 
Broad use of fibrosis output measures, all of which well 
established in literature.  
 
 
It is unlikely that the non-effect was due to a resistant scar, as both models had exhibited the 




However, before declaring strong conclusions, one must consider methodological aspects that 
may have obstructed an effect being realised. The main considerations are: 
1) Inadequate dose 
2) Inadequate delivery method 
3) MSC heterogeneity 
4) Xenogeneic effect (human MSCs in a mouse model) 
 
0.75 x 106 cells was chosen as the maximum safe single bolus in the fibrotic models, based on 
preliminary work during which tail-vein injections of 1 x 106 cells would occasionally lead to 
catastrophic embolic phenomena (pulmonary emboli or cerebrovascular events) immediately 
after injection (death in less than 2 minutes) in approximately 1 in 10 cases. This never happened 
with 0.75 x 106 cells. The published data suggests that very few investigators had trialled human 
cells via the tail-vein of mice to ameliorate fibrosis (Table 1.1)45. The total doses have ranged from 
1 x 106 to 3 x 106 in chronic liver injury models207, though a greater range have been trialled in the 
setting of acute liver injury208. Existing data has not adequately examined the optimal dosing 
regimen to deliver a desired therapeutic effect, and comparisons between studies will be 
confounded by variations in model of injury, timing of dose, type of MSC and outcome measures. 
Hong et al transplanted human UCT-MSC into rats with dimethylnitrosamine-induced liver injury 
(0.01% supplemented diet given ad libitum for 4 weeks) at varied doses, either as single infusions 
or as split dosing. They found that the anti-fibrotic effect was dose dependent, but probably not 
enhanced by split infusions209. Higher doses of single infusions (3 and 6x106) led to a significant 
reduction of collagen-1 gene expression compared to the lowest dose (1x106) (p<0.05). There was 
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a trend to a dose-dependent reduction of fibrosis as measured by PSR CPA, although this was not 
statistically significant: 1x106 - 1.45%; 3x106 - 0.8%; 6x106 -0.1%. However, Hong’s study was in 
rats, not mice. Miryounesi et al highlighted the possible benefits of split dosing over single 
infusions by infusing 3x106 human BM-MSC in a murine CCl4 injury model (IP twice per week for 
9 weeks in NMRI mice)207. This was administered as a single infusion at week four or as a split dose 
of 1x106 MSC on three occasions at weeks 4, 5 and 6 of a 9-week injury protocol. Mice were 
sacrificed for assessment at the end of injury and the single treatment arm showed no significant 
reduction in fibrosis versus the untreated arm as measured by CPA, although there was a 
significant reduction in the expression of Col1α1 (p<0.05). The staggered treatment arm produced 
a significantly reduction in fibrosis as measured by CPA (2.5% vs 6%), and Col1α1 gene expression 
(both p<0.05) compared to the untreated control and the single-treatment arm. It is plausible that 
earlier MSC infusions make the injured environment more tolerable for later MSC infusions by 
inducing the down-regulation of cytotoxic T-cell, and up regulation of regulatory T-cells, thus 
making it less likely that they will succumb to cytotoxic lysis108. Early MSC infusions may dampen 
the IFN-γ signal108, thereby removing the stimulus for MSC to express MHC-antigens210, and 
allowing their continued immune-privileged state. However, this was a speculative conclusion by 
the authors with no data to support their claim. 
 
Intertwined with the dosing issue, is the mode of delivery. Systemic infusion provides the least 
invasive and most practical mode of cell therapy delivery in humans. Direct access to the liver is 
difficult, and is associated with complications. The risks are compounded in those with established 
liver disease. Therefore, to be able to translate the preclinical findings in this study, we chose to 
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evaluate the efficacy of tail-vein systemic injection of MSCs in our mouse models. This study goes 
on to explore and discuss the bio-distribution and persistence of systemically injected MSCs in 
Chapter 6.  
 
As already discussed in Chapter 4, the term mesenchymal stromal cell describes a very 
heterogeneous cell population. MSCs from different tissue sources are likely to have very different 
biological effects, as they are known to have vastly different biological functions, differential 
potential and transcriptomic signatures211–214. The ISCT accept this as a critical shortcoming of the 
field, and therefore expect only that MSCs are clearly defined by their source, mesogenic potential, 
cell surface markers, culture conditions, and any relevant functional assays178,215. For this reason, it 
is difficult to compare and generalise conclusions from experiments using MSCs, and one can only 
safely deduce that S2-selected and unselected MSCs from the 2 donors trialled in this study do 
not affect liver fibrosis in the models that have been tested. Only one study to date has examined 
the effect of MSCs from different tissue sources on liver fibrosis. Briquet et al. compared the effect 
of well characterised human bone marrow, umbilical cord and liver MSCs on an IP CCl4 model of 
liver fibrosis in mice, and found no difference in fibrosis as measured by CPA when injected by 
tail-vein after the cessation of injury114.  
 
Testing human MSCs in a xenogeneic model is a critical limitation of this study216. Xenogeneic 
MSCs may be subject to accelerated immune clearance. However, there are little data to support 
that notion. MSCs are considered to be immuno-privileged as they do not express class II217 major 
histocompatibility complex (MHC) molecules, very low levels of class-I MHC molecules and or co-
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stimulatory antigens CD80 and CD86 in vitro, which forms the basis of their allogeneic use175. 
However, the immuno-privilege of allogeneic MSC is a contentious issue, as in the presence of an 
inflammatory milieu (especially one containing high concentrations of IFN-γ), the expression of 
MHC-I and -II antigens are increased, rendering MSC susceptible to cytotoxic lysis210,218. However, 
this is in-part countered by their ability to induce an increase in regulatory T-lymphocytes, and 
suppress CD4+ and CD8+ memory and cytotoxic cells219–221, in areas of injury. Nevertheless, 
adoptively transferred syngeneic and xenogeneic MSC are readily cleared within days both in pre-
clinical and clinical settings, despite benefit out-lasting their presence175. Moreover, the clinical 
relevance of human MSCs having (or not having) an effect in animal model systems is debatable, 
as it assumes a requisite homology of disease and homeostatic pathways between the model and 
the human. For example, human MSCs use indoleamine 2,3-dioxygenase to suppress T-cells, 
whereas mouse MSCs utilise nitric oxide219,222. Similarly, the well characterised dichotomy of pro-
inflammatory and fibrogenic Ly-6chi monocyte derived macrophages and “restorative” Ly-6clo 
macrophages are critical modulators of fibrosis in mice58; however, the human counterparts are 
less well characterised, and a similar differentiation of fibrogenic and restorative macrophages has 
not yet been described. Human CD14+16+ tissue macrophages share functional similarities with 
the pro-fibrogenic Ly-6chi macrophages in mice, whilst also possessing high phagocytic activity 
akin the restorative Ly-6clo macrophages223,224. Therefore even though human MSCs have been 
shown to have significant effects of murine pathology by other investigators, including pathways 
that may be relevant to fibrosis202, the relevance in humans remains foggy. Using humanised 




The data in this chapter suggests that MSCs given during the injurious phase neither prevented 
fibrosis, nor influenced chronic hepatic inflammation. As described in Chapter 3, the fibrogenic 
pathways of both the CCl4 and TAA models are driven by hepatocyte death, oxidative stress and 
inflammation. Data from others in the Newsome laboratory have shown that the same MSCs used 
in this study can abrogate oxidative stress in an acute CCl4 injury model (Alfaifi M, 2018, PhD 
Thesis, University of Birmingham) and immunomodulate to increase hepatic T-helper cell 
populations and polarise macrophages from M1 to M2 in the inflammatory biliary injury model202 
(MDR2 knockout mice). It is plausible, that the alleviation of oxidative stress is short-lived (72 
hours) after infusion, and overwhelmed in the setting of continuing injury. Moreover, the 
immunomodulatory effects may again be short lived and not be critical to the fibrotic pathways, 
as MSC infusions were not seen to affect fibrosis readouts in the MDR2 model. The isolated rise 
in serum ALT noted when MSCs were administered during CCl4-induced injury may represent a 
flux in oxidative stress, especially in the absence of finding any changes in inflammatory infiltrate. 
As such, it would be worth a further exploration, but others in the Newsome laboratory are 
focussing on the effect of MSC therapy on redox homeostasis, and the focus of my study is fibrosis. 
In the absence of any significant effect on fibrosis, I chose not to pursue this angle any further.  
 
5.6.1. Summary 
The work in this chapter is a robust, statistically powered analysis of the effect of human UCT-
MSCs on fibroplasia and fibrosis resolution in two well characterised models of murine liver 
fibrosis. The absence of any effect is not MSC donor specific, and not a function of prospective 
enrichment for syndecan 2. Notwithstanding the potential limitations of using a xenogeneic 
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model, and the possibility that MSCs from other tissue sources may have a different effect, it is 
safe to recommend that future investigators require a significant deviation in methodology or 









persistence of human MSCs 
injected by tail-vein in mice 






6.1. Background and context 
Systemic infusion provides the least invasive and most practical mode of cell therapy delivery. 
Direct access to the liver is difficult and is associated with complications. The risks are 
compounded in those with established liver disease due to coagulopathy and portal hypertension. 
Therefore, we chose to evaluate the efficacy of tail-vein systemic injection of MSCs in our mouse 
models. 
 
In the absence of eliciting any substantial effect of human UCT-MSC therapy on fibrosis regression 
or resolution, we sought to examine the bio-distribution and persistence of MSCs following tail-
vein injection.  
 
6.1.1. CryovizTM imaging of nanocrystal labelled MSCs 
The Qtracker® Cell Labeling Kits (Q25001MP; Life technologies, Invitrogen, UK) aggregates Qdot® 
nanocrystals into the cytoplasm and organelles of intact cells within an hour of incubation, by an 
enzyme-independent mechanism. The technology avoids degradation and photo bleaching225,226. 
The nanocrystals are inherited by daughter cells for at least six generations, and offer long-term 
photo-stability and fluorescence for up to a week when tested in a number of cell lines according 
to the manufacturers product specification; this retention facilitates cell migration to be tracked 
in vivo227. Other investigators have demonstrated no impact of Qdot® labeling on MSC 
proliferation and DNA damage for up to 120 hours228. However, a dose dependent effect on 
cytokine release and apoptosis was seen, though not at the concentrations recommended by the 
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manufacturer. Few labelling techniques have demonstrated such stability without affecting cellular 
function or viability. One exception is the novel 89Zr labelling method which exhibits a half-life of 
nearly 80 hours, thereby enabling high resolution in vivo tracking for up to 3 weeks229.  
 
Cellular aggregation of nanocrystals registers as a fluorescent unit that can be detected by the 
CryovizTM technology. The CryovizTM or cryomicrotome imaging system requires cryopreserved 
tissues to be sectioned at 20µm thickness to acquire high-resolution bright field and fluorescence 
images. The 2D planar images can then be reformatted to produce 3D renderings and thereby 
enable 3D interrogation230. This resulting cellular-level resolution of tagged cells in vivo in an 
“intact” mouse can facilitates a high throughput and highly granular assessment of tagged-cell 
distribution231. The technology quantifies the number of cells distributed throughout the whole 
body, and provides a considerably greater resolution of cellular tracking than other whole-body 
imaging methods such as positron emission tomography of radiolabelled MSCs229, or even 
magnetic resonance imaging of MSCs loaded with supermagnetic particles232. The major 
disadvantage of the CryovizTM system is that it requires mice to be euthanised prior to imaging, 
whereas the other methods permit imaging in live animals and thereby open the potential for 
serial imaging over time within the same mouse.  
 
Ex vivo histological assessment is the most common approach to localise labelled MSCs, whether 
it be via basic IHC (using Qdots®, vital dyes or green-fluorescent protein)233,234 or in situ 
hybridisation in sex or species-mismatched samples233. Though these techniques can provide in 
situ visualisation within the context of tissue structure, they require the cells to be abundant 
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enough to be detected. Contemporary PCR-based techniques including RT-PCR can overcome 
some of the issues of sensitivity with an estimated threshold for detection as low as one human 
MSC in 600,000 murine cells235. Nevertheless, tissue collection from different organ compartments 
throughout the body is highly intensive, invasive, and susceptible to sampling bias. CryovizTM 
overcomes each of these issues and provides the state-of-the-art ex vivo imaging option (Figure 
6.1).  
 
Industry collaborators BioInVision Inc. (Cleveland, USA) kindly provided the images and crude 
quantification of the labelled MSCs in frozen mice using CryovizTM, following the in vivo 
experiments that I conducted myself in Birmingham. 
 
6.2. Aims of the chapter 
The aims of the work in this chapter were to: 
• Map the bio-distribution of Qdot® nanocrystal labelled human UCT-MSCs injected by the 
tail-vein of immunocompetent mice with established liver fibrosis. 








Figure 6-1: Image acquisition using CryovizTM technology: localising MSCs 
The technology and software provided 20µm sections through a fixed plane (coronal) of the cryopreserved 
whole mice, which were subsequently rendered in to three-dimensional maps for localisation of fluorescently 
labelled cells. The top (bright field) and bottom (fluorescent) images of the whole mouse show corresponding 
coronal sections through a frozen mouse using the CryovizTM technology and software. The fluid-filled gut 
can be seen to be auto fluorescent (yellow) and fluorescently labelled MSCs can be seen to aggregate in the 
lungs (speckled red distribution) in the middle image. The bottom left (bright field) and right (fluorescent) 
images are magnified corresponding sections from the whole mouse. The fluorescent bright-red aggregated 
MSCs are easily seen in the lungs, but are more sparse in the liver. Of interest, the band-like pink auto-
fluorescence (highlighted by star) are likely to demarcate bands of fibrosis or inflammatory infiltrate, which 




6.3. Qdot® nanocrystal labelling of human UC MSCs 
6.3.1. Labelling uptake efficacy 
 
Figure 6-2: Flow cytometric analysis of Qdot® uptake by MSCs in culture 
Human UCT-MSCs were expanded in culture to passage 3 and enzymatically detached from the tissue culture 
flasks at a confluence of 70-80%. 1x106 cells from each of three tissue culture flasks (green, blue and red 
histograms) were labelled with Qdot®-605 nanocrystals as per manufacturer’s instructions. The labelled cells 
were examined for fluorescence on the PE channel using a Cyan ADP flow cytometer. The proportion of 
labelled cells were determined using the Overton subtraction technique (percentages above the histograms) 
against the histogram of unlabelled cells (UC)).  
 
The Qtracker® cell tagging protocol labelled 75.4±4.1% (mean ± standard deviation) of human 
UCT-MSCs after triplicate testing using MSCs from different starting vials. The consistency of 
percentage uptake reassured me that the numbers detected in vivo would be faithfully 
comparable between mice.  
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6.3.2. The effect of label uptake on cellular viability 
 
Figure 6-3: Cell viability of Q-dot®-labelled and unlabelled MSCs 
3 sets of 1x106 MSCs were labelled with Q-dot®-605 nanocrystals as per manufacturers instructions and assessed 
for cellular viability after 1 and 24 hours in culture medium by the Trypan-blue exclusion method using a 
haemocytometer. The percentage of viable cells (unstained) were charted. 3 sets of a matched number of 
unlabelled MSCs were similarly examined as a control. Data summary bars represent the mean and range. There 
were no significant difference in cell viability between the two groups.  
 
The Qtracker® cell tagging protocol did not affect cell viability both in the immediate aftermath 
of incubating with the nanocrystals, and after 24 hours of further in vitro culture.   


















6.4. Bio-distribution and persistence of Qdot® labelled UC MSCs 
We injected 1x106 MSC Qdot® -605 labelled MSCs via tail-vein in to ten mice with established 
hepatic fibrosis as described in Figure 6.4. Two mice were euthanised by a Schedule 1 approved 
CO2 asphyxiation technique at each of the five time points after injection.  
 
 
Figure 6-4: Schematic of experiment to explore the bio-distribution tail-vein-
injected MSCs in a model of liver fibrosis 
Age-matched male C57Bl/6 mice were twice injected with CCl4 diluted in mineral oil (1:3) at a dose of 1μl/g 
bodyweight (dashed vertical arrows) IP, followed by 10 injections at a dose of 2µl/g bodyweight (blocked 
vertical arrows) over 6 weeks. Mice were injected with 1x106 S2-selected MSCs (labelled using Qdot®-605) in 
200uL of sterile 0.9% saline carrier on day 6 of recovery after the last IP injection. Two mice were euthanised 
by CO2 asphyxiation on each of indicated time points (blue circles) after the last MSC injection, and prepared 
for whole-body bio-distribution analysis by CryovizTM technology. In brief, the carcasses were submerged and 
embedded in PolyFreeze Tissue Freezing Medium (SHH0026; Sigma, UK), and rapidly frozen on a bed of dry 
ice. They were then stored at -80°C until shipment to BioInVision Inc. (Cleveland, USA). 
 
At 1 hour after injection, a mean of 88.3% of MSCs were in the lung, with 5.9% in the liver. The 







Figure 6-5: 3-dimensional rendering of CryovizTM images to illustrate the 
distribution of MSCs in the injected CCl4-injected mice at advancing time points 
after tail-vein injection 
The images represent 3-dimensional reconstructions of 2-dimensional sections constructed by the CryovizTM 
software viewed along the sagittal (A, C, E, G, I) and coronal (B, D, F, H, J) planes. The bright yellow dots denote 
MSCs in the ghost-like representations of the underlying organs (red – lungs; green – liver; purple - spleen). 
Mice were euthanised for analysis 1 hour (A, B), 1 day (C, D), 3 days (E, F), 6 days (G, H) and 8 days (I, J) after 






Figure 6-6: 3-dimensional rendering of CryovizTM images to illustrate the 
distribution of MSCs in the lungs, liver and spleen at advancing time points after 
tail-vein injection 
The images are 3-dimensional reconstructions of 2-dimensional sections constructed by the CryovizTM 
software. The bright yellow dots represent MSCs in the brown ghost-like representations of the underlying 
organs (A, D, G, J, M – lungs; B, E, H, K, N – liver; C, F, I, L, O - spleen). Mice were euthanised for analysis 1 hour 
(A – C), 1 day (D – F), 3 days (G – I), 6 days (J – L) and 8 days (M – O) after tail-vein injection of fluorescently 




A correction of this value using the estimated proportion of cells that take up Qdot® nanocrystal 
labelling (75.4%) suggests a very faithful cell preparation and injection protocol with minimal loss 
of cells in the process (9.85x105 cells compared to the intended 1x106).  
 
The majority of cells were cleared rapidly, with only 17.6% of the average baseline number of cells 
being detectable after 24 hours. The total rate of clearance subsequently slowed with 6.9% of cells 
still detectable after 3 days. 4.8% after 6 days and 1.8% after 8 days (Figure 6.5-6.7).  
 
The rate of clearance was more rapid from the lung than in is the liver (Figure 6.8). The change in 
the relative proportions of cells in the liver and lung may reflect cells moving from the lung to the 
liver between day 1 and day 6 after injection, though it is not possible to know for sure without 
repeated tracking of cells within the same mouse, and correcting for rates of proliferation and 
death in each organ compartment. This is not possible using the available means in this 









Figure 6-7: Analysis of MSC numbers in the lungs, liver and spleen at advancing time 
points after tail-vein injection 
The charts depict the numbers of detectable cells in the different organ compartments with advancing time after 
tail-vein injection of human UCT-MSCs in mice with established fibrosis as described in Figure 6.4. Cells were 
labelled with Qdot®-605 nanocrystals and detected using the aforementioned CryovizTM system. Data summary 
bars represent the mean and range. The y-axis depicts the number of cells using a log10 scale.  
 
























Figure 6-8: Changes in relative proportions of detectable cells in the liver in lung 
with advancing time 
The analyses depict the change in the proportion of the total number of detectable cells in the liver and lung 
with advancing time following the tail-vein injection of Qdot®-labelled human UCT-MSCs in mice with 



































6.5.1. MSC labelling efficiency is consistent 
Approximately 75% of the MSCs were labelled by the Qdots® on each of the incubation runs with 
little variance. It is unclear why the label uptake efficiency differs from other investigators. For 
example, Auletta managed a 70% uptake using human BM-MSCs236, Rak-Raszewska showed an 
85% uptake in two different murine stem cell populations225, and Alfaifi, using the same human 
UCT-MSCs in the same laboratory as this body of work,  reported a 92% labelling efficiency (Alfaifi 
M, 2018, PhD thesis, University of Birmingham). However, differences in how uptake efficiency was 
calculated may account for the different reported values; Alfaifi and Rak-Raszewska used manual 
counts of positively stained cells after fluorescent imaging, whereas this study used flow 
cytometry, and was therefore subject to less user bias. Nevertheless, the vital finding was 
consistency – repeated labelling yielded consistent uptake efficiency, which provided assurance 
and confidence that the numbers detected in vivo would be faithfully comparable between mice. 
Moreover, the adjusted cell numbers an hour after injection were very close to the intended 
injection number of 1x106, suggesting very little cell loss in the preparation phase, and a consistent 
and reliable preparation protocol. The labelling protocol had no effect on cell viability, in keeping 
with published data225, and the persistence of fluorescent cell detection to day 6 and 8 in vivo 
were very much in keeping with the advertised photo-stability of a week. However, one must be 
mindful of data suggesting that Qdots® may deplete from some in vitro cell cultures (mouse 
embryonic stem cells and mouse tissue-specific stem cells), with a drop from 80-90% cellular 
labelling on day 0, down to 10-40% by day 3 in culture225. Though this drop was not reported in 
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all cell types, it would have been prudent to determine the labelling efficiency over time in vitro 
using the cells I used for the in vivo cell tracking experiments. One must interpret the results of 
this chapter in knowledge of this limitation.  
 
6.5.2. The pulmonary “first-pass” effect – Big round pegs don’t fit through small 
square holes 
The findings in this study are not novel237, though they are the first to confirm the bio-distribution 
and persistence of systemically injected MSCs in a murine liver fibrosis model using the Qdot® 
and CryovizTM system. After systemic injection, MSCs get trapped in the first small-calibre capillary 
bed the encounter; in the case of peripherally injected MSCs, the first capillary bed is in the 
lungs238. This “passive entrapment” is a primarily consequence of the cells being too big to traverse 
narrower vessels. Though endogenous, inactivated BM derived MSCs are small (~10µm), ex-vivo 
expanded MSCs grow, reaching sizes greater than 30µm in diameter by the 7th day of culture239. 
However, in health, the estimated diameter of both human and murine pulmonary capillaries is 
approximately 8µm, a terminal arteriole 10µm, and venule is 20µm237,240. There are physical limits 
to how much cellular deformability can overcome this disparity without compromising cellular 
viability or vascular patency241. 
 
6.5.3. Changing the bio-distribution of systemically injected MSCs 
Having identified the issue of pulmonary trapping as a critical roadblock for intravenous MSC 
therapy, a logical next step to investigate whether MSC therapy affects fibrosis would be to 
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increase the delivery of MSCs to the liver. The most effective way to do this would be inject MSCs 
via the portal vein or hepatic artery to facilitate passive “hepatic entrapment”. This would facilitate 
an examination of MSC distribution and persistence via a more direct route, but one could again 
examine the effect of MSC therapy on fibrosis. If a dose-dependent effect was observed, then one 
could examine modes of enhancing the delivery of systemically injected MSCs to the liver, to 
replicate the effect of the much more invasive portal vein or hepatic artery injection. This mode 
of deliver is technically difficult requiring a procedure under anaesthesia in mice, and practical 
clinical translation is less feasible and less attractive.  
  
A number of investigators have developed ex vivo culture protocols to yield smaller MSCs239,242–
244, with an increased capacity to traverse the lung unimpeded243. Similarly, pulmonary vasodilators 
have been used to good effect245. Other investigators have utilised cytokine pre-treatment or 
“licensing” to reduce pulmonary sequestration in the immediate aftermath of systemic injection 
with different cytokine mono-treatments and cocktails eliciting different effects246. This allies to 
an observed effect on in vivo longevity after different licencing techniques45, including the pre-
incubation of MSCs with organic compounds such as hyperosmolaric hydroxyethyl starch, which 
was shown to both decrease MSC size, change bio-distribution and increase the viability of 
systemically injected MSCs247. Alternative cell detachment techniques of in vitro preparations have 
changed the bio-distribution of systemically injected cells. Pronase detachment markedly 
increased the relative proportion of cells in the liver in the first 15 hours after tail-vein infusion248. 
However, the analysis was of proportional radioactivity at different sites after infusing 




6.5.4. MSC homing to areas of injury 
MSC homing has been described as active or passive arrest of MSCs within the vasculature 
followed by transmigration across the endothelium249. We know from many dedicated 
mechanistic studies that MSCs migrate to sites of injury, like leukocytes, often in response to 
chemotactic cues39, attach the endothelium250, and have the capacity for diapedesis251.   
 
Unfortunately, this part of the study was not designed to examine a difference in migration and 
homing to the injured livers versus uninjured livers, as no uninjured age matched control mice 
were infused with labelled cells. Colleagues in the Newsome laboratory found no difference 
between the percentage of detectable cells in the liver 24 hours after labelled MSC injection in an 
acute CCl4 model of hepatic injury versus an uninjured control (Alfaifi M, 2018, PhD thesis, 
University of Birmingham). However, one would envisage that cells engrafting to the liver after 1st 
pass pulmonary retention238 would respond to chemotactic cues, and differences in the relative 
percentages of detectable cells between the liver and lung in the following 3-5 days may be more 
informative in the chronic setting.   
 
The phenomenon of label detection in the liver in preference to the lung after the initial pulmonary 
sequestration, as seen in Figure 6.8, is not necessarily a function of hepatic injury. Bansal et al. 
documented a similar finding in uninjured mice injected with 89Zr-labelled human MSCs229. 7 days 
after injection, there was proportionately greater radioisotope reading from the liver (50% of the 
injected dose) than the lung (27% of the injected dose). The liver has been repeatedly shown to 
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be the preferred destination for injected MSCs after the lung following systemic intravenous 
injection252,253. It is unclear whether the inverse proportional relationship between the cells in the 
lung and liver are a consequence of migration, or a differential in the cell death rates in the two 
organ compartments (i.e. is the pulmonary environment more hostile than the hepatic 
environment?). Certainly, the increase in measured number of cells in the liver between days 3 
and 6 after injection may suggest migration to the liver, or a greater proliferative index than cell 
death.  
 
6.5.5. The fate of MSCs after systemic injection 
One must be mindful of the possibility of a false positive signal. Label detection, by whichever 
means including CryovizTM as described in the introduction to this chapter, is subject to false 
positive input as a result of label redistribution by phagocytic monocytes following uptake of 
cellular debris from dying MSCs237. The relevance of this becomes apparent when considering 
contemporary data that has demanded a re-examination of some fundamental assumptions 
about MSC therapy. Upon injection, MSCs quickly lose cellular integrity, start to fragment and 
become apoptotic247. Moreover, the MSC fragments are subject to opsonisation, and start falling 
victim to phagocytosis by circulating monocytes and tissue macrophages254. Upon efferocytosis, 
they induce changes in the macrophage polarisation, by which they can effect 
immunomodulation, whether it be by the PGE2-dependent255, or IDO-dependent pathways204. 
These data would, in part, start to  explain the paradox that MSCs seem to be therapeutically 
efficacious despite a lack of engraftment and rapid clearance256, in that they act via a surrogate. 
Moreover, amongst patients with GvHD, only those with high cytotoxic activity against MSCs 
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responded to MSC infusions204. If, in fact, MSC apoptosis is critical to their downstream clinical 
effect, perhaps efforts to enhance MSC survival in vivo should be redirected to predisposing MSCs 
to apoptosis257. Other work in the Newsome laboratory has shown MSC therapy has induced 
macrophage polarity changes in murine models of PSC without exploring interim MSC 
apoptosis202. However, the work in Chapter 5 did not reveal an MSC-therapy induced change in 
macrophage polarity in either the resolution of fibrogenic phases. 
 
6.5.6. Summary 
The data from this chapter describes the pulmonary sequestration and subsequent rapid clearance 
of human UCT-MSCs administered by tail-vein injection in mice with established liver fibrosis. A 
negligible proportion of MSCs persist globally after a week (1.8%), and less than 3.5% of the 
injected cells (positive labelled units) are in the liver at 24 hours. The findings are in keeping with 
existing data that describe the pulmonary first pass phenomenon. Bypassing pulmonary 
entrapment by portal vein or hepatic artery injection in chronic hepatic fibrosis models may inform 
of any direct effect MSCs have on fibrosis, but the experiments are technically very difficult. As 
such, in Chapter 7, this study proceeds to examine whether MSCs have any direct effect on the 




The effect of MSC 
conditioned media on LX2 





7.1. Background and context 
A complex interplay between cells and the local microenvironment governs hepatic fibrosis and 
its regression63,206, but the lynchpin around which the complexity is interwoven is the 
myofibroblast. Upon activation, hepatic stellate cells transdifferentiate to become myofibroblasts 
that secrete ECM, and TIMP to maintain the matrix. With continuing injury, they proliferate in 
response to mitogens like PDGF, and become increasingly resistant to inactivation and apoptosis. 
However, regression is marked by myofibroblast inactivation, senescence or apoptosis51. The 
diminished effect of myofibroblasts enables restorative macrophages to effect the dissolution of 
ECM by the unopposed action of MMPs (Figure 1.1). This is a simplified version of events which 
are more completely described in Chapter 1, and in dedicated review articles63.  
 
Systemic MSC administration had no effect on liver fibroplasia or fibrosis regression (Chapter 5). 
A possible reason could be an inadequate delivery of MSCs to the site of the pathology due to 
pulmonary entrapment238, though this theory makes assumptions about the mechanism of action 
by which MSCs may act to disrupt fibrosis – that being the need for proximity and persistence as 
discussed in Chapter 6. To explore this further, I chose to examine the direct effect of MSC 
conditioned medium on stellate cell biology. I chose not to explore the direct cell-cell induced 
effects of MSCs on HSCs as the work in Chapter 6 has already shown how sparsely MSCs locate in 
the liver. Even if MSCs were injected via the portal vein, one would have to demonstrate that MSCs 
could migrate across the capillarised sinusoidal endothelium in cirrhotic livers in to the Space of 




Primary isolated stellate cells would have been an ideal substrate upon which to test the action of 
MSC conditioned medium. They retain their in vivo state and exhibit the plasticity required to 
realise an effect of therapy259. However, despite my own previous success in using a protocol of 
enzymatic and mechanical disruption and digestion followed by density gradient centrifugation 
to isolate murine hepatic stellate cells154, the yield and purity was extremely variable, with a 
significant burden of non-parenchymal cell contamination (results not shown). Moreover, isolating 
human primary stellate cells was hindered by infrequent and unpredictable access to human 
tissue, with concerns of inter-batch cell heterogeneity260.  
 
With a view to maintaining substrate homogeneity, I chose to utilise LX2 cells. Of all the human 
HSC cell lines, LX cells have been most extensively characterised260,261, and tested upon. LX cells 
are generated by plasmid transfection of primary stellate cells conferring SV40 T antigen 
immortalisation, with LX2 cells undergoing clonal expansion under low-serum (1-2% FBS) 
conditions260. They have a reported phenotype that is closest to activated HSCs in vivo, and are 
known to express a catalogue to genes typically expressed in activated stellate cells including 
PDGFβ, TGFβ, collagen types I and IV, vimentin, desmin, and αSMA261. For this reason they are 
regarded as first choice when modelling activated human HSCs262.  
 
7.2. Aims of the chapter 
The aims of the work in this chapter were to:  
• Examine the effect of MSC conditioned medium on LX2 cell biology 
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7.3. Characterising LX2 cells 
LX2 cells were obtained from Dr. Scott Friedman (Mount Sinai Hospital, New York, USA), and 
stored between in liquid nitrogen at a concentration of 1x106 in 1mL of serum with 10% dimethyl 
sulfoxide (DMSO). For use, cells were plated in low-serum (2% FBS) LX2 complete medium as 
described in section 2.13.1 for 8 hours, and serum-starved (supplemented with 0.1% BSA) for 24 
hours prior to experimentation. 
 
This part of the study characterised the behaviour of LX2 cells in low-serum (2% FBS), high-serum 
(10% FBS) and serum-free conditions (0.1% BSA). It was critical to assess the baseline phenotype 
of LX2 cells in 10% FBS as it would form the negative control for the intervention experiments 
using MSC conditioned media (CM). Attempts to culture MSCs at lower serum concentrations (2% 
FBS) led to considerably attenuated proliferation. As such, MSC-CM was collected using standard 
MSC culture media (10% FBS), but without FGF (Section 2.2.1).  
 
Regardless of the culture medium, LX2 cells adopted an activated contracted fibroblastic 
appearance on uncoated plastic (Figure 7.1, Panel A). All cells expressed the intermediate 
cytoskeletal filament vimentin that is typical of cells of mesenchymal origin. Magnified images 
clearly demonstrate the cytoplasmic reticular pattern of a cytoskeletal framework highlighted by 
vimentin staining (Figure 7.1, Panels E-G). Moreover, as has been previously shown in the landmark 
papers that originally characterised LX2 cells260, and in keeping with a partially activated 
phenotype, all LX2 cells express αSMA in a similar cytoskeletal pattern (Figure 7.1, Panels E-G) 




Figure 7-1: Expression of intermediate filaments by LX2 cells in different culture 
media 
LX2 cells adopted a contracted fibroblastic appearance (A) upon in vitro culture. They were expanded (see 
Section 2.13.1) in low-serum media containing 2% foetal bovine serum (FBS) (B & E), serum-free media 
supplemented with 0.1% bovine serum albumin (BSA) (C & F), and high-serum conditions containing 10% FBS 
(D & G). Upon immunocytochemical examination (Section 2.13.2) the cells universally expressed cytoskeletal 
proteins α smooth muscle actin (αSMA) (B-D), a marker of stellate cell activation and vimentin (E-G), a marker 
of cells of mesenchymal origin in all culture media. Scale bar (–) measures 100µm. 
 
Nevertheless, an examination of the mRNA expression (Figure 7.2) of αSMA (ACTA2) and COL1A1 
revealed that cells cultured in media containing 10% FBS adopt a more activated phenotype in 
having significantly greater expression of both than cells grown in low-serum conditions (ACTA2, 
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4.3-fold mean difference, p<0,.001; COL1A1, 2.0-fold mean difference, p=0.002). Conversely, 
serum-starved cells express less COL1A1 (0.5-fold mean difference, p<0.001) than cells grown in 
low-serum conditions, suggesting a less fibrogenic phenotype. However, neither media 
containing 10% FBS, nor serum starved media affected the expression of PPAR-gamma – a marker 
of both primary stellate and LX2 cells quiescence48. It is likely that the cells are activated enough 
in all three culture conditions to suppress the expression of PPAR-gamma which is typically 
expressed in quiescent cells that return to a fat-storing and flattened phenotype which was not 
seen in these experiments.  
 
In keeping with the more activated phenotype, LX2 cells in 10% FBS expressed 1.6-fold more 
PDGFR-B mRNA (p<0.001) than cells grown in low-serum conditions. Conversely, serum-starved 
cells expressed significantly less PDGFR-B (0.6-fold difference, p<0.001), but the cells were still 
mitotically responsive to PDGF-BB ligand – a defining characteristic of activated stellate cells260. 
Ki67 (a marker of proliferating cells), seemed to be positive regardless of PDGF-BB response which 







Figure 7-2: mRNA expression of genes related to stellate cell activation in different 
culture media 
Expression of activation-associated genes in unstimulated LX2 (A: ACTA2, B: COL1A1, C: PPARg; against 
housekeeping gene SRSF4) was assessed by qPCR as described in section 2.14. Expression was analysed in 
cells from three different vials (N=3). Cells were cultured in low-serum (2% foetal bovine serum (FBS)) 
conditions, serum-free media supplemented with 0.1% bovine serum albumin (BSA), or high-serum media 
(10% FBS) for 72 hours. Each data point represents the average of technical triplicates. Data were summarised 








Figure 7-3: Response of LX2 cells to PDGF-BB   
Expression of PDGFR-B in LX2 cells (against housekeeping gene SRSF4) was assessed by qPCR as described in 
section 2.14 (A). Expression was analysed in cells from three different vials (N=3). Cells were cultured in low-
serum (2% foetal bovine serum (FBS)) conditions, serum-free media supplemented with 0.1% bovine serum 
albumin (BSA) and high-serum media (10% FBS) for 72 hours. Each data point represents the average of 
technical triplicates. LX2 cells were stimulated with platelet derived growth factor-BB (PDGF-BB) at a 
concentration of either 1ng/mL or 10ng/mL in low-serum (2%FBS) media. CyQUANT® analysis was used to 
determine the number of cells after 24 hours (Section 2.13.4) (B). Immunocytochemical analysis with ki67 for 
proliferating cells (C) (Section 2.13.2). The proportion of proliferating cells (N=3 plates for each growth 
condition) were compared after analysing 500 cells in each plate. Data were summarised by mean and 





Figure 7-4: Proliferation and senescence of LX2 cells in different culture media 
Following in vitro expansion, the numbers of LX2 cells were analysed at serial time points (1, 24, 36, 48 and 72 
hours) in different growth media conditions using CyQUANT® analyses (Section 2.13.4) (A). Cells were cultured 
in low-serum media containing 2% foetal bovine serum (FBS) (B & F), serum free media supplemented with 
0.1% bovine serum albumin (BSA) (C & G), and high-serum conditions containing 10% FBS (D & H). Data from 
the CyQUANT® tests were summarised by mean and standard deviation of the numbers of cells at 72 hours; 
groups were compared by Student’s t-test. The experiment was repeated thrice, and each data point 
represents the mean of technical triplicates on each plate. Immunocytochemical analysis with p21 (B-D) was 
used as a surrogate for identifying senescent cells, and ki67 for proliferating cells (F-H) (Section 2.13.2), using 
haematoxylin to identify nuclei. The proportion of non-senescent cells (E) and proliferating cells (I) in different 
culture conditions (N=3 plates for each growth condition) were compared between groups after analysing 
500 cells in each plate. Data were summarised by mean and standard deviation and all groups compared by 





LX2 cells were more numerous in media with 10% FBS at 24, 36, 48 and 72 hours (p<0.05 at each 
time point) than cells in low-serum conditions as measured by CyQUANT® analysis (Figure 7.4, 
Panel A). There were no differences in senescence as assessed by p21 IHC (Figure 7.4, Panels B-E), 
or apoptosis as measured by Annexin-V flow cytometry (Figure 7.5). Ki67 seemed to be 
constitutively expressed in all growth media to support that it seems an unreliable marker of 
proliferation in LX2 cells (Figure 7.4, Panels F-I). In the absence of differences in senescence and 
apoptosis it seems likely that LX2 cells in 10% FBS media may have had a proliferative advantage 






Figure 7-5: Apoptosis of LX2 
cells in different culture media   
 
After seeding and serum-starving LX2 cells 
in culture, they were grown in low-serum 
conditions containing 2% foetal bovine 
serum (FBS), 10% FBS or serum-free media 
supplemented with 0.1% bovine serum 
albumin (BSA) for 48 hours (Section 
2.13.1). A positive control was designed by 
culturing cells in low-serum media for 44 
hours, and adding 6nM Glytoxin for the 
final 4 hours. Cells were then assessed for 
apoptosis using a commercially available 
Annexin-V apoptosis detection kit 
whereby cells were stained for FITC-
conjugated Annexin-V as a marker for 
apoptosis, and PE-conjugated propidium 
iodide (PI) as a marker for necrosis and 
examined by a flow cytometer for FITC-
positive / PE-negative events – apoptotic 
cells, as demarcated by the red box (A). 
Data were summarised by mean and 
standard deviation. Mean proportions of 
apoptotic cells were compared against 
results in the low-serum group by 
Student’s t-test (B); p<0.05 were deemed 
significant 
 
Cells in serum-free conditions were less numerous than cells in 2% and 10% FBS, despite no 
differences in Ki67 and P21 staining. They were more prone to apoptosis which at least in part 
accounted for the differences in cell numbers, though I am not able to reliably comment on 
proliferative differences with this selection of tests. Dye dilution assays (using next-generation 




Overall, these findings suggest that the different growth media conditions affect LX2 cell biology 
in nuanced ways, and reinforce the need to clearly define the culture conditions and activation 
phenotype before undertaking an intervention experiment. The results also reflect the bi-
directional plasticity of LX2 cells on uncoated plastic; despite a naturally semi-activated state, they 
have the capacity to express a more and less fibrogenic phenotype in different conditions. This is 
critical for the assessment on an intervention on their biology. This is particularly pertinent, as 
previous examinations of MSC therapy on stellate cell biology have shown conflicting results, with 
some authors demonstrating fibrogenic attenuation132,137, whilst others showing fibrogenic 
accentuation118. Thus, I chose not to further activate the LX2 cells with TGFβ treatment132, as I did 




7.4. The effect of MSC conditioned media on LX2 cell activation 
In the absence of S2-selection related or donor related variations in the effect of MSCs in vivo 
(Chapter 5), I chose to examine the effect of S2-selected MSCs from a single donor. CM was 
prepared as stated above, and described in section 2.2.1.  
 
 
Figure 7-6: mRNA expression of genes related to stellate cell activation in MSC 
conditioned media 
MSC conditioned media (CM) was collected after 24 hours of culture with syndecan-2 selected MSCs at a 
starting confluence of 60-80% as described in section 2.2.1. The CM was then diluted in fresh complete media 
(containing 10% foetal bovine serum) to an end-dilution of either 50% or 10% CM. Expression of activation-
associated genes in LX2 cells cultured in CM for 72 hours (A: ACTA2, B: COL1A1, C: PPARg, D: PDGFR-B; against 
housekeeping gene SRSF4) was assessed by qPCR as described in section 2.14. Each experiment had an N=3, 
and each data point represents the average of technical triplicates. Data were summarised by mean and 
standard deviation and test samples (those with CM) were compared against cells in complete medium 




The CM partially suppressed the fibrogenic phenotype of LX2 cells by significantly attenuating the 
mRNA expression of COL1A1 (100% CM, 0.3-fold mean difference, p=0.003; 50% CM, 0.3-fold 
mean difference, p=0.004; 10% CM, 0.4-fold mean difference, p=0.007)), but had no effect on the 
expression of ACTA2, PPAR-gamma, or PDGFR-B (Figure 7.6). The absence of effect of ACTA2 
mRNA expression was mirrored by the ICC examination of αSMA expression in CM and control 
(Figure 7.7).  
 
 
Figure 7-7: Expression of αSMA in 
LX2 cells in MSC conditioned media 
 
MSC conditioned media (CM) was collected after 
24 hours of culture with syndecan-2 selected 
MSCs at a starting confluence of 60-80% as 
described in section 2.2.1. The CM was then 
diluted in fresh complete media (containing 10% 
foetal bovine serum) to an end-dilution of either 
50% or 10% CM. Upon immunocytochemical 
examination (Section 2.13.2) the cells universally 
expressed α smooth muscle actin (αSMA), a 
marker of stellate cell activation in CM and in 





7.5. The effect of MSC conditioned media on LX2 senescence, proliferation 
and viability 
MSC-CM did not affect LX2 cell senescence as examined by p21 ICC or senescence associated β-
galactosidase activity (Figure 7.8). However, the CM did have a dose-dependent effect on LX2 cell 
apoptosis as measured by Annexin-V flow cytometry, without apparently affecting cell 
proliferation (notwithstanding the aforementioned limitations of Ki67 ICC as a proliferative index 





Figure 7-8: LX2 cell senescence in 
MSC conditioned media 
MSC conditioned media (CM) was collected after 
24 hours of culture with syndecan-2 selected 
MSCs at a starting confluence of 60-80% as 
described in section 2.2.1. The CM was then 
diluted in fresh complete media (containing 10% 
foetal bovine serum) to an end-dilution of either 
50% or 10% CM. Senescence associated β-
galactosidase activity (Section 2.13.3) was 
assessed after 48 hours of culture in negative-
control media (A), a positive control (100ng/mL 
IGF-1) (B), or CM (Panels C-E); blue staining 
indicated the presence of β-galactosidase. Scale 
bar (–) measures 250µm. Upon 
immunocytochemical examination (Section 
2.13.2) the percentage of cells not expressing 
p21 (a surrogate marker of senescence) were 
calculated after analysing 500 cells on each plate 
(N=3 for each group). Data were summarised by 
mean and standard deviation and test samples 
(those with CM and positive control) were 
compared against cells in complete medium 
containing 10% FBS (negative control); p<0.05 





Figure 7-9: LX2 cell proliferation and 
viability in MSC conditioned media 
MSC conditioned media (CM) was collected after 24 hours 
of culture with syndecan-2 selected MSCs at a starting 
confluence of 60-80% as described in section 2.2.1. The CM 
was then diluted in fresh complete media (containing 10% 
foetal bovine serum) to an end-dilution of either 50% or 
10% CM. The total number of LX2 cells after 48 hours of 
growth in different culture conditions was examined using 
the CyQUANT® technique as described in section 2.13.4 
(A). The percentage of apoptotic LX2 cells in different 
culture conditions after 48 hours was assessed by staining 
with FITC-conjugated Annexin-V and PE-conjugated 
propidium iodide (PI) and examined by a flow cytometer 
for FITC-positive / PE-negative events – apoptotic cells (B) 
(Section 2.13.5). The percentage of proliferating cells 
following 48 hours in different culture conditions were 
assessed by immunocytochemical analysis with ki67 (C) 
(Section 2.13.2) and analysing 500 cells in each plate. Each 
experiment had an N=3 in each group. Data were 
summarised by mean and standard deviation and test 
samples (those with CM) were compared against cells in 
complete medium containing 10% FBS (control); p<0.05 







MSC-derived soluble molecules carried by the CM, partially attenuated the fibrogenic phenotype 
of LX2 cells in decreasing the transcription of COL1A1, and significantly promoted LX2 cell 
apoptosis in a dose-dependent fashion. The results support a primary anti-fibrotic effect of agents 
within the MSC secretome, which seems to be independent of in-vitro priming. A number of 
available strategies can be utilised to interrogate the cellular secretome, and downstream analysis 
can hypothesise and interrogate putative anti-fibrotic agents263. One could speculate the 
possibility that the dose-dependent effect of CM may reflect nutrition depletion from the growth 
medium. A further in vitro examination using a Transwell co-culture system (MSCs separated from 
LX2 cells seeded at different densities) would answer this question. 
 
7.6.1. Aligning the findings to the existing literature 
Parekkadan et al. undertook a robust in-vitro analysis by indirect Transwell co-culture of human 
BM-MSCs and a different immortal human stellate cell line – TWNT-4137,264. As with the results in 
this chapter, the authors demonstrated a MSC dose-dependent reduction of procollagen type I, 
inhibition of stellate cell proliferation, and induction of stellate cell apoptosis. Neutralising 
antibodies against IL-10 and TNF-α negated the MSC-induced effects on HSCs. The authors 
demonstrated that the secretion of IL-10 by MSCs to be a dynamic response to TNF-α and HSC-
derived IL-6. The concentrations of TNF-α required to induce the secretion of IL-10 were not 
readily achieved by co-culture, but may hint to the need for in vivo priming in an injured milieu 
where the cytokine concentrations are higher.  However, this chapter’s results suggest that MSC-
CM acts to suppress LX2 cells independent of MSC priming. The authors also demonstrated 
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antibody-neutralisation of HGF led to a reduction in SC apoptosis back to baseline levels. 
However, these results fail to acknowledge the extremely short half-life of HGF in vivo of less than 
5 minutes, limiting its utility as a paracrine agent, unless the source is producing large quantities 
and is in close proximity to the stellate cells265,266. Nevertheless, the half-life may depend of how 
the HGF is transported; exosomes (which I will go on to discuss) can package a membrane-bound 
“pay-load” for delivery at distant sites in protected conditions, and may overcome this issue267.  
 
More recently, An et al. explored the effect of human UCT-MSC secretome on primary human 
HSCs and immortalised cell lines, including LX2 cells268. The authors demonstrated that TGFβ-
induced primary HSC activation as evidenced by the expression of αSMA , COL1A1 and COL1A2 
was suppressed by the MSC-secretome, and this was in-part replicated to statistical significance 
in LX2 cells. However, unlike the results in this chapter and Parekkadan’s study, the secretome had 
no effect on LX2 apoptosis or senescence. The authors went on to identify anti-fibrotic candidates 
in the secretomes using nanochip liquid chromatography / quadrupole time-of-light mass 
spectrometry. Enriched proteins in the secretomes were loaded in to a pathway analysis database 
(GeneGo), and MetaCore mapping tools focussing on proteins involved in fibrogenic pathways. 
The authors identified candidate proteins, of which only milk fat globule-EGF factor 8 (MFGE8) 
was noted to diminish TGFβ-induced αSMA expression in primary HSCs in a dose-dependent 
fashion; it worked via down-regulating TGFβ-receptor type I. Of note, the authors went on to 




Meier et al. demonstrated a down-regulation of αSMA translation in LX2 cells by MSC-CM, but 
did not comment on COL1A1 expression132. Subsequent MSC-CM cytokine array analysis revealed 
elevated levels of insulin-like growth factor binding protein-2 (IGFBP-2), IL-6, IL-1Ra, and 
monocyte chemotactic protein-1 (MCP-1). IGFBP-2 regulates insulin-like growth factor-I, which is 
a potent cytoprotective and anabolic hormone produced by the liver; up-regulated IGF-I was 
shown to promote resolution during experimental liver fibrosis269. IL-6 has well-recognised 
cytoprotective functions270. IL-1Ra inhibits pro-inflammatory IL-1271, whilst MCP-1 is a pro-
inflammatory cytokine that attracts macrophages – which are critical to the resolution of fibrosis35, 
and may account for the elevated levels of MMP-9 the authors demonstrated in vivo after injecting 
micro-encapsulated MSCs IP to attenuate CCl4-induced liver fibrosis in mice. However, the authors 
did not examine whether these agents were critical for the observed in vitro effect.  
 
An assessment of the direct effect of MSC or MSC-CM on HSCs or ECM bypasses the possibility 
that MSCs may work via trophic mediators174 – agents that facilitate an effector change in an 
intermediate cell to induce it to secrete a biologically active agent or change in function that in 
turn has an indirect effect on the desired outcome. An interrogation of such an effect would 
respect the complex interaction of multiple cell lines in vivo that govern fibroplasia and its 
regression. Moreover, such effects are attractive to investigate as MSC therapy has been shown 
to effect a biological change that outlives their persistence in vivo in multiple different pathologies 
including cerebrovascular events and ischaemic heart disease175. With respect to liver fibrosis, 
MSC-derived trophic factors such as FGF2 have been shown to indirectly regulate HSC activation 
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and persistence by interfering with the secretion of hepatocyte-derived cytokine Dlk1 which was 
shown to be critical for HSC activation and persistence138.  
 
Based on the findings in this chapter, and allied to existing published data, one may conclude it 
reasonable to pursue an approach to enhance the delivery of MSCs to the liver (discussed in 
Chapter 6), thereby enhancing whatever effect it may have via their secretome, directly or 
indirectly on myofibroblasts. On the other hand, one could trial the therapeutic potential of MSC-
derived secreted agents, to overcome the pulmonary sequestration. In fact, the aforementioned 
study by An et al. examined the effect of injecting the secretome from human UCT-MSCs in to 
mice with TAA-induced and CCl4-induced established liver fibrosis268. Having identified MFGE8 as 
a putative direct anti-fibrotic from their in vitro work, the authors demonstrated an anti-fibrotic 
action of the whole secretome and isolated recombinant MFGE8. The effects of both were 
abrogated by the use of a neutralising antibody. Other authors have examined other 
characteristics and components of the secretome. Exosomes and microvesicles are membrane-
bound extracellular vesicles (ECV) that are critical to intercellular communication and the 
modulation and mediation of a number of cellular processes267. MSC-ECVs carry a complex cargo 
of lipids, nucleic acids and proteins, which in all may contain > 850 unique gene products and > 
150 miRNAs272,273. Upon release ECVs can either be taken up by target cells, or be carried to distant 
sites, and protect their load until they reach their target site267. As such, the therapeutic potential 
of MSC-ECVs have become a target of research interest, including their utility in liver fibrosis. Li et 
al. published data to demonstrate an UCT-MSC exosome-induced reversal of TGFβ-induced 
activation of a human HSC line – HL7702, but did not interrogate the contents of the ECVs any 
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further133. Another study has implicated MSC-ECV-microRNAs in the suppression of HSC 
activation via inhibition of the Hedgehog pathways274.  
 
However, as eluded to earlier, not all examinations of the effect of MSC on stellate cells in vitro 
have demonstrated a favourable effect. Baligar et al. demonstrated activation and increased 
proliferation of primary HSCs in vitro upon incubation with murine AT-MSC-CM, which was 
attributed to MSC-derived TGFβ – an agent widely accepted as critical to the immunomodulatory 
functions of MSCs118. This finding was at odds with their subsequent in vivo findings of a reduction 
of established fibrosis with decreased hepatic TGFβ, following intra-splenic injection of syngeneic 
AT-MSC. The study is an example of the many that have failed to replicate in vitro mechanisms 
with in vivo findings in the field.  
 
7.6.2. In vitro models need to improve 
As with the results of this chapter, the discordance between results found in vitro and in vivo is 
ubiquitous in life sciences, and in particular in liver fibrosis research, owing largely to how 
inadequate the models are45,118,259,275. The data by An et al. sits apart in marrying robust in vitro 
analysis of standard 2D monoculture experiments to an in vivo mechanism of action.  
 
One must be cognisant of the strengths and limitations of widely used in vitro models of liver 
fibrosis. 2D monolayer stellate cell cultures are easy to set up and reproducible; primary stellate 
cells and immortalised cell lines adopt an activated myofibroblast-like phenotype when plated on 
uncoated tissue-culture plastic in the presence of serum, with the potential for further activation 
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and reversion upon manipulation and drug testing73. However, the spontaneous activation and 
maintenance of a myofibroblastic phenotype on plastic does not recapitulate the in vivo 
counterpart. Though the archetypal hallmarks of activation are conserved (e.g. ACTA2, COL1A1), 
there is only a 25% overlap of differential gene expression between myofibroblasts in vivo and in 
vitro276. Notwithstanding the absence of cell-cell and cell-ECM interactions, myofibroblasts on 
plastic adopt an unnatural elongated shape, with a large proportion of the cell covered in plastic 
that provides a tensile force of over 10,000kPA277. Comparatively, the environment of a normal 
liver exerts approximately 0.5kPA, and a fibrotic liver up to 20kPA278. Environmental stiffness has 
been shown to be a critical fibrogenic stimulus for stellate cell activation279.   
 
A number of strategies have been developed to improve cell culture models for liver fibrosis. The 
use of low elastic modulus Matrigel® provides a commercially available, soft ECM base upon which 
to culture stellate cells; it has been shown to encourage a quiescent phenotype in cell lines and 
primary stellate cells260,280. 2D co-culture with other cells (e.g. hepatocytes) recapitulate cellular 
aspects of the natural environment of stellates in vivo, and have been shown to influence stellate 
cell behaviour (promote quiescence) in vitro281. More recent efforts to improve in vitro systems 
have responded to the call for 3D structure and the expression of a physiological framework of 
ECM73,282,283.  The most accessible example of this would be the use of 3D co-culture spheroids. A 
number of different techniques have been utilised to develop and maintain 3D spheroids275 
whereby typically (though not exclusively) a core of hepatic stellate cells are surrounded by a sheet 
of hepatocytes284,285. Individual laboratories have developed their own techniques, but 
commercially available hanging drop culture systems (e.g. InSphero) has made the technology 
241 
 
more accessible and enabled standardisation of protocols286. The culture system has been shown 
to be phenotypically stable for up to 5 weeks, and can be engineered to include other important 
cell types including Kupffer cells287. However, the spheroids are small (<200µm) and technically 
challenging to manipulate. The technology is expensive, labour intensive and outputs require 
proteomic or mRNA analysis. Another approach taken by researchers is to preserve native tissue 
architecture by the extraction of precision cut liver slices. They are acquired by cutting explanted 
liver (from animal or human) to a thickness of up to 250µm by the use of vibratome. The slices 
can be subsequently cultured for up to a week, but researchers are still ascertaining the 
phenotypic flux of different components of the tissue over prolonged incubation. Few 
investigators have yet used this technology for a base for fibrosis research owing largely to a lack 
of accessibility288.  Recellularisation of decellularised liver scaffolds perhaps represent the current 
state-of-the-art of in vitro modelling of the liver. Healthy or diseased liver can be stripped to a 
framework of native ECM and vasculature, and repopulated with cells that behave more naturally 
in a familiar 3D environment289. This represents the future, as the technology is yet to be used as 
a model to test fibrotic pathways and intervention.  
 
The apparent improvements of the in vitro models has not yet translated to routine use. Many of 
the techniques have not been fully characterised as fibrotic models and unfamiliarity breeds 
suspicion and doubt. Moreover, they remain inaccessible for most. However, the field should be 
encouraged to embrace contemporary technologies and knowledge, especially in appreciation of 
how sub-optimally the standard 2D in vitro models perform. They may be reproducible and easy 
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to use, but one must reconcile the current lack of effective translation from bench to clinic with 
the failure of the in vitro systems to adequately model.  
 
7.6.3. Summary 
MSC-derived soluble molecules carried by the CM, partially attenuated the fibrogenic phenotype 
of LX2 cells and significantly promoted LX2 cell apoptosis in a dose-dependent fashion. 
Notwithstanding the limitations of the in vitro modelling platform, the findings demand a further 
assessment of the utility of MSCs in vivo. Injection of the secretome would be the most direct 
approach to determine an in vivo effect on established liver fibrosis. An effect would implicate 












8.1. Summary of findings 
The research arc described in this thesis was set out to explore the effect of MSC therapy on liver 
fibrosis. Intravenously injected MSCs from human UCT neither resolved established liver fibrosis, 
nor abrogated fibrogenesis in two well-characterised murine models of toxin-mediated chronic 
hepatic injury. Tail-vein injected MSCs were subject to the pulmonary “first-pass” effect with few 
MSCs homing to the liver. However, MSC conditioned medium had a direct anti-fibrotic effect on 
human stellate cell line, LX2 cells, by attenuating the expression of COL1A1 mRNA and promoting 
LX2 apoptosis. The findings of this robust and statistically powered set of experiments strongly 
support a recommendation that the anti-fibrotic effects of human UCT-MSCs given via tail-vein 
should not be tested in murine models without a significant deviation in protocol to overcome a 




8.2. Strengths and limitations 
The strengths and limitations of each of the study parts were described in each of the results 
chapters, whilst delineating the context of the findings within the extant published literature, and 
unpublished data from our own laboratory. The key strengths were as follows: 
• I described the feasibility and safety of two limitable models of liver fibrosis 
• The peak fibrosis, especially in the chronic TAA model, showed features consistent with 
advanced scarring akin to cirrhosis, with dense fibrous bands, bridging fibrosis and nodule 
formation. This afforded greater parallels to human disease. 
• I delineated the in-house variability of relevant fibrosis outputs in each of our fibrosis 
models, thereby allowing appropriate statistically powered tests.  
• I used a breadth of different readouts for both the in vivo and in vitro experiments to test 
the effect of the intervention on fibrosis, adding validity to the findings, and was in keeping 
with ideal recommendations73. Moreover, efforts were made to reduce user bias, by 
examining as much of the available tissue as possible rather than using representative 
sampling.  
• The use of two fibrosis models confirmed that the experimental findings were not model-
specific.  
• I clearly defined the MSCs used in the experiments in line with ISCT recommendations. 
This is critical in a field plagued by cell identity heterogeneity.  
• I used state-of-the-art cell tracking technology to determine the bio-distribution and 
persistence of human MSCs injected by tail vein in mice subjected to a chronic hepatic 
injury. The CryovizTM technology allowed quantitative analysis of cell numbers in 3D-
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rendered representations of whole mice; it avoided highly intensive, invasive techniques 
of detection that are subject to a high degree of sampling error. 
 
The conclusions drawn from the research in this thesis were made in knowledge of the limitations 
that have been extensively described throughout the results chapters. The key limitations are 
summarised as follows: 
• Murine models have low fidelity to the human counterpart, in that the mode of chronic 
injury by which fibrosis is achieved in both chronic CCl4 and TAA is not replicated in human 
disease. However, the end fibrotic scar itself is thought to have parallels to human hepatic 
scar, thereby offering high discrimination.  
• There was high variability in the end fibrotic burden in the mice despite identical injury 
conditions. Though this may have been attributable in part to not actively controlling for 
the dose in the TAA model (given ad libitum), the variation in the CCl4 model (in which the 
dosing was weight-based) was presumably a consequence of an unmeasured variable. This 
limitation was addressed in the power calculations mentioned above.  
• It is possible that an anti-fibrotic effect of MSCs was not realised as a consequence of 
inadequate dosing. However, as described in the Discussion section of Chapter 5, my single 
bolus dosing was limited by fatal thromboembolic events at higher doses. Moreover, the 
cumulative doses used were in the range of previously published positive results. 
Nevertheless, I would only know this for sure by delivering a greater cumulative dose by 
more regular dosing throughout either resolution or injury.  
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• Tail-vein cell-therapy seems to be universally limited by the pulmonary first pass 
phenomenon – as was the case in Chapter 6. However, other investigators have 
demonstrated an effect on end organs (immunomodulatory effect) despite this. It is 
unclear whether enhancing MSC delivery to the liver would unmask a therapeutic effect; I 
have discussed this at length in Chapter 7, and later in this discussion.  
• Moreover, I have discussed the questionable validity of xenogeneic cell therapy testing 
(human MSCs in murine models); biological pathways may not be analogous.  
• The bio-distribution experiments were not designed to examine whether the MSCs 
preferentially homed to areas of injury (fibrotic liver), as an uninjured control was not used.  
• LX2 cells were chosen for ease-of-use and presumed homogeneity as isolation of primary 
stellate cells proved to be inconsistent. It would have been useful to demonstrate an effect 
of MSC-CM on primary murine stellate cells, as well as human cells, to further bridge the 
findings in this experiment from bench to clinic.  
• 2D cell-centric in vitro models have a number of limitations, which I have described in 
Chapter 7, and later in this discussion. Primary to these limitations are the artificial mode 
of HSC activation, and the absence of interaction with ECM and other cell types that are 




8.3. Further experiments 
Notwithstanding the limitations of the 2D “cell-centric” in vitro model used, the discordance 
between the in vitro and in vivo findings demand further attention. An et al. performed a series of 
elegantly designed tests to interrogate the cellular secretome for putative anti-fibrotic candidates 
using liquid chromatography and mass-spectrometry allied to pathway analysis databases268. A 
similar approach could be taken to interrogate the secretome of the MSCs donated by OTL for 
this body of work. However, it would be prudent to acknowledge the evidence-based interest in 
ECVs within the secretome. For reasons already described in chapter 7, ECVs provide a more 
realistic and believable therapeutic unit than free cytokines and growth factors, in that they carry 
a “pay-load” of multiple agents including proteins, mitochondria and nucleic acids which may 
have a context-dependent pleiotropic effect when working in concert. Moreover, the load is 
membrane-bound, thereby not only protecting it from degradation, but also influencing the way 
it is utilised at the effector site134. The therapeutic effect of ECVs, the secretome, or even selected 
agents within the secretome could be examined in models of liver fibrosis following tail-vein 
injection; a favourable therapeutic effect would then marry the in vitro findings to in vivo utility. 
This would inform the subsequent investigative pathway.  
 
A more complete examination of the effect of MSCs in murine models of liver fibrosis would 
require an exploration of the effects of MSCs from different tissue sources, and syngeneic MSCs. 
The existing data is explored in Chapter 1, in which I have laid out the need for further exploration 
before firm conclusions are drawn. 
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8.4. Commentary on broader aspects of MSC research 
Beyond their use in liver fibrosis, there remain fundamental issues with MSC therapy that need to 
be addressed before the scientific and clinical communities can expect robust and reproducible 
translation of laboratory findings to clinical benefit45. MSCs as identified by the International 
Society for Cellular Therapy guidelines, still represent a heterogeneous population of cells and the 
definition of MSC would benefit from further refinement, as described in chapter 4. In conjunction 
with this, another major challenge for allogeneic MSC therapy is inter-batch variability290. Donor-
to-donor functional variability will only be apparent if relevant functional assays are carried out 
on a sample-by-sample basis; however, the functional assay used should be specific to the 
intended action of the MSCs, rather than universal to all MSC therapy45. Furthermore, future 
exploration of MSC biology needs to tackle the impact of MSC preparation on functionality. Most 
pre-clinical studies use continuous culture-expanded MSC, whereas clinical studies often use off-
the-shelf freshly thawed cryopreserved MSC, which may have a profound effect of MSC 
immunomodulatory action290,291. These details need to be considered when translating preclinical 
studies to clinical study design. In light of these issues, studies should include details of isolation 
techniques, any prospective enrichment, cell surface marker profile with respect to the 
International Society for Cellular Therapy guidance, all functional assays including mesodermal 
lineage differentiation and cell preparation information including culture conditions, passage 
number and any licensing45. A growing body of work has challenged the fundamental assumptions 
about how MSCs exert a biological effect in vivo227,257. MSC survival and persistence may not be 
desirable; instead, their apoptosis, and subsequent efferocytosis by host phagocytic cells may 
induce an effector phenotype in the engulfing cell257. This has been shown to be the likely 
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mechanism by which MSCs act in GvHD. The limitations of our understanding of some of the core 
fundamentals describe some of the broad challenges that need to be addressed as MSC-based 
therapies continue to be investigated for a number of different indications256. The difficulties of 
acquiring relevant pre-clinical data to explore mechanisms of actions are discussed earlier and 
also elsewhere178. It has driven some investigators to pursue clinical trials in the absence of 
reproducible and relevant preclinical evidence of mechanisms of actions. After all, the clinical 
efficacy of MSCs in clinical trials to treat GvHD could not be predicted based on the 
immunosuppressive activity of donor MSCs evaluated in vitro292.  
 
At the time of writing this report, there are 59 MSC-based clinical trials currently recruiting patients 
and registered with clinicaltrials.gov. However, it remains a challenge to draw conclusions about 
MSC therapy from the trials for a number of reasons178: heterogeneity of cells between 
laboratories, unclear MSC identity, a failure to demonstrate dose-dependent effects and an 
inability to readily reproduce findings are but a few examples. The commercialization of MSCs 
may have a number of scientific advantages in terms of speed, but unfortunately a number of 
industry sponsored trials are not published – thereby skewing the available public knowledge 
base. It highlights the importance of establishing and maintaining international registries of MSC 




8.5. Commentary on broader aspects of pre-clinical fibrosis research 
The inadequacy of preclinical models of liver fibrosis is a crippling barrier to meaningful 
translational science. The absence of an effective anti-fibrotic therapy after 30 years of research is 
testament to that fact. I have described the need to interrogate the potential of contemporary 
modelling techniques including 3D co-culture spheroids, recellularised liver scaffolds and 
precision-cut liver slices to move the field of meaningful in vitro modelling forward in chapter 7. I 
am mindful not to draw strong conclusions based on the results of chapter 7 in light of the known 
infidelity of the in vitro modelling system used.  
 
Moreover, in-vivo models are not as predictable and reproducible as advertised168. There is 
significant heterogeneity within controlled experiments as demonstrated by the results in chapter 
3. Existing recommendations to increase the statistical validity of animal research fall short in not 
recommending statistically powered tests based on meaningful outcomes73,206 (Table 5.1). 
Considering the heterogeneity of results conducted by one investigator in one unit in this study, 
one can assume that results between units are not uniformly comparable, thereby necessitating 
in-house exploration of outcome variability. Though cumbersome, it provides necessary rigour 
and is in line with the ethical Principles laid out by Russell and Burch 70 years ago159: 
 
The other great progressive human activity is art, which is so closely related to 
science as to be virtually the same activity. Thus it comes that the greatest scientific 
experiments have always been the most humane and the most aesthetically 
252 
 
attractive, conveying that sense of beauty and elegance which is the essence of 
science at its most successful159. 
 
Russell and Burch’s seminal text – The principles of Humane Experimental Technique – was 
published 70 years ago, and still acts as a cornerstone of ethical scientific research. The excerpt 
above distils much of foundation of the 3Rs principle for the more ethical use of animals in 
scientific research. Slow adoption prompted the Principles to be transcribed to law by the 
implementation of EU Directive 2010/63 – a collection of 66 restrictive articles that decree that 
wherever possible, alternative scientific methods that do not need the use of live animals, should 
be applied in experimental research162. 
 
The variability of fibrosis amongst individuals subjected to the same chronic injury protocol 
focuses the need to track the burden of fibrosis and its regression within individuals. The 
limitations of serial histological assessment in clinical trials are well recognised and is not a viable 
option in small animal studies. Therefore, the development of a non-invasive biomarker of fibrosis 
or resolution would not only facilitate serial assessments to determine a meaningful response to 
therapy in an individual subject (animal model or human), but also profoundly reduce the number 
of animals required per experiment in alignment with the 3Rs principles. Detlef Schuppan 
described the desired characteristics of a non-invasive marker of liver fibrosis in 2008206: 
• The marker should be liver-specific 




• Results should be reproducible 
• Levels should predict disease progression or regression 
• Levels should provide a measurement of stage of fibrosis, activity of matrix deposition, or 
activity of matrix removal.  
 
Unfortunately, as of yet, none of the available advances in biomarkers have been sufficiently 
validated to become the staple of pre-clinical or clinical experimentation293–296. Many of the 
available non-invasive markers are summarised in a recent review article73. Validating a bio-marker 
would go a long way to “squaring the circle” of finding the elusive effective anti-fibrotic agent to 
serve a growing population in need.  
 
To reiterate some of the discussion in chapter 3, experimental biologists must by cognisant of the 
limitations of the rodent models they use. The chronic CCl4 and TAA models deliver fibrosis with 
pre-dominant HSC activation; yet neither recapitulate mechanisms of fibrogenesis in human 
disease45. They do not reflect the time course or scale of human cirrhosis, and are driven by 
mechanisms that have no common human counterpart166. The advent of humanised animal 
models promised to shorten the bridge from animal experimentation to clinical translation45. A 
series of experiments by Bility et al. demonstrated the recapitulation of fibrotic responses from 
long-term viral hepatitis infection297. However, they represent a poor mimic of human disease with 
a limited anti-viral immune response. Nevertheless, they provide a proof-of-concept, and 
advances in this field may overcome many of the concerns of applicability of xenogeneic cell 




The emerging technologies afford a great deal of hope and optimism. Characterisation of 
contemporary in vitro and in vivo models will continue to shorten the gap between the models 
and human disease, enhance our understanding of the complex interplay of different aspects of 
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